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Abstract 
Hypertension is the major risk factor for coronary disease worldwide. Primary 
hypertension is idiopathic in origin but is thought to arise from multiple risk 
factors including genetic, lifestyle and environmental influences. Secondary 
hypertension has a more definite aetiology; its major single cause is primary 
aldosteronism (PA), the greatest proportion of which is caused by aldosterone-
producing adenoma (APA), where aldosterone is synthesized at high levels by an 
adenoma of the adrenal gland. There is strong evidence to show that high 
aldosterone levels cause adverse effects on cardiovascular, cerebrovascular, 
renal and other systems. Extensive studies have been conducted to analyse the 
role that regulation of CYP11B2, the gene encoding the aldosterone synthase 
enzyme plays in determining aldosterone production and the development of 
hypertension. One significant regulatory factor that has only recently emerged is 
microRNA (miRNA). miRNAs are small non-coding RNAs, synthesized by a series of 
enzymatic processes, that negatively regulate gene expression at the post-
transcriptional level. Detection and manipulation of miRNA is now known to be a 
viable method in the treatment, prevention and prognosis of certain diseases. 
The aim of the present study was to identify miRNAs likely to have a role in the 
regulation of corticosteroid biosynthesis. To achieve this, the miRNA profile of 
APA and normal human adrenal tissue was compared, as was the H295R 
adrenocortical cell line model of adrenocortical function, under both basal 
conditions and following stimulation of aldosterone production. Key 
differentially-expressed miRNAs were then identified and bioinformatic tools 
used to identify likely mRNA targets and pathways for these miRNAs, several of 
which were investigated and validated using in vitro methods. The background to 
this study is set out in Chapter 1 of this thesis, followed by a description of the 
major technical methods employed in Chapter 2.  
Chapter 3 presents the first of the study results, analysing differences in miRNA 
profile between APA and normal human adrenal tissue. Microarray was 
implemented to detect the expression of miRNAs in these two tissue types and 
several miRNAs were found to vary significantly and consistently between them. 
Furthermore, members of several miRNA clusters exhibited similar changes in 
expression pattern between the two tissues e.g. members of cluster miR-29b-1 
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(miR-29a-3p and miR-29b-3p) and of cluster miR-29b-2 (miR-29b-3p and miR-29c-
3p) are downregulated in APA, while members of cluster let-7a-1 (let-7a-5p and 
let-7d-5p), cluster let-7a-3 (let-7a-5p and let-7b-5p) and cluster miR-134 (miR-
134 and miR-382) are upregulated. Further bioinformatic analysis explored the 
possible biological function of these miRNAs using Ingenuity® Systems Pathway 
Analysis software. This led to the identification of validated mRNAs already 
known to be targeted by these miRNAs, as well as the prediction of other mRNAs 
that are likely targets and which are involved in processes relevant to APA 
pathology including cholesterol synthesis (HMGCR) and corticosteroidogenesis 
(CYP11B2). It was therefore hypothesised that increases in miR-125a-5p or miR-
335-5p would reduce HMGCR and CYP11B2 expression.  
Chapter 4 describes the characterisation of H295R cells of different strains and 
sources (H295R Strain 1, 2, 3 and HAC 15). Expression of CYP11B2 was assessed 
following application of 3 different stimulants: Angio II, dbcAMP and KCl. The 
most responsive strain to stimulation was Strain 1 at lower passage numbers. 
Furthermore, H295R proliferation increased following Angio II stimulation. 
In Chapter 5, the hypothesis that increases in miR-125a-5p or miR-335-5p 
reduces HMGCR and CYP11B2 expression was tested using realtime quantitative 
RT-PCR and transfection of miRNA mimics and inhibitors into the H295R cell line 
model of adrenocortical function. In this way, miR-125a-5p and miR-335-5p were 
shown to downregulate CYP11B2 and HMGCR expression, thereby validating 
certain of the bioinformatic predictions generated in Chapter 3.  
The study of miRNA profile in the H295R cell lines was conducted in Chapter 6, 
analysing how it changes under conditions that increase aldosterone secretion, 
including stimulation Angiotensin II, potassium chloride or dibutyryl cAMP (as a 
substitute for adrenocorticotropic hormone). miRNA profiling identified 7 
miRNAs that are consistently downregulated by all three stimuli relative to basal 
cells:  miR-106a-5p, miR-154-3p, miR-17-5p, miR-196b-5p, miR-19a-3p, miR-20b-
5p and miR-766-3p. These miRNAs include those derived from cluster miR-106a-
5p/miR-20b-5p and cluster miR-17-5p/miR-19a-3p, each producing a single 
polycistronic transcript. IPA bioinformatic analysis was again applied to identify 
experimentally validated and predicted mRNA targets of these miRNAs and the 
key biological pathways likely to be affected. This predicted several interactions 
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between miRNAs derived from cluster miR-17-5p/miR-19a-3p and important 
mRNAs involved in cholesterol biosynthesis: LDLR and ABCA1. These predictions 
were investigated by in vitro experiment. miR-17-5p/miR-106a-p and miR-20b-5p 
were found to be consistently downregulated by stimulation of aldosterone 
biosynthesis. Moreover, miR-766-3p was upregulation throughout. Furthermore, I 
was able to validate the downregulation of LDLR by miR-17 transfection, as 
predicted by IPA. 
In summary, this study identified key miRNAs that are differentially-expressed in 
vivo in cases of APA or in vitro following stimulation of aldosterone biosynthesis. 
The many possible biological actions these miRNAs could have were filtered by 
bioinformatic analysis and selected interactions validated in vitro. While direct 
actions of these miRNAs on steroidogenic enzymes were identified, cholesterol 
handling also emerged as an important target and may represent a useful point 
of intervention in future therapies designed to modulate aldosterone 
biosynthesis and reduce its harmful effects. 
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Definitions/Abbreviations 
11β-HSD2  11β-hydroxysteroid dehydrogenase type 2 
17βHSD1/3   17β-hydroxysteroid dehydrogenase type 1/3 
17-OH-P   17-hydroxyprogesterone 
17-OH-PREG   17-hydroxypregnenlone 
18-OH-B   18-hydroxycorticosterone 
21C   21 carbons 
3β-HSD   3β-hydroxysteroid dehydrogenase 
3β-HSD2   3β-hydroxysteroid dehydrogenase type 2 
3'UTR    3 prime untranslated region 
5'UTR    5 prime untranslated region 
A    Adenosine 
AB   Amyloid β  
ABCA1   ATP-Binding Cassette, Sub-Family A (ABC1), Member 1 gene 
ACA    Adrenocortical adenoma 
ACAT   Acyl-CoA: cholesterol acyltransferase 
ACC    Adrenocortical carcinoma 
ACE    Angiotensin Converting Enzyme 
ACTH    Adrenocorticotropic Hormone 
AD   Alzheimer disease 
Adx    Adrenodoxin 
A'dione   Androstenedione 
Adr    Adrenodoxin 
AETIO   Aetiocholanolone 
AF-1   Activation function-1 
AGO1-4   Argonaute Protein 1-4 
AGT    Angiotensinogen gene 
AKT   V-Akt Murine Thymoma Viral Oncogene 
Aldo    Aldosterone 
ANDRO   Androsterone 
Angio II   Angiotensin II 
APA    Aldosterone-producing adenoma 
APAF1   Apoptotic peptidase-activating factor 1 gene 
ARE   AU-rich elements 
AT1    Angiotensin type 1 receptor 
AT2    Angiotensin type 2 receptor 
ATP1A1  ATPase, Na+/K+ Transporting, Alpha 1 Polypeptide 
ATP2B1   Plasma membrane calcium-transporting ATPase 1 gene 
ATP2B3  Plasma membrane calcium-transporting ATPase 3 gene 
AU    Arbitrary units 
AVP   Arginine vasopressin 
AVS   Adrenal venous sampling 
BAH   Bilateral adrenal hyperplasia 
BCL2   B-Cell CLL/Lymphoma 2 gene 
BCL2L12  BCL2-Like 12 (Proline Rich) gene 
BMI    Body mass index 
BMP             Bone morphogenetic protein  
BP    Blood pressure 
bp    Base pairs 
BRCA1   Breast Cancer 1, Early Onset gene 
BrdU   Bromodeoxyuridine 
BRIGHT   British Genetics of Hypertension 
C    Cytosine 
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C17    Carbon 17 
C19    Carbon 19 
C20    Carbon 20 
C21    Carbon 21 
CAH    Congenital adrenal hyperplasia 
cAMK    Ca2+/ calmodulin-dependent protein kinase 
cAMP    Cyclic adenosine monophosphate 
CASP2/7  Caspase 2/7, Apoptosis-Related Cysteine Peptidase 
CCF   Cosmic Calf Serum 
CCND1  Cyclin D1 gene 
CDK4/ 6  Cyclin-Dependent Kinase 4/ 6 gene    
cDNA    Complementary DNA 
CDS   Protein coding sequence 
CE   Cholesteryl ester 
CHD   Coronary heart disease 
CK1   Casein Kinase 1 
CpG   Cytosine guanine nucleotides site 
CRE   cAMP-response element 
CREB   cAMP-response element binding protein 
CRH    Corticotrophin-releasing hormone 
CT   Computerised tomography 
Ct    Cycle threshold 
CTNNB1  Catenin (Cadherin-Associated Protein), Beta 1 gene 
CVD   Cardiovascular disease 
CYB5A   Cytochrome b5 gene 
CYP11A1   Cytochrome P450, Family 11, Subfamily A, Polypeptide 1 gene 
CYP11B1   11β-hydroxylase gene 
CYP11B2   Aldosterone synthase gene 
CYP17A1   17α-hydroxylase/17,20 lyase gene 
CYP19A1   Aromatase gene 
CYP21A1   21-hydroxylase gene 
CYP450   Cytochrome P450 enzymes 
DAG   Diacyglycerol 
DASH    Dietary approaches to stop hypertension 
dbcAMP   Dibutyryl cAMP 
DBD   DNA binding domain 
DBP    Diastolic blood pressure 
DCP1/ 2   Decapping enzyme 1/ 2 
DDX6    DEAD (Asp-Glu-Ala-Asp) Box Helicase 6 
DGCR8   DiGeorge Syndrome Critical Region in Gene 8 
DHA    Dehydroepiandrosterone 
DHEA    Dehydroepiandrosterone 
DHEAS   Dehydroepiandrosterone sulphate 
DMSO    Dimethyl sulphoxide 
DNA    Deoxyribonucleic acid 
dNTPs   Deoxynucleotide triphosphates 
DOC    11-deoxycorticosterone 
DPBS   Dulbecco's Phosphate-Buffered Saline 
dsDNA   Double-stranded deoxyribonucleic acid 
DUF   Domain of unknown function 
EDC4    Enhancer of MRNA decapping 4 
EDTA    Ethylenediamine tetra-acetic acid 
EGFR   Epithelial growth factor receptor 
eIF    Eukaryotic initiation factor 
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ELAVL1   ELAV-like RNA binding protein 1 gene 
ENac   Enhance epithelial sodium channel 
ERK1/2  Extracellular signal regulated kinase 1/ 2 
EH   Essential hypertension 
Exp5   Exportin 5 
F2   Fusion protein 
FAD    Flavin adenine dinucleotide 
FDR   False discovery rate 
FDX1    Adrenodoxin 
FDXR    Adrenodoxin reductase 
FFPE   Formalin-fixed paraffin-embedded 
FH   Familial hypercholesterolemia 
FHHt   Familial hyperkalaemic hyprtension 
FHA   Familial hypoalphalipoproteinemia 
FMN    Flavin monoluceotide 
G    Guanine 
g    G-force (relative centrifugal force) 
G1   Gap 1 phase in cell cycle 
GAPDH  Glyceraldehyde-3-Phosphate Dehydrogenase gene 
GC   Glucocorticoid  
GJA1/ CX43  Gap Junction Protein, Alpha 1 
GRA    Glucocorticoid Remediable Aldosteronism 
GR   Glucocorticoid receptor 
GRE   Glucocorticoid response elements 
GSC    Goosecoid homeobox gene 
GW182   Glycine-tryptophan protein of 182 kD 
GWAS    Genome-wide association study 
HCC   Hepatocellular carcinoma cell 
HCV   Hepatitis C virus 
HDL   High density lipoprotein 
HIF1A   Hypoxia inducible factor 1, alpha subunit gene 
HMGCoA  3-hydroxy-3-methylglutaryl-CoA 
HMGCR  3-hydroxy-3-methylglutaryl-CoA reductase gene 
HSL   Hormone-sensitive lipase 
HSP   Heat-shock protein 
HRE   Hormone responsive element 
HSDIIβ2   11β-hydroxysteroid dehydrogenase 
ICAM1   Intracellular adhesion molecule 1 
ICMT    Isoprenylcysteine carboxyl methyltransferase gene 
IGF-1/ 2  Insulin-Like Growth Factor 1/ 2 
IGF1R   Insulin-like growth factor 1 receptor 
IMM   Inner mitochondrial membrane 
IL3/ 6   Interleukin 3/ 6 
ITS    Insulin-transferrin-selenium 
IUPAC   International Union of Pure and Applied Chemistry 
IPA   Ingenuity Pathway Analysis 
IP3   Inositol trisphosphate 
JNC 6/ 7/ 8  Sixth/ Seventh/ Eighth Joint National Committee Report 
K+    Potassium ions 
kb    Kilobases 
KCNJ5 Potassium Channel, Inwardly Rectifying Subfamily J, Member 5 
gene 
kD  KiloDaltons 
KLHL3   Kelch-Like Family Member 3 
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KRAS    Kirsten rat sarcoma viral oncogene homolog gene 
LBD   Ligand binding domain 
LC:MS/MS   Liquid chromotography tandem mass spectrometry 
LD    Linkage disequilibrium 
LDL   Low-density lipoprotein 
LDLR   Low-density lipoprotein receptor gene 
LNA   Locked nucleic acid 
LOD    Logarithm of the odds 
LXR   Liver X receptor 
MAP3K  Mitogen-Activated Protein Kinase Kinase Kinase  
MARK2/PAR-1 Microtubule affinity-regulating kinase 2 
Mb    Megabases 
mCCD   Mouse cortical collecting duct 
MCL1   Myeloid Cell Leukaemia 1 gene 
MCP1   Monocyte chemoattractant protein 1 
MDR/ TAP  Transporter, ATP-Binding Cassette, Sub-Family B 
miRISC   miRNA-induced silencing complex 
miRNA   Micro ribonucleic acid (microRNA) 
ml   Mililitre 
mM   Milimolar 
MP   Membrane potential 
MR    Mineralocorticoid receptor 
mRNA   Messenger ribonucleic acid 
MRX34  miR-34a mimic 
MTDH   Metadherin 
mTOR   Mechanistic Target of Rapamycin (Serine/Threonine Kinase) 
MVE   Multivesicular endosomes 
MYLIP   Myosin regulatory light chain interacting protein (IDOL) 
Na+    Sodium ions 
NAD    Nicotinamide adenine dinucleotide 
NADPH   Nicotinamide adenine dinucleotide phosphate 
NBRE   NGFI-B response element 
ncRNA   Non-coding RNA 
NE   Nuclear envelope 
NF-1    Nuclear-factor 1 
NGF   Nerve growth factor  
NGFI-B  Neuronal growth factor-induced clone B 
NLS   Nuclear localisation signal 
nM   NanoMolar 
nm   Nanometer 
NOR-1   Neuron-derived orphan receptor 1 
NPC   Nuclear pore complex 
NR3C2   Nuclear receptor subfamily 3 gene (MR gene) 
NR3C1  Nuclear receptor subfamily 1 gene (GR gene) 
NR4A2/ 3   Nuclear Receptor Subfamily 4, Group A, Member 2/ 3 
NURR-1  Nur-related factor 1 
OncomiR  Oncogenic miRNA 
OMM   Outer mitochondrial membrane 
PA   Primary aldosteronism 
PABP    Poly A binding protein 
PAI1   Plasminogen activator inhibitor type 1 
PBS   Phosphate buffered saline 
PCR    Polymerase chain reaction 
pEZX    Reporter construct 
pGL3    Reporter construct 
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PH   Primary hypertension 
PI3K   Phosphoinositide 3-Kinase 
PIP2   Phosphatidylinositol 4,5-bisphosphate 
PKA    Protein kinase A 
PKC   Protein kinase C 
PLC   Phospholipase C 
PMEPA1/ TMEPAI  Prostate transmembrane protein, androgen induced 1 gene 
Pol II    RNA polymerase II 
POR   P450 oxidoreductase gene 
PPARD   Peroxisome proliferator-activated receptor delta  
PREG    Pregnenolone 
Pre-miRNA   Precursor miRNA 
Pri-miRNA   Primary miRNA 
PTK2B   Protein tyrosine kinase 2 beta gene 
qRT PCR   Quantitative reverse transcription polymerase chain reaction 
QTL    Quantitative Trait Locus 
RAAS    Renin-angiotensin-aldosterone system 
RAF1    Raf-1 proto-oncogene, serine/threonine kinase 
Ran-GTP   Ras-related nuclear protein-guanosine-5'-triphosphate 
RAS    Renin-angiotensin system 
RISC    RNA-induced silencing complex 
RLC    RNA-induced silencing complex (RISC) loading complex 
RNA    Ribonucleic acid 
RNAi    RNA interference 
RNF111   Ring finger protein 111 gene 
ROS   Reactive oxygen species 
rpm    Revolutions per minute 
RQ    Relative quantification 
RRM   RNA recognition motif 
rRNA   Ribosomal RNA 
RT    Reverse transcription 
RU-486  Glucocorticoid antagonist 
RUNX3  Runx-related transcription factor 3 gene 
RXR   Retinoid X Receptor 
S    Synthesis phase of cell cycle 
S1P/ S2P   SREBP-specific proteases 
SBP    Systolic blood pressure 
SCC   Cholesterol side-chain cleavage enzyme (Desmolase,   
   CYP11A1) 
SEM    Standard error of the mean 
SERPINE1/ PAI1  Serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 gene 
SF-1  Steroidogenic factor 1 
SGK1    Serum/glucocorticoid regulated kinase 1 gene 
SH   Secondary hypertension 
siRNA    Short interfering ribonucleic acid 
SKI   SKI Proto-Oncogene gene 
SLC9A1 Solute Carrier Family 9, Subfamily A (NHE1, Cation Proton 
Antiporter 1), Member 1 gene 
SNP  Single nucleotide polymorphism 
snRNA   Small nuclear RNA 
SMAD4   SMAD family member 4 gene 
SMURF1   SMAD specific E3 ubiquitin protein ligase 1 gene 
srRNA   Small regulatory RNA 
SRB1   Scavenger receptor B1 
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SRE   Sterol regulatory response element 
SREBP-1   Sterol regulatory element binding protein 1 
StAR   Steroidogenic acute regulatory protein 
STAT   Signal transduction and activator of transcription protein 
T    Thymine 
TASK-1  Potassium channel subfamily K member 3 (KCNK3) 
TBE    Tris/Borate/EDTA 
TBP    TATA-binding protein 
TCF4   Transcription Factor 4 gene 
TCF   T cell factor protein 
TE    Tris/EDTA 
TF   Transcription factor 
TGIF1   TGFB-induced factor homeobox 1 gene 
TGF-β   Transforming growth factor-beta 
THA    Tetrahydro-11-dehydrocorticosterone 
THAldo   Tetrahydroaldosterone 
THB    Tetrahydrocorticosterone 
THDOC   Tetrahydrodeoxycorticosterone 
THE    Tetrahydrocortisone 
THF    Tetrahydrocortisol 
THS   Tetrahydrodeoxycortisol 
Tm    Melting temperature 
TNF    Tumour necrosis factor gene 
tPA   Tissue plasminogen activator 
TRBP    Tar RNA binding protein 
tRNA   Transfer RNA 
U    Uracil 
UPL    Universal ProbeLibrary 
UV    Ultraviolet 
VCL    Vinculin 
VEGF   Vascular endothelial growth factor 
VLDLR   Very low density lipoprotein receptor 
WHO   World Health Organization 
WGS   Whole genome sequencing 
WNT1/ 3/ 4 Wingless-Type MMTV Integration Site Family, Member 1/ 3/ 4 
gene 
WRE   WNT response element 
XRN-1/2   5'-3' exoribonuclease 1/2 
ZF    Zona fasciculata 
ZFYVE9   Zinc finger, FYVE domain containing 9 gene 
ZG    Zona glomerulosa 
ZR    Zona reticularis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Introduction 
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1.1 Hypertension 
The blood circulates through the vascular system under an oscillating pressure 
generated principally by the beating action of the heart and the tone of the 
resistance artery smooth muscle walls. At diastole, blood pressure is at its 
lowest (diastolic blood pressure: DBP) and at systole, it is at its highest (systolic 
blood pressure: SBP). Both DBP and SBP vary between individuals and both tend 
to increase with age. The higher the blood pressure, the greater the risk of 
cardiovascular, cerebrovascular and renal damage. Blood pressure high enough 
to present such a risk is called hypertension. The World Health Organisation 
reports that hypertension is accountable for up to 60% of cerebrovascular 
disease and up to 50% of ischaemic heart disease (IHD) and is the number one 
risk factor for mortality worldwide (WHO 2002). In the United States, the 
lifetime risk of hypertension is estimated to be 90% in people aged 55–56 years 
(Chobanian AV 2003).  
It is important to emphasise that, within the general population, DBP and SBP 
are normally distributed. The distinction between normal blood pressure and 
hypertension is therefore arbitrary. The hypertension classification from the 
2014 Evidence-Based Guidelines (Chobanian AV 2003) for the Eighth Joint 
National Committee Report (JNC 8) (James, Oparil et al. 2014) is shown in Table 
1-1. 
Table 1-1: Classification of hypertension based on the JNC 8. JNC 8 is based on previous 
classification under JNC6 and JNC7. 
JNC 6 SBP/DBP JNC 7 
 
Optimal < 120/80 Normal 
 
Normal 
Borderline 
120-129/80-84 
130-139/85-89 
Pre-hypertension 
 
 
Hypertension ≥ 140/90 Hypertension 
 
Stage 1 
Stage 2 
Stage 3 
140-159/90-99 
160-179/100-109 
180/110 
Stage 1 
 
Stage 2 
 
While hypertension, the so-called silent killer, is thus readily diagnosed and 
treated and there now exists a battery of relatively side effect-free treatments 
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that delay and reduce its destructive effects, only in a very small minority of 
cases can it be cured due to the identification of a single cause. In the remaining 
majority, no unequivocal fundamental cause can be found and these are grouped 
into the category of essential or primary hypertension. However, it is certain 
that there is a spectrum of contributing causes: partly aspects of lifestyle and 
partly inherited factors, which interact with each other. 
A number of lifestyle factors contribute to increased blood pressure and amplify 
its effect. One study assessed the impact of diet and macronutrient intake on 
SBP and DBP (Eckel, Jakicic et al. 2014). The dietary patterns were 
characterized by a combination of daily food intake with, in particular, high 
sodium and potassium content (Eckel, Jakicic et al. 2014). Numerous 
experimental and epidemiological data confirm the advantages of salt restriction 
on blood pressure (Batuman 2013). The Dietary Approaches to Stop Hypertension 
(DASH) trial found that decreasing salt intake from 8 g per day to 6 g 
(intermediate reduction) and 4 g (low reduction) reduced SBP by an average of 
11.5 mmHg in hypertensive and 7.1 mmHg in normotensive people (Sacks, 
Svetkey et al. 2001). A meta-analysis reported that sodium intake of ≤2g/day 
versus ≥2g/day significantly reduced SBP by 3.4 mmHg and DBP by 1.5 mm Hg in 
adults and suggested that most people are likely to benefit from reducing their 
sodium intake (Aburto, Ziolkovska et al. 2013). 
There is good evidence linking physical activity and hypertension (Kokkinos, 
Manolis et al. 2009, Cornelissen and Smart 2013), cardiovascular disease (CVD) 
(Myers 2003), type II diabetes mellitus (Kokkinos, Myers et al. 2009) and blood 
lipids (Krotkiewski, Mandroukas et al. 1979). Overweight women who performed 
one-hour exercise sessions 3 times per week for 6 months decreased BP 
(Krotkiewski, Mandroukas et al. 1979). Fitness status and exercise aptitude 
inversely correlate with mortality risk in healthy people (Kokkinos, Myers et al. 
2008) and in subjects with pre-hypertension (Kokkinos, Myers et al. 2009) and 
hypertension (Kokkinos, Manolis et al. 2009). A moderate increase in exercise 
capacity may prevent the progression of pre-hypertension to hypertension 
(Faselis, Doumas et al. 2012). 
Obesity associates with elevated blood pressure (Sánchez-Castillo, Velásquez-
Monroy et al. 2005, Jensen, Ryan et al. 2014). A 5% weight loss causes reduction 
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of 3 mmHg in SBP and 2 mmHg in DBP (Jensen, Ryan et al. 2014). Aucott et al 
reported that a 10 kg weight loss decreases DBP by 4.6 mmHg and SBP by 6 
mmHg. However, huge weight loss as a result of surgical intervention makes 
little difference to blood pressure (Aucott, Poobalan et al. 2005). 
A significant proportion of increased blood pressure in essential hypertension is 
heritable. Data from family and twin studies indicate a heritable component of 
between 30% and 50% (Miall and Oldham 1963). The search for responsible genes 
has been intense and a variety of biological systems have been implicated, 
including those involved in corticosteroid biosynthesis. These will be reviewed in 
Section 1.4. Several methods, including candidate gene analysis, linkage analysis 
and genome-wide association study (GWAS) have been employed in the search. 
These are discussed further in Sections 1.6.2 to 1.6.4. 
The adrenal cortex has been convincingly identified as a contributor to the 
genetic component of essential hypertension. The following sections explain the 
structure, biosynthesis, control of secretion and mechanism of action of its 
products with particular reference to aldosterone. The importance of cholesterol 
metabolism in biosynthesis is emphasised. The implication of corticosteroids in 
the aetiology of hypertension and heart disease is then reviewed. This includes 
their role in essential hypertension but also information on the growth and 
effects of the various types of adrenocortical neoplasms. A major experimental 
goal is assessment of the importance of miRNA species in the normal function of 
the gland and in the growth and function of tumours. Finally, it is asked, ‘Do 
miRNAs offer an additional means of therapy for adrenal disorders?’. 
1.2 The adrenal cortex 
1.2.1 Structure of the adrenal gland 
 
The adrenal glands are paired glands located at the apex of each kidney as 
shown in Figure 1-1a. Each gland is comprised of an inner medulla – the source 
of catecholamine hormones – and a cortex, which synthesises and secretes the 
corticosteroids. Each gland is surrounded by a fibrous capsule, is supplied with 
blood by three arteries; superior suprarenal artery (branching from the inferior 
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phrenic artery), middle suprarenal artery (branching from the abdominal aorta) 
and inferior suprarenal artery (branching from the renal artery) and is drained by 
the suprarenal vein; the right suprarenal vein drains into the inferior vena cava 
and the left suprarenal vein drains into the left renal vein or the left inferior 
phrenic vein. The cortex consists of three layers of variable width (Figure 1-1b); 
they produce different hormones and their activities are controlled 
independently (see sections 1.4.2). The outermost layer is the zona glomerulosa 
and its principal product is aldosterone. In man, this zone may not always form a 
continuous layer; glomerulosa cells are small. Beneath this is the widest zone, 
the zona fasciculata, the principal product of which is cortisol. Fasciculata cells 
are typically large and contain lipid vacuoles rich in cholesterol. Innermost, 
adjacent to the medulla, is the zona reticularis which secretes largely adrenal 
androgens. Importantly, the adrenocortical blood flow is centripetal so that the 
zona glomerulosa has no direct humoral contact with the inner zones.  
 
Figure 1-1: The anatomy of the adrenal gland. 
(a) The macroscopic anatomy of the adrenal gland. (b) cross sectional diagram and microscopic 
section of the adrenal cortex. Adapted from (Droual 2015). 
 
1.2.2 The corticosteroids 
The corticosteroids are 21C compounds, consisting of a cyclopenteno-
perhydrothrenanthrene base, which is approximately planar, with a β-
orientated, 2-carbon side chain, the first carbon of which bears a ketone group,   
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and two angular methyl groups at C18 and C19. The numbering of the rings and 
the carbon atoms is shown in Figure 1-2. From this basic planar structure, 
substituents such as hydroxyl groups of specific location and orientation 
determine the biological properties of the individual compounds. For example, 
aldosterone in Figure 1-3 is able to perform its function by virtue of its 
hemiacetal substituent, formed from its 11β-hydroxyl group and its unique 18-
aldehyde group. Cortisol, in contrast, is hydroxylated at carbons 11, 17 and 21 
(Figure 1-3). Corticosteroid systematic names are listed in Table 1-1. 
 
Figure 1-2: The basic carbon structure present in all steroid hormones.  
The carbon rings are identified by the letters A to D, universally recognised by the International 
Union of Pure and Applied Chemistry (IUPAC). 
 
 
 
 
 
Figure 1-3: The chemical structures of aldosterone and cortisol. 
Structures of aldosterone (left) and cortisol (right) based on the basic 4 rings of carbon; the 
numbering of the carbon atoms is determined by the International Union of Pure and Applied 
Chemistry (IUPAC). 
 
Aldosterone structure Cortisol structure 
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Table 1-1: Adrenal steroid products, their systematic names and their abbreviations. 
Steroid Product Systematic name Abbreviation 
11-Deoxy-Corticosterone 
 
21-dihydroxypregn-4-ene-3,20-dione DOC 
11-Deoxy-Cortisol 
 
17α,21-dihydroxypregn-4-ene-3,20-dione S 
17-Hydroxy-Pregnenolone 
 
3β,17α-dihydroxypregn-5-ene-20-one 17-OH-PREG 
17-Hydroxy-Progesterone 
 
17α-hydroxypregn-4-ene-3,20-dione 17-OH-P 
18-Hydroxycorticosterone 
 
11β,18,21-trihydroxypregn-4-ene-3,20-dione 18-OH-B 
Aldosterone 
 
11β-21-dihydroxypregn-4-ene-3,20-dione-18-al Aldo 
Androstenedione 
 
androst-4-ene-3,17-dione A’dione 
Corticosterone 
 
11β,21-dihydroxypregn-4-ene-3,20-dione B 
Cortisol 
 
11β,17α,21-trihydroxyprepn-4-ene-3,20-dione F 
Dehydroepiandrosterone 
 
3β-hydroxyandrost-5-ene-17-one DHEA 
Pregnenolone 
 
3β-hydroxypregn-5-ene-20-one PREG 
Progesterone 
 
pregn-4-ene-3,20-dione P 
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The substrate for steroidogenesis is cholesterol. The structure of this important 
sterol is shown in Figure 1-4. Its central role in steroid metabolism is discussed 
further in section 1.3.  
 
Figure 1-4: Chemical structure of cholesterol. 
Cholesterol structure based on the basic 4 rings of carbon; the numbering of the carbon atoms is 
determined by the International Union of Pure and Applied Chemistry (IUPAC). 
 
1.2.3 Corticosteroid effects and mechanism of action 
1.2.3.1 The steroid receptors: structure function and distribution 
1.2.3.1.1 Cortisol action through the glucocorticoid receptor 
 
Cortisol is mainly synthesized in the zona fasciculata, with a small amount from the 
zona reticularis. Its secretion is regulated by adrenocorticotropic hormone (ACTH) 
from the anterior pituitary which, in turn, is controlled by corticotropin-releasing 
hormone (CRH) and arginine vasopressin (AVP) from the hypothalamus. Cortisol exerts 
negative feedback inhibition on the anterior pituitary and the hypothalamus. The 
main function of cortisol is to control blood glucose level. Cortisol stimulates 
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conversion of non-glucose molecules into glucose (gluconeogenesis), glycogenolysis, 
catabolism of protein in muscle and lipolysis in adipocytes. Cortisol is also involved in 
the inflammatory response, where it inhibits the synthesis and action of histamine, 
prostaglandins and leukotrienes. Cortisol also decreases the effectiveness of T and B 
lymphocytes. 
Cortisol acts by binding to glucocorticoid receptor (GR), a member of the nuclear 
receptor superfamily (Griekspoor, Zwart et al. 2007). There are 2 known GR isoforms, 
GRα and GRβ, encoded by a single gene – NR3C1 located on chromosome 5 (5q31) – by 
means of alternative splicing (Smoak and Cidlowski 2007). GRα binds cortisol, while 
GRβ – which differs from GRα at its C-terminus – does not bind to cortisol but does 
bind the glucocorticoid antagonist, RU-486 (Lewis-Tuffin, Jewell et al. 2007). GR can 
be found in almost cells in the body.  
GRα consists of 4 main domains: the N-terminal domain, DNA binding domain (DBD), 
ligand binding domain (LBD) and C-terminal domain. The N-terminal domain itself 
contains the transcription-enhancing activation-function-1 region (AF-1), which 
upregulates gene expression, as well as a site for SUMOylation (modification regulated 
by ubiquitin-related proteins at the post-translation level), ubiquitination 
(modification regulated by ubiquitin) and important basal transcription machinery 
(BTM). The DBD is highly conserved and comprises two α-helices that coordinate two 
zinc fingers essential for dimerization of the hormone-receptor complex and its 
binding to glucocorticoid response elements (GRE), nuclear translocation and 
transactivation. The LBD function is to conserve competency of GR for hormone 
binding (Meijsing, Elbi et al. 2007). The C-terminal domain carries binding sites for 
heat-shock proteins (hsp) and the nuclear localisation signal (NLS) (Smoak and 
Cidlowski 2007, McMaster and Ray 2008).  
Cortisol is lipophilic and can therefore diffuse through the plasma membrane passively 
to binds to GRα in the cytoplasm. Prior to binding, the GR is enveloped in a complex 
of chaperones, including heat shock proteins (hsp90, hsp70, hsp56, hsp40) (Dittmar, 
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Banach et al. 1998) and immunophilins (i.e FKBP59, cylclophilin 40) (Renoir, Mercier-
Bodard et al. 1995), which protect it from degradation and maintain binding affinity. 
A cortisol molecule binds to the GR complex causing dissociation of GRα from the rest 
of the complex (hsps and immunophilins) and migration to the nucleus. The ligand-
receptor complex then binds to GRE as homo- or hetero-dimers, either increasing 
transcription of certain genes through stabilisation of the pre-initiation complex, or 
inhibiting transcription of others (Zennaro 1998). See Figure 1-5.  
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Figure 1-5: Intracellular action of glucocorticoid from cytoplasm to nucleus.  
Glucocorticoid (GC) enters the cell membrane by diffusion. Glucocorticoid receptor (GR) usually form complexes with multiple proteins in the cytoplasm and remain inactivated. Once 
GC bind to GR complexes, GR dissociates from the attached protein and forms a dimer with another GR that bind to GC. GC-GR dimers translocate into the nucleus. Then, target 
gene transcription is initiated. Binding of activated GR homodimer to GREs (glucocorticoid response elements) promoter region activates gene transcription that encode anti-
inflammatory mediators (i.e lipocortin-1, interleukin-10 and inhibitor of nuclear factor KB). RNA poly (RNA polymerase). Modified from (Holgate and Polosa 2008)). 
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For example, the GRE located in the lipocortin gene activates transcription of this 
anti-inflammatory gene. Protein-protein interactions also occur; the ligand-receptor 
complex protein interacts with signal transduction and activator of transcription 
proteins (STATs).  The ligand-receptor complex can also interact simultaneously with 
DNA and protein. For example, interaction of GRα complex with GREs and STATs in 
the Toll-like receptor 2 (TLR-2) gene (Smoak and Cidlowski 2007) is important in 
pathogen recognition and the activation of innate immunity (Takeda and Akira 2005). 
1.2.3.1.2 Aldosterone action through the mineralocorticoid receptor (MR) 
 
Aldosterone acts mainly on epithelial cells of the renal collecting duct where 
transport of Na+, K+ and water occur (Muto 1995). The epithelial cell reabsorbs Na+ 
and water via a specific epithelial sodium channel, ENaC, located at the apical 
membrane. At the basolateral membrane, transport is driven by the Na+/K+-ATPase 
pump, which exchanges sodium ions for potassium and hydrogen ions. Aldosterone 
acts to increase the opening time of existing ion channels or to increase the total 
number of channels at the membrane (Connell and Davies 2005). By stimulating the 
opening of sodium and potassium channels in the luminal membrane and increasing 
the activity of the Na+/K+-ATPase pump at the basolateral membrane (Kobori, 
Nangaku et al. 2007), aldosterone will increase sodium chloride reabsorption and 
potassium secretion in the collecting duct of the nephron (Kobori, Nangaku et al. 
2007). 
Aldosterone acts through the mineralocorticoid receptor (MR) or corticosteroid Type I 
binding site (Baxter, Schambelan et al. 1976). MR is expressed in a variety of 
epithelial cells – including renal, lung and colon tissue (Funder 2005, Viengchareun, Le 
Menuet et al. 2007). 
The genes encoding MR (NC3C2) and GR (NC3C1) lie on human chromosomes 4 and 5, 
respectively, but are closely related. They share 90% amino acid homology (Laudet, 
Hänni et al. 1992) and are 94% identical in their DNA-binding domain (Connell and 
Davies 2005).  The MR has equal affinity for cortisol and aldosterone, and plasma   
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concentration of cortisol is a hundred-fold higher than that of aldosterone 
(Funder 2005). This would lead to almost total exclusion of aldosterone from 
MR binding due to cortisol. However, the 11β-hydroxysteroid dehydrogenase 
type 2 enzyme (11β-HSD2), which co-localises with MR in certain key target 
tissues, converts cortisol to the non-MR-binding cortisone in humans (and also 
the major rodent glucocorticoid corticosterone to 11-dehydrocorticosterone in 
rats and mice) (Funder, Pearce et al. 1988). Furthermore, 11β-HSD2 converts 
NAD to NADH, which inactivates glucocorticoid-MR complexes (Funder 2004). 
The ability of cortisol to bind MR is also reduced because most of it is bound to 
globulin in the plasma (Shigehiro and Tohru 1982). MRs are also present in non-
epithelial tissues such as in cardiovascular and central nervous system where it 
promotes fibrosis, cardiac hypertrophy, impaired vascular function, regulates 
blood pressure and influences salt appetite (Connell and Davies 2005). 
Like the GR, the MR is cytoplasmic in the absence of ligand (Binart, Lombes et 
al. 1991). Aldosterone is, again, a lipid-soluble hormone that can easily diffuse 
into the cytoplasm through the cellular membrane. Once aldosterone enters 
cells to bind and activate MR in the cytosol, the aldosterone-MR complex 
translocates to the nuclear compartment to bind the specific hormone 
responsive element (HRE) (So, Chaivorapol et al. 2007). This step is followed by 
recruitment of chromatin remodelling complexes to activate the transcriptional 
machinery and modulate the expression of aldosterone target genes 
(Viengchareun, Le Menuet et al. 2007). See Figure 1-6. 
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Figure 1-6: Intracellular action of mineralocorticoid (aldosterone) from membrane to cytoplasm into nucleus. 
MR is stimulated by MC (mineralocorticoid; aldosterone) and this will lead to chaperone dissociation. The MR:MC complex is translocated into the nucleus and activates the hormone 
response element in the promoter region of target genes. The Na+ absorption action of aldosterone depends on SGK1, which de-represses the activity of ENac. Aldosterone also 
stimulates the expression of TGF-β and PAI1, ROS. Through the non-genomic pathway, aldosterone activates the EGFR and phosphorylates ERK1/2 to upregulate the pro-
inflammatory transcription factors i.e. ICAM1, MCP1 and IL6. All of these will lead to renal fibrosis and scarring. Mineralocorticoid (MC), mineralocorticoid receptor (MR), epithelial Na+ 
channel (ENaC), transforming growth factor-beta (TGF-beta), plasminogen activator inhibitor, type 1 (PAI1), reactive oxygen species (ROS), epithelial growth-factor receptor (EGFR), 
extracellular-signal-regulated kinase 1 (ERK1)/ERK2, intracellular adhesion molecule 1 (ICAM1), interleukin 6 (IL6), monocyte chemoattractant protein 1 (MCP1). Modified from 
(Perico, Benigni et al. 2008).
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1.3 Cholesterol: origin and transport 
All steroid hormones are synthesized from cholesterol, most of which is imported 
from circulating lipoproteins (Carr and Simpson 1981) as low-density lipoprotein 
(LDL). Each LDL complex contains approximately 1500 cholesteryl ester (CE) particles 
coated with phospholipid, unesterified cholesterol and B-100 apoprotein (MS Brown 
1986). Adrenal cells can also synthesise cholesterol de novo from acetyl CoA through 
the mevalonate pathway (Borkowski, Levin et al. 1967, Azhar and Reaven 2002) See 
Figure 1-7. Cholesterol is stored as cholesteryl ester in cytoplasmic lipid droplets 
(Gwynne and Strauss 1982). 
 
Figure 1-7: Cholesterol synthesis pathway.  
HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) is the rate-limiting enzyme for cholesterol 
production, also known as statin target for treatment of hypercholesterolemia. 
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Human steroidogenic cells employ receptor-mediated-endocytosis via the low density 
lipoprotein receptor (LDLR), which translocates LDL from the circulation into the cell. 
LDLR is a glycoprotein receptor located at the cell membrane, encoded by the LDLR 
gene on chromosome 19p13.1-13.3 (Francke, Brown et al. 1984). After formation of 
the LDL-LDLR complex, it passes into the cell, fusing with lysosomes into which free 
cholesterol is released. This can be transported to mitochondria for steroidogenesis or 
re-esterified and stored in lipid droplets (Azhar and Reaven 2002). LDLR dissociates 
and is recycled to the cell surface to repeat endocytosis. 
The level of cholesterol in the cell is controlled by sterol response element binding 
proteins (SREBPs) (Kim, Miyazaki et al. 2002). In cholesterol-deficient cells, the 
SREBP-specific proteases (S1P and S2P) cleave SREBPs to release the activated N-
terminal from the membrane. This enables the binding protein to enter the nucleus 
and bind to sterol regulatory response elements (SREs) and activate the genes 
involved in cholesterol, fatty acid and triglyceride synthesis (Kim, Miyazaki et al. 
2002). 
A recent study showed that acyl-CoA:cholesterol acyltransferase (ACAT) esterifies 
free cholesterol for storage in lipid droplets and that this process is modulated by 
hormone-sensitive lipase (HSL) (Miller and Auchus 2011). HSL is stimulated by ACTH to 
increase the availability of free cholesterol. ACTH also can inhibit ACAT action, 
increasing intracellular cholesterol homeostasis by pumping intracellular cholesterol 
out to the circulation, thus reducing the level of cholesterol in the cell (Oram and 
Lawn 2001).  
A major part of steroidogenesis is intra-mitochondrial. Cholesterol is translocated 
from the outer mitochondrial membrane (free cholesterol availability for 
steroidogenesis (Miller and Auchus 2011). The ATP-binding cassette transporter 
subfamily A member 1 (ABCA1), a membrane protein, contributes to intracellular 
transport of cholesterol from the outer mitochondrial membrane (OMM) to the inner 
mitochondrial membrane (IMM) by steroidogenic acute regulatory protein (StAR). At 
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the IMM, cholesterol side-chain cleavage enzyme, (P450scc, also known as CYP11A) 
converts insoluble cholesterol to soluble pregnenolone by removing all but C20 and 
C21 of the side chain. See Figure 1-8 (Miller 1988). 
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Figure 1-8: Pathway of cholesterol biosynthesis and its relation with LDLR, HMGCR and CYP11B2.  
LDL binds to LDLR for LDL:LDL complex internalization. In the endosome, LDLR will be recycled back to the membrane while LDL will be processed in the lysosome to produce free 
cholesterol. Cholesterol movement into the mitochondrion is strictly controlled by StAR. In the mitochondrion, cholesterol will be synthesized to aldosterone via multiple enzymatic 
processes. The intracellular cholesterol is exported via ABCA1, an ATP-binding transporter. RABCA1: ATP-binding cassette A1 transporters; DOC: Deoxycorticosterone; HMGCR: 3-
Hydroxy-3-Methylglutaryl-CoA Reductase; LDL: low density lipoprotein; LDLR: low density lipoprotein receptor; StAR: steroidogenic acute regulatory protein; SRE: Sterol Response 
Elements; SREB: sterol-response element–binding protein. Modified from (Qiagen , Singh, Yadav et al. 2015).
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1.3.1 StAR 
StAR protein possesses a hydrophobic cholesterol-binding pocket that enables transfer 
of cholesterol from OMM to IMM (Mathieu, Fleury et al. 2002). It is a 30 kDa 
mitochondrial peptide synthesized from a 37 kDa precursor (Miller 2007) and is 
expressed in all steroidogenic tissues. It belongs to the StAR-related lipid transfer 
(START) family of proteins (Soccio and Breslow 2003). There are multiple START 
domains mediating lipid transfer intracellularly. StarD4 and D5 are thought to be 
responsible for cholesterol movement from cytoplasmic lipid droplets to OMM 
(Riegelhaupt, Waase et al. 2010). StarD4 and D5 have StAR-like activity in COS-1 cell 
transfected with P450scc enzymes (Soccio, Adams et al. 2005). It is estimated that 
approximately 400 cholesterol molecules per minute are translocated into 
mitochondria by each newly-synthesized molecule of StAR (Ikonen 2008).  
StAR gene transcription is modulated by many transcription factors, including 
steroidogenic factor-1 (SF-1), cAMP response element mediator, dosage-sensitive sex 
reversal-adrenal hyperplasia congenital critical region on the X-chromosome (DAX-1), 
GATA-4, CCAAT-enhancer-binding protein-β (C/EBPβ) and activator protein-1 (AP-1) 
(Reinhart, Williams et al. 1999). SF-1 null mice do not express StAR mRNA, 
demonstrating that StAR is dependent on SF-1 for its transcription (Caron, Ikeda et al. 
1997). SF-1 activates the StAR promoter region at six binding sites (Reinhart, Williams 
et al. 1999). Its transcription is also activated by cAMP signalling through the cAMP-
response element (CRE)-binding protein (CREB) and CRE (Manna and Stocco 2007). In 
lipoid congenital adrenal hyperplasia (CAH), steroidogenesis activity is severely 
impaired and cholesterol accumulates within the cytoplasm due to inactivating 
mutations of StAR. In rodents, where steroidogenic cells derive cholesterol from HDL 
through the scavenger receptor B1 (SRB1) (Johnson, Svensson et al. 1998), absence of 
adrenal StAR leads to increased SRB1 expression (Cao, Zhao et al. 1999). However, 
steroidogenesis is not fully StAR-dependent; COS-1 cells (non-steroidogenic) 
transfected with F2 (a fusion protein with H2N–P450scc–Ferredoxin Reductase–
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Ferredoxin–COOH) are steroidogenic despite the absence of StAR (Black, Harikrishna 
et al. 1994).  
1.3.2 SF-1 
The orphan nuclear receptor Steroidogenic factor-1 (SF-1) is known to have a vital 
role in steroidogenic tissue development and differentiation. It is encoded by the 
NR5A1 gene (nuclear receptor subfamily 5, group A, member 1). Mutation of NR5A1 
can lead to infertility and absence of puberty.  SF-1 is involved in the expression of all 
steroidogenic enzymes in adrenocortical and gonads. SF-1 activates the promoter 
region of steroidogenic enzymes including CYP11B1, P450cc, StAR and CYP21. 
Responsiveness to cAMP can be altered due to overlapping of a cAMP-sensitive 
promoter region with SF-1 (Val, Lefrançois-Martinez et al. 2003). In in vivo studies, 
disruption of the SF-1 gene leads to failure of adrenal and gonad development (Luo, 
Ikeda et al. 1994). The activation function-2 (AF-2) domain located in the ligand-
binding domain (LBD) of SF-1 has a significant effect on SF-1 function and is important 
to transactivation of target genes. It is reported that even a single point mutation in 
the AF-2 domain of SF-1 significantly affects SF-1 transactivation, transforming it into 
a negative mutant with regards to PKA-C-dependent activation (Jacob and Lund 
1998). 
1.3.3 HMGCR 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) represents the rate-
limiting step for cholesterol biosynthesis. It catalyses the conversion of 3-
hydroxy-3-methylglutaryl coenzyme A (HMGCoA) to mevalonic acid ((Bochar DA 
1999) and Figure 1-8). 
HMGCR is a target for statins, drugs used to treat high cholesterol levels. Statin as a 
cholesterol-lowering agent has been widely used as effective therapy for 
hypercholesterolaemia for more than 30 years (Goldstein and Brown 1990). Initially, 
the Framingham study found that there was strong correlation between high plasma 
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cholesterol and coronary heart disease (CHD) mortality and later specified this was 
due to LDL (Tobert 2003). However, this remains controversial, with strong evidence 
to show that that inhibiting HMGCR lowers the progression of atherosclerotic 
development (Blankenhorn, Azen et al. 1993, Jukema, Bruschke et al. 1995, Salonen, 
Nyyssönen et al. 1995). Over the 5 years of the 4s trial (Scandinavian Simvastatin 
Survival Study), 4000 patients received either simvastatin or placebo, the former 
significantly reducing mortality due to a decreased number of coronary deaths. This 
support and confirms that lowering cholesterol effectively reduces CHD morbidity and 
mortality (Pedersen, Berg et al. 1996). 
HMGCR is also expressed in glial cells of the brain, controlling de novo synthesis of 
cholesterol assisted by ABCA1 importation of extracellular cholesterol. Overexpression 
of HMGCR along with underexpression of ABCA1 leads to accumulation of cholesterol 
intracellularly, resulting in increased amyloid beta (Aβ) synthesis and greater risk of 
Alzheimer’s disease (AD) (Rodríguez-Rodríguez, Mateo et al. 2009). 
Apart from cholesterol synthesis, HMGCR also contributes to stimulated migration of 
primordial germ cells to mesoderm from the embryonic endoderm. HMGCR mutants 
fail to show this migration, affecting the development of gonadal mesoderm and 
terminating embryogenesis (Van Doren, Broihier et al. 1998). 
1.3.4 LDLR 
LDLR is a glycoprotein receptor at the cell membrane (Figure 1-8) that binds and 
internalizes ligands (i.e cholesterol-containing lipoprotein LDL), enzyme complexes 
(i.e protease or protease inhibitor), vitamins and much else from the extracellular 
area (Willnow, Nykjaer et al. 1999, Gent and Braakman 2004). In humans, LDLR is 
encoded by the LDLR gene located on chromosome 19p13.1-13.3 (Francke, Brown et 
al. 1984). 
The mammalian LDLR family can be divided into several groups including the most 
important, the very-low density lipoprotein receptor (VLDLR) and apolipoprotein E 
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receptor 2 (Gent and Braakman 2004). Some of the family members play essential role 
neuronal migration, embryonic development and synaptic transmission (May, Bock et 
al. 2003, Schneider and Nimpf 2003). 
Once the internalization of LDL occurs, it reduces expression of HMGCR to decrease 
cholesterol production and stimulate the Acyl-CoA cholesteryl acyl transferase (ACAT) 
to form CE from cholesterol, thus reducing cholesterol toxicity intracellularly 
(Shimomura, Bashmakov et al. 1997, Tamura and Shimomura 2005). 
LDLR-impaired mice given high cholesterol diet present with hyperlipidaemia, and 
increased reactive oxygen species (ROS) cause vascular structure alterations (Kypreos 
and Zannis 2006, Lauzier, Delemasure et al. 2011). Another study delivered restored 
LDLR gene expression through intravenous injection of  adenovirus in LDLR-null mice, 
thereby reducing LDL and VLDL in the circulation (Ishibashi, Brown et al. 1993).  
LDLR defects are the most common cause of familial hypercholesterolemia (FH) and 
increase the risk of coronary artery disease due to severe elevation of serum LDL (Go 
and Mani 2012). In FH, 1 in 500 cases are due to heterozygote mutations and 1 in a 
million to homozygote mutation (Helen H. Hobbs 1992). In homozygotic FH, serum LDL 
levels are up to 800 mg/dL (normal is <100 mg/dL) with significant severe 
accumulation of atherosclerotic plaques at the cardiac arteries and valve. In 
heterozygotic cases, patients typically present with double the normal plasma LDL 
concentration and a 2-fold risk of coronary artery disease relative to the general 
population (Go and Mani 2012). 
1.3.5 ABCA1 
ATP-binding cassette transporter subfamily A member 1 (ABCA1) is a membrane 
protein essential to intracellular cholesterol homeostasis (Oram and Lawn 2001). The 
main function of ABCA1 is to pump out intracellular cholesterol to the circulation thus 
reducing the level of cholesterol in the cell (Figure 1-8). Defects of ABCA1 (i.e in 
familial hypoalphalipoproteinemia,or FHA, or in Tangier Disease) result in severely 
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defective cholesterol efflux and accumulation of intracellular cholesterol ester 
(Bodzioch, Orso et al. 1999). During reverse cholesterol transport, ABCA1 mediates 
the cholesterol and phospholipid transfer onto Apo-A1, an anti-atherosclerotic 
property of HDL. ABCA1 transcription is known to be stimulated by cAMP and LXR-RXR 
pathways in macrophages (Abe-Dohmae, Suzuki et al. 2000, Schwartz, Lawn et al. 
2000), so it is suggested that the alteration of ABCA1 expression may decrease the 
transition to foam cell and reduce progression of atherosclerotic plaques.  
In severe accumulation of cholesterol in the cell, one study proposed that it will lead 
to β-cell apoptosis and impaired insulin secretion (Unger 1995). This was further 
supported by a study with ABCA1-null mice, which have impaired glucose tolerance 
despite normal insulin sensitivity, suggesting that β-cell function is impaired 
(Brunham, Kruit et al. 2007). Mice lacking LXR-β, a transcription factor that activates 
ABCA1, have accumulation of lipid in the islets of β-cells, impaired glucose tolerance 
and reduced β-cell function (Gerin, Dolinsky et al. 2005). 
Lipid-rich diets stimulate mesangial cell proliferation and increase glomerulosclerosis 
due to deposition of lipid and accumulation of foam cells in the mesangial areas 
(Song, Li et al. 2000). ABCA1-deficient mice develop kidney glomerulonephritis, 
severe placental malformation and HDL deficiency (Christiansen-Weber, Voland et al. 
2000). 
1.4 Biosynthesis of corticosteroids 
1.4.1 Enzymes  
1.4.1.1 The hydoxysteroid dehydrogenases 
Hydroxysteroid dehydrogenases catalyse the oxidation of steroid hydroxyl substituents 
to ketone (oxo) groups. Their actions are locus- and orientation-specific. Enzymes 
include: 
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1. 3β-Hydroxysteroid dehydrogenase: converts pregnenolone to progesterone, 
17α-hydroxypregnenolone to 17α-hydroxyprogesterone and 
dehydroepiandrosterone to androsterone 
2. 11β-Hydroxysteroid dehydrogenase: converts cortisol to cortisone 
3. 17-Hydroxysteroid dehydrogenase: converts androstenedione to testosterone 
4. 20α-Hydroxysteroid dehydrogenase: converts progesterone to 20-α-
dihydroprogesterone 
1.4.1.2 The mixed function oxidases 
Mixed-function oxidases create hydroxyl groups (‘hydroxylation’) using a molecule of 
oxygen, the second atom of which is reduced to water. They are haem-containing 
enzymes specific for locus and orientation. Cytochrome P450 (CYP450) enzymes 
participate in steroidogenesis and the synthesis of bile acids, prostaglandins and fatty 
acids as well as the metabolism of drugs and natural products. They contain haem and 
are capable of catalysing numerous reactions including hydroxylation, peroxidation, 
sulfoxidation, N-oxidation, epoxidation, deamination and desulfuration (Lisurek and 
Bernhardt 2004, Hille, Hu et al. 2009). There are six cytochrome P450 enzymes 
involved in steroidogenesis:  
1. cholesterol side-chain cleavage enzyme, SCC, desmolase (CYP11A1) 
2. 11β-hydroxylase (CYP11B1) 
3. aldosterone synthase (CYP11B2) 
4. 17α-hydroxylase/17,20-lyase (CYP17A) 
5. aromatase (CYP19) 
6. 21-hydroxylase (CYP21). 
Cytochrome P450s act as monooxygenases, using reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) as an electron donor for molecular oxygen reduction: 
RH+NAD(P)H+O2→ROH+NAD(P)+H2O 
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Ferredoxin proteins mediate electron transfer. Adrenodoxin (also called ferredoxin 1 
or FDX-1) is the human adrenal ferredoxin that helps transfer electrons from NADPH 
to CYP450 enzymes, mediating ferredoxin function, as shown in Figure 1-9 (Imamichi, 
Mizutani et al. 2014).  
 
Figure 1-9: Mitochondrial and microsomal P450 redox partners.  
FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), NADPH (nicotin-amide adenine 
dinucleotide phosphate). Modified from (Cederbaum 2015). 
 
The steroidogenic pathways within the adrenal cortex are illustrated in Figure 
1-10 and Figure 1-11. In the zona glomerulosa, there is a single linear pathway 
to aldosterone, whereby cholesterol undergoes side-chain cleavage to 
pregnenolone by CYP11A1, and is then oxidised to progesterone by 3βHSD2. A 
series of hydroxylation reactions then convert progesterone to aldosterone. The 
unique final reaction, catalysed by CYP11B2 (aldosterone synthase), involves 
three consecutive modifications, each utilising one NADPH molecule, one 
oxygen molecule and a mitochondrial electron transfer (Payne and Hales 2004):  
1) 11β-hydroxylation of DOC to produce corticosterone  
2) 18-hydroxylation to 18-hydroxy corticosterone 
3) 18-methyloxidation to formaldosterone 
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Corticosterone is also synthesised in the zona fasciculata but, in the absence of 
aldosterone synthase, is not processed further. However, the human zona fasciculata, 
unlike the zona glomerulosa, does express 17α-hydroxylase (CYP17A1). This 
microsomal enzyme acts on either pregnenolone or progesterone; their 17α-
derivatives are then subject to further conversions to form cortisol. 11β-Hydroxylase 
(CYP11B1), which catalyses the final step from 11-deoxycortisol to cortisol, has 
considerable homology with aldosterone synthase. These two enzymes are discussed 
in more detail in Section 1.4.2.3. 
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Figure 1-10: Chemical structure of steroid hormones in aldosterone and cortisol biosynthesis. Red indicates CYP11B2- and CYP11B1-mediated conversions. 
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Figure 1-11: Steroid hormone biosynthesis pathway. Reactions within the yellow dotted line occur in the zona glomerulosa. 
The conversion of cholesterol to pregnenolone is catalysed by P450scc (CYP11A1). Pregnenolone is converted to progesterone by 3βHSD. Progesterone undergoes 21-hydroxylation 
by CYP21A1 to produce DOC (11-Deoxycorticosterone). The conversion of DOC to aldosterone involves 3 reactions: 11β-hydroxylation of DOC to produce corticosterone, 18-
hydroxylation to yield 18-hydroxycorticosterone and 18-methyloxidation to form aldosterone.
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1.4.2 Control of corticosteroid biosynthesis and secretion 
1.4.2.1 Cortisol 
1.4.2.1.1 Hypothalamo-pituitary-adrenocortical (HPA) Axis 
 
The production of cortisol is primarily regulated by ACTH via the hypothalamo-
pituitary-adrenocortical (HPA) axis (Figure 1-7). Stimulation of the HPA axis occurs 
through stressors such as anxiety, pain, fear, arousal, aversive reaction and many 
others (Jeansok J. Kim 2001, Heinrichs and Koob 2004). This activates release of 
corticotropin-relasing hormone (CRH) and arginine vasopressin (AVP) from the 
hypothalamus into the hypothalamo-pituitary portal system. CRH increases cAMP and 
Ca2+ levels in corticotropic cells. Both cAMP and Ca2+ are known to increase pro-
opiomelanocortin (POMC) mRNA levels. Aside from these second messengers, POMC 
gene transcription is also regulated by a variety of hormones and neuropeptides. 
POMC is a precursor polypeptide (241 amino acid residues) that is cleaved to form 
multiple peptide hormones including ACTH, melanotropins and opioid peptides of the 
β-endorphin family (Boutillier, Monnier et al. 1995). These initiate ACTH release by 
the corticotropic cells (Vedder 2007). ACTH activates transmembrane heterotrimetric 
G protein ACTH receptors (MCR2) to generate cAMP as a second messenger (Côté, 
Payet et al. 1999). cAMP then activates cAMP-dependent protein kinase A (PKA), 
which phosphorylates target proteins. Increased cortisol exerts negative feedback 
inhibition on CRH and ACTH at the transcriptional and secretion levels (Kellendonk, 
Tronche et al. 2002). Other stimulants of the HPA include interleukin-3 (IL-3) and 
interleukin-6 (IL-6) (Weber, Michl et al. 1997).  
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Figure 1-12: The Hypothalamic-Pituitary-Adrenocortical (HPA) Axis. 
CRH in the hypothalamus stimulates ACTH at the anterior pituitary. By activating ACTH receptors in 
the adrenal gland, this will lead to cortisol secretion in the adrenal zona fasciculata. High levels of 
cortisol will inhibit the production of ACTH and CRH via a negative feedback-loop. Corticotropin-
releasing hormone (CRH); ACTH: Adrenocorticotropic hormone. 
 
1.4.2.2 Aldosterone 
1.4.2.2.1 The Renin-angiotensin-aldosterone system (RAAS) 
 
The RAAS is summarised in Figure 1-13. Its active product is angiotensin II (Angio II), a 
pressor octapeptide which is released in response to sodium deprivation or falls in 
intravascular volume. It stimulates the zona glomerulosa to produce aldosterone, 
principally through the Angiotensin Type 1 receptor (AT1), which will lead to 
aldosterone secretion (Guo, Sun et al. 2001). Binding of Angio II to the AT1 receptor 
activates the phosphoinositide-specific phospholipase C (PLC) to hydrolyse 
phosphatidylinositol 4,5-biphosphate (PIP2) and generate two second messengers, 
DAG and inositol 1,4,5-triphosphate (IP3). Diacyglycerol (DAG) has been shown to 
stimulate PKC (Bollag, Barrett et al. 1990) and selective PKC inhibitors reduce Angio 
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II-induced aldosterone synthesis (Kapas, Purbrick et al. 1995). IP3 stimulates 
aldosterone production by activating the calcium/calmodulin-dependent protein 
kinases (CaMK) and increasing calcium concentration in the cytoplasm (Hattangady, 
Olala et al. 2012); again , their inhibition decreases Angio II-induced aldosterone 
synthesis (Ganguly, Chiou et al. 1990). 
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Figure 1-13: Regulation of aldosterone biosynthesis under the Renin-Angiotensin-Aldosterone System (RAAS). 
Low intravascular blood volume (and therefore pressure) activates renin activity (secreted from renal juxtaglomerular kidney cells) and conversion of angiotensinogen to Angio I. ACE 
secretion from lungs and renal cells convert the Angio I to Angio II. Angio II binds to AT1-receptor and activates PLC. PLC then hydrolyses PIP2 and generates IP3 and DAG. 
Subsequently DAG activates PKC for vasoconstriction at the afferent arteriole of kidney and reduces aldosterone synthesis. IP3 activates the calmodulin/Ca2+-dependent protein 
kinase (CaMK), increases intracellular calcium and activates CREB. Another cascade involved in increasing aldosterone secretion involves potassium. Increased extracellular 
potassium leads to cell membrane depolarisation and opening of the voltage-dependent Ca2+ channel, activating cAMP and CREB. ACTH also stimulates aldosterone by binding of the 
ACTH receptor. This leads to dephosphorylation of ATP by adenyl cyclase to generate cAMP. cAMP then activates the PKA and leads to CREB phosphorylation; through several 
enzymatic processes it will increase aldosterone production.  ACTH: Adrenocorticotropic hormone, AT1-receptor: Angiotensin type 1 receptor, CaMK: Calmodulin kinase, IP3: Inositol 
triphosphate; MP: Membrane potential; PKC: Protein kinase C; PKA: Protein kinase A; PLC: Phospholipase C; PIP: Phosphatidyl inositol diphosphate, SF-1: Steroidogenic factor 1. 
Modified from (Delcayre and Silvestre 1999) 
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1.4.2.2.2 Potassium ions (K+) 
 
Zona glomerulosa cells are highly sensitive to changes in potassium level. An increase 
in serum potassium of 0.1mEq/l increases serum aldosterone by 25% (Himathongkam, 
Dluhy et al. 1975). Increased extracellular K+ concentration depolarises the cell 
membrane, opening voltage-dependent L- and T-type Ca2+ channels. The consequent 
influx of Ca2+ again activates CaMK, which phosphorylate transcription factors 
required for CYP11B2 expression (Connell and Davies 2005). Further Ca2+ is released 
from intracellular stores (Spät and Hunyady 2004). 
1.4.2.2.3 Adrenocorticotrophic hormone (ACTH) 
 
In humans and experimental animals, acute infusion of ACTH stimulates aldosterone 
production through the cAMP pathway (Connell and Davies 2005). However, chronic 
stimulation of ACTH suppresses plasma aldosterone (Hattangady, Olala et al. 2012). 
Chronically, ACTH may convert the phenotype of glomerulosa cells into cortisol-
producing fasciculata cells or divert precursors from the mineralocorticoid to the 
glucocorticoid pathway (Hornsby, O′Hare et al. 1974). 
1.4.2.2.4 Endothelin, serotonin and adipose tissue 
 
Endothelin is a potent vasoconstrictor and may stimulate zona glomerulosa cells to 
secrete aldosterone (Pecci, Cozza et al. 1994, Zhang, Azhar et al. 2012). Although the 
number of endothelin receptors is equal to those of AT1, endothelin is a weak 
aldosterone secretagogue compared to Angio II, K+ and ACTH (Williams 2005). 
Serotonin is also a weak stimulator of aldosterone synthesis; the serotonin precursor, 
5-hydroxytryptophan increases plasma aldosterone while serotonin antagonist reduces 
it (Shenker, Gross et al. 1985). 
Adipose cells secrete several products of linoleic acid oxidation and other 
secretagogues that stimulate aldosterone production (Goodfriend, Ball et al. 2002, 
Ehrhart-Bornstein, Lamounier-Zepter et al. 2003). Plasma aldosterone levels and body 
57 
 
mass index correlate positively and there is an increased prevalence of 
hyperaldosteronism in obese patients (Calhoun and Sharma 2010). Recently, a study 
utilising human adrenal and H295R cells reported that obesity (endogenous leptin) and 
infusion (exogenous leptin) increased CYP11B2 expression and aldosterone in dose-
dependent manner (Huby, Antonova et al. 2015). 
1.4.2.3 CYP11B1 and CYP11B2 
Aldosterone synthase (also known as CYP11B2 or P450c11b2) has a molecular mass of 
48.5 kDa and is expressed in the zona glomerulosa, where it is located on the inner 
mitochondrial membrane (Curnow, Tusie-Luna et al. 1991). CYP11B2 gene 
transcription can be stimulated by Angio II, cAMP and K+ (Clyne, Zhang et al. 1997). In 
gene transfection studies, CYP11B2 promoter activity is directly activated by Nur-
related factor 1 (NURR-1 or NR4A2) and neuron-derived orphan receptor 1(NOR-1 or 
NR4A3) (Nogueira, Xing et al. 2009); both can be upregulated in the zona glomerulosa 
by Angio II (Bassett, Suzuki et al. 2004). 
The 11β-hydroxylase enzyme (P450c11b1) is encoded by the CYP11B1 gene, which is 
highly homologous with CYP11B2; they exhibit 95% similarity in the coding sequence 
and 90% similarity in intronic regions (Payne and Hales 2004). CYP11B1 and CYP11B2 
are located in tandem, 40 kb apart, on chromosome 8q21; each consists of 9 exons. 
See Figure Figure 1-14. The greatest difference between the genes lies in their 5’ 
untranslated regions, accounting for the differences in their expression (Mornet, 
Dupont et al. 1989), while minor differences in their coding regions result in their 
differing enzymatic functions. 
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Figure 1-14: Genomic tandem structure of CYP11B2 and CYP11B1 and the Ideogram of 
human chromosome 8.  
CYP11B2 and CYP11B1 located at 8q24.3. Red indicates the centromere. Modified from (Portrat, 
Mulatero et al. 2001, NCBI 2014). 
 
1.4.2.3.1 Polymorphisms of CYP11B2 and CYP11B1 
 
The CYP11B2 and CYP11B1 genes are highly polymorphic. The most commonly-studied 
CYP11B2 polymorphism is a C/T variant located at position ‑344, relative to the 
coding region (rs1799998). This polymorphism has been significantly associated with 
altered blood pressure and aldosterone levels (White and Slutsker 1995). Davies et al 
(1999) reported that the T-allele at -344 occurs more frequently in hypertensive 
patients and associates with significantly higher levels of aldosterone metabolite 
(tetrahydroaldosterone) in the urine compared to -344C groups (Davies, Holloway et 
al. 1999). This site corresponds to a steroidogenic factor-1 (SF-1) binding site,  
although in vitro analysis showed the polymorphism had no significant effect on SF-1 
binding (Bassett, Zhang et al. 2002). More recently, analysis suggests that rs1799998 is 
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not itself a functional polymorphism (Niu, Guo et al. 2010), it may be in linkage 
disequilibrium with one. 
1.4.2.3.2 Transcription Factors and miRNA influencing CYP11B2 and CYP11B1 expression 
 
Transcription factors (TFs) bind specific sites in the promoter/ 5’UTR region of a gene 
to inhibit or stimulate gene expression. TFs, such as neuronal growth factor-induced 
clone B (NGFI-B), regulate aldosterone synthase, 11β-hydroxylase, 3β-hydroxysteroid 
dehydrogenase, 17α-hydroxylase, and 21-hydroxylase in the adrenal gland (Nogueira 
and Rainey 2010, Romero, Gomez-Sanchez et al. 2010). The members of the NGFI-B 
nuclear orphan receptor superfamily include NR4A1 (Nur77, NGFI-B), NR4A2 (Nurr1) 
and NR4A3 (Nor1), and are abundantly expressed in the adrenal cortex (Romero, 
Gomez-Sanchez et al. 2010). NGFI-B is upregulated in the presence of Angio II in the 
H295R adrenocortical cell line (Romero, Gomez-Sanchez et al. 2010)  and a NGFI-B 
response element (NBRE) has been identified within the CYP11B2 promoter that 
regulates transcription (Nogueira and Rainey 2010). Other important transcription 
factors for CYP11B2 and CYP11B1 are cAMP-responsive element binding proteins 
(CREBs), which are shown to be subject to Angio II-regulated phosphorylation in 
several tissues. NURR1 can act synergistically with members of the CREB family to 
increase CYP11B2 expression (Nogueira and Rainey 2010). 
Transcription of CYP11B1 is also modulated by SF-1 (Wang, Bassett et al. 2000). In a 
luciferase reporter construct study, co-transfection of vectors encoding SF-1 up-
regulated expression of CYP11B1 but not CYP11B2; also,  mutation of SF-1 inhibited 
CYP11B1 transcription (Bassett, Zhang et al. 2002). According to Bassett et al, the 
exception of CYP11B2 from being downregulated by SF-1 is probably due to the 
concentration of SF-1 plasmid used in the study. Other study showed that SF-1 has a 
repressor domain, therefore this enable the SF-1 to downregulate CYP11B2 and not 
vice versa (Ou, Mouillet et al. 2001). 
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In addition to the transcription factors modulating CYP11B2 and CYP11B1, another 
factor of importance has emerged: microRNA (miRNA). This will be further discussed 
in Section 1.7.1. 
1.5 The adrenal cortex and disease 
Disruption of corticosteroidogenesis has profoundly negative health implications. 
Adrenal failure (Addison’s disease) disrupts both electrolyte and energy metabolism 
and, without treatment, is fatal. The effects of excess cortisol or aldosterone have 
already been described and are similarly debilitating. These extreme conditions are 
rare, comprising principally adrenocortical neoplasia and monogenic disorders of 
specific enzymes’ gene expression. These are briefly summarised below. Recent 
studies, however, suggest that small deviations from normal gene expression, when 
sustained over a lifetime as the result of, for example, polymorphic variation or 
changes in regulatory factors, may be important and common determinants of health. 
1.5.1 Adrenal tumours 
1.5.1.1 Aldosterone-producing adenoma (APA) 
Primary aldosteronism (PA) is the most common cause of secondary hypertension 
(Scholl and Lifton 2013) and is characterized by high blood pressure, increased 
aldosterone secretion, hypokalaemia and low renin level. It may be associated with 
increased risk of renal (Rossi, Bernini et al. 2006) and cardiac disease (Anand, Mooss 
et al. 2006). In 30-40% of patients, PA is due to a unilateral aldosterone-producing 
adenoma (APA) (Ye, Mariniello et al. 2007, Sahay and Sahay 2012)  and more than 60% 
of PA is due to bilateral adrenal hyperplasia (BAH) (Freel and Connell 2005). Adrenal 
carcinoma is much less frequent. According to the Endocrine Society’s diagnostic 
guidelines (2008), the initial step differentiating APA from BAH is a computerised 
tomography (CT) scan, which will also exclude adrenal carcinoma where the lesion is 
usually more than 4 cm. APAs are usually less than 3 cm. BAH shows abnormality of 
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both adrenal glands. Confirmation is by adrenal venous sampling (Sahay and Sahay 
2012). Differences between APA and BH are summarized in the Table 1-2. 
Table 1-2: Major differences between Aldosterone Producing Adenoma (APA) and Bilateral 
Adrenal Hyperplasia (BAH). ACTH: Adrenocorticotrophic Hormone; AVS: A drenal Venous 
Sampling; PA: Primary Aldosteronism; ZF: Zona Fasciculata; ZG: Zona Reticularis. 
Modified from (Freel and Connell 2005). 
  
Feature Aldosterone-Producing 
Adenoma 
Bilateral adrenal 
hyperplasia 
Approximate 
proportion of all PA 
1/3 2/3 
Imaging common 
finding 
Unilateral solitary Normal or bulky 
adrenal 
Common pathologic 
findings 
Predominantly ZF cells Multiple nodules in the 
ZF or diffuse 
hyperplasia of ZG 
Postural response  Variable (many adenomas 
are ACTH responsive) 
Maintained 
Finding on AVS Increased aldosterone to 
cortisol ratio in affected 
adrenal side 
No difference in 
aldosterone to cortisol 
ratio between adrenal 
veins 
Treatment Laparoscopic surgery Medication 
(Aldosterone 
antagonists) 
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1.5.1.2 Gene mutations in APA 
1.5.1.2.1 KCNJ5 
 
In APA, about 30–60% of cases have somatic mutation of the G-protein-activated 
inward rectifying potassium channel Kir3.4, which is encoded by the KCNJ5 gene 
(Gomez-Sanchez and Oki 2013). The Kir3.4 channel is a tetrameric complex with an 
extracellular pore-forming region that binds with other K+ channels (e.g. Kir3.1) to 
form heterotetrameric or homotetrameric complexes (Ishihara, Yamamoto et al. 
2009, Zennaro and Jeunemaitre 2011). Mutation of K+ channels can alter the 
selectivity filters to K+, making them non-selective channels (Heginbotham, Lu et al. 
1994, Dibb, Rose et al. 2003).  
In the resting state, zona glomerulosa cells have negative resting potentials and 
steroidogenesis remains inactive (Guagliardo, Yao et al. 2012); K+ channels, including 
Kir3.4, TASK-1 to TASK-5 and Twik-Related Potassium Channel 1, are all intact and 
intracellular K+ is released to extracellular compartments. Angio II decreases K+ 
transport through the channel and also decreases the expression of Kir3.4 channel. 
This causes membrane depolarization and voltage-dependent Ca2+ channels to open, 
increasing Ca2+ influx and stimulating the calcium-calmodulin pathway. These events 
increase the expression of CYP11B2 and therefore aldosterone production. In the case 
of a somatic mutation of KCNJ5, there is a loss of selectivity of the Kir3.4 channel, 
allowing the influx of Na+ that leads to membrane depolarization, calcium influx and 
subsequent increase in CYP11B2 gene expression (Choi, Scholl et al. 2011). 
1.5.1.2.2 ATP1A1 and ATP2B3 
 
In a study of 112 APA patients, 6.3% had a somatic mutation of ATP1A1 together with 
increased CYP11B2 gene expression (Williams, Monticone et al. 2014). In an earlier 
study of a European cohort, the prevalence of the somatic mutation of ATP1A1 was 
5.2% of 308 APA patients (F. Beuschlein 2013). ATP1A1 exchanges three Na+ in the 
cytoplasm for two K+ from the extracellular compartment, each time an ATP is 
hydrolysed (Kaplan 2002). The ATP1A1 gene encodes the Na+/K+-ATPase 1 that 
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responsible for maintaining the electrochemical gradient of Na+ and K+ across the 
plasma membrane. Blockade of the Na+/K+-ATPase pump by ouabain increases 
aldosterone synthesis in a dose-dependent manner (Yingst, Davis et al. 1999). The 
ATP1A1 knockout mouse has been shown to have higher plasma aldosterone compared 
to its wild-type counterpart (Moseley, Huddleson et al. 2005).  
ATP2B3 encodes the plasma membrane Ca2+ ATPase 3 (known as PMCA3), important 
for exporting Ca2+ from the cytoplasm to extracellular compartments (Di Leva, Domi 
et al. 2008). The mutation of this gene is predicted to increase intracellular Ca2+ 
concentration and increase aldosterone synthesis (F. Beuschlein 2013). This is 
supported by the finding that almost 1% of APA have an ATP2B3 mutation and high 
levels of CYP11B2 gene expression (Williams, Monticone et al. 2014). 
1.5.1.2.3 WNT β-catenin Pathway in APA 
 
Alteration of WNT/β-catenin signalling was detected in 70% of APA (Berthon, Drelon 
et al. 2014). The Wnt/β-catenin is important in embryonic development and cell 
renewal (Berthon, Sahut-Barnola et al. 2010) and has been associated with the 
development of numerous cancers (Anastas and Moon 2013).  
Initially, WNT (previously called Int-1) was shown to induce breast tumours in the 
mouse (Nusse and Varmus 1982). WNT1 stands for Wingless-type MMTV integration site 
family, member 1. In the absence of WNT ligands, β-catenin (encoded by CTNNB1 
gene) is phosphorylated by a complex consisting of casein kinase I (CKI), GSK3β, AXIN 
and APC at N-terminal serine/ threonine residues. The phosphorylated β-catenin is 
ubiquitinylated and degraded by proteasomes. However, in the present of WNT 
ligands, it binds to Frizzled/LRP receptor which inhibits the complex destruction and 
therefore stabilizes β-catenin. β-Catenin is translocated to the nucleus and co-
operates with transcription factors of the LEF/TCF family (Berthon, Sahut-Barnola et 
al. 2010). The lymphoid enhancer factor (LEF)/T cell factor protein (TCF) recruits β-
catenin along with its co-activators to the WNT response element (WREs) to stimulate 
the transcription of target genes (Arce, Yokoyama et al. 2006). β-Catenin mutation 
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has been observed in ACA and ACC tissue (Tissier, Cavard et al. 2005). Furthermore, 
mutation at the third exon of CTNNB1 causes abnormal accumulation of β-catenin 
leading to various pathological adrenal conditions such as the primary pigmented 
nodular adrenocortical disease  and sporadic secreting adrenocortical adenomas 
(Tadjine, Lampron et al. 2008). There is abundant evidence that alteration of WNT/β-
catenin can modulate adrenocortical tumours: the β-catenin blocker PKF115-584 
inhibits adrenocortical carcinoma cell proliferation (Doghman, Cazareth et al. 2008). 
Therefore, WNT/β-catenin pathway might be a potential therapeutic target. 
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1.5.1.2.4 Steroidogenic Enzymes Mutation Causing Congenital Adrenal Hyperplasia 
(CAH). 
 
In rare cases, mutation of gene can cause severe abnormalities and lead to 
hypertension. There are common clinical signs that relate to genetic 
abnormalities as shown Table 1-3. 
 
Table 1-3: Steroidogenic Enzymes that contribute to CAH. 
Enzyme Aldosterone  
synthase 
3-β 
hydroxysteroid 
dehydrogenase 
11-β 
hydroxylase 
17-α 
hydroxylase 
21- 
hydroxylase 
Encoding gene CYP11B2 HSD3B2 CYP11B1 CYP17 CYP21A 
Incidence Rare Rare 1 in 10000 Rare 1 in 14000 
Ambiguous 
genitalia  
Nil  Males 
Mild in females 
Females Males 
Failure of 
pubertal 
development 
in females 
Females 
Glucocorticoids Normal Low Low Low Low 
Mineralocorticoids Low Low High High Low 
Androgens Normal Low in males 
High in females 
High low High 
Blood pressure Low Low High High Low 
Sodium level Low Low High High Low 
Potassium level High High Low Low High 
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1.6 Hypertension studies 
1.6.1 Monogenic disorders 
Numerous monogenic disorders leading to hypertension have been identified. The 
majority affect electrolyte transport at the distal tubule, directly or indirectly, by 
altering mineralocorticoid secretion. Monogenic disorders share several common final 
mechanisms: they escalate sodium and chloride reabsorption at the distal nephron, 
cause plasma volume expansion and decrease plasma renin activity (Garovic, Hilliard 
et al. 2006, Simonetti, Mohaupt et al. 2012). Although such disorders are rare, they 
illustrate the clear genetic influence on BP and haemodynamic, and are of great 
research interest. Monogenic hypertension can present with severe hypertension, 
early onset (although not always) and often with a positive family history. Low-renin 
activity and metabolic acidosis with hyperkalaemia or metabolic alkalosis with 
hypokalaemia are characteristic but plasma aldosterone concentration may be low as 
that of the minor mineralocorticoid, DOC, is often markedly increased (Simonetti, 
Mohaupt et al. 2012). Examples of monogenic disorders are shown in Table 1-4.  
Smaller but still significant variations in the activity of these systems may exist to a 
wide extent in the general population. These have been sought using various different 
techniques. 
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Table 1-4: Summary of Monogenic Loci Associated with BP (Modified from Padmanabhan, 
Caulfield et al. 2015). 
  
Locus Gene Monogenic Syndrome  Inheritance Blood 
pressure 
1p36.13 CLCNKB Bartter syndrome, type 3 Autosomal 
recessive 
Low 
1p31.1 ATP1A1 Sporadic aldosterone 
producing adenoma 
 High 
2q36.2 CUL3 Pseudohypoaldosteronism, 
type IIE 
Autosomal 
dominant 
High 
3p25.3 VHL von Hippel–Lindau 
syndrome 
Autosomal 
dominant 
High 
3p21.3 CACNA1D Sporadic aldosterone 
producing adenoma 
 High 
4q31.2 NR3C2 Hypertension exacerbation 
in pregnancy, 
Pseudohypoaldosteronism 
type I 
Autosomal 
dominant 
Low 
8q24.3 CYP11B1, 
CYP11B2 
Familial hyperaldosteronism 
type 1 glucocorticoid 
remediable aldosteronism, 
 
Autosomal 
dominant 
High 
  Corticosterone 
methyloxidase II deficiency 
Autosomal 
recessive 
High 
  Steroid 11β-hydroxylase 
deficiency 
Autosomal 
recessive 
High 
10q11.2 RET Multiple endocrine 
neoplasia, type IIA 
Autosomal 
dominant 
High 
10q24.3 CYP17A1 17-alpha-hydroxylase 
deficiency 
Autosomal 
recessive 
High 
11q24.3 KCNJ5 Familial Hyperaldosteronism 
type III 
Autosomal 
dominant 
High 
12p12.3 WNK1 Pseudohypoaldosteronism 
type IIC Gordon syndrome 
Autosomal 
dominant 
High 
16p12.2 SCNN1B, 
SCNN1G 
Liddle Syndrome Autosomal 
dominant 
High 
16q13 SLC12A3 Gitelman syndrome Autosomal 
recessive 
Low 
16q22.1 HSD11B2 Apparent Mineralocorticoid 
Excess 
 High 
Xq28 ATP2B3 Sporadic 
aldosteroneproducing 
adenoma 
 High 
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1.6.2 Candidate gene analysis 
 
Candidate gene analysis predicts from clinical and physiological research over many 
years those genes affecting blood pressure and tests their importance in study 
populations. This is illustrated by studies of CYP11B1 and CYP11B2 and other genes 
that affect their expression. Angiotensinogen, which is encoded by the AGT gene, a 
constituent of the renin-angiotensin-aldosterone system, cleaves product of 
angiotensin I, angiotensin II and angiotensin III which are regulators of BP via water 
and sodium homeostasis (Padmanabhan, Caulfield et al. 2015). Many SNPs have been 
identified in the coding and non-coding regions of the AGT gene. Although AGT SNPs 
have been reported to associate with hypertension, results have been inconsistent.  
The SNPs -217AA and -6GG associated with increased risk of hypertension, and a weak 
linkage was also found for the G-217A and A-6G polymorphisms (Wu, Chiang et al. 
2004). 
Choi et al identified a KCNJ5 gene mutation in APA and in hereditary hypertension 
(Choi, Scholl et al. 2011). To date, 5 different types of KCNJ5 mutation have been 
identified and most of them cause depletion in membrane selectivity, causing sodium 
leakage that leads to membrane depolarization and opening of voltage-gated Ca2+ 
channels, as described above (Williams, Monticone et al. 2014). 
1.6.3 Linkage analysis 
 
The aim of linkage analysis is to identify genomic loci that influence specific 
characteristics, known as quantitative trait loci (QTL). The best example of linkage 
studies in hypertension is probably the British Genetic of Hypertension (BRIGHT) study 
(Caulfield, Munroe et al. 2003). The increased use of genome-wide association studies 
(GWAS) (see below) has reduced linkage analysis use, but the recent availability of 
whole-genome sequencing (WGS) may cause it to increase again (Ott, Wang et al. 
2015). Linkage is assessed by a specific score called logarithm of the odds (LOD), the 
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standard score for linkage mapping of major genes, based on disease related 
phenotypes; positive LOD scores indicate the presence of linkage (Morton 1996).  
Identification of specific regions of the chromosome linked to a monogenic trait in 
hypertension can be performed using linkage analysis by genotyping (Padmanabhan, 
Caulfield et al. 2015). Louis-Dit-Picard et al combined linkage analysis with whole 
exome sequencing to identify KLHL3 gene mutations in familial hyperkalemic 
hypertension (FHHt) (Louis-Dit-Picard, Barc et al. 2012). A list of linkage studies is 
provided in Table 1-5. 
Table 1-5: Selected linkage studies in hypertension 
Study Chromosomal 
Region 
Participant 
(Pan, Chen et al. 
2000) 
17q 
 
59 Han Chinese families in Taiwan 
 
 
(Rao, Province et al. 
2003) 
2p HyperGEN network; 
650 African American sibling pairs 
915 white sibling pairs 
 
(Province, Kardia et 
al. 2003) 
2p GenNet, GENOA, HyperGEN, SAPPHIRE 
network; 
6245 participant 
 
(Shmulewitz, Heath 
et al. 2006) 
20p12 2188 participant from Pacific Island of 
Kosraen, Federated States of Micronesia 
 
(Caulfield, Munroe et 
al. 2003) 
6q British Genetics of Hypertension (BRIGHT) 
study; 
2010 sibling pairs from 1599 severely 
hypertensive family  
 
(Koivukoski, Fisher 
et al. 2004) 
2p12-q22.1 
3p14.1-q12.3 
Metaanalysis in Caucasians 
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1.6.4 Genome-wide association studies 
 
The genome-wide association study (GWAS) identifies genomic variation associated 
with a specific trait – in particular disease – across the human genome. The method is 
currently being used to look for association between BP and SNPs distributed 
throughout the entire genome by linear regression for continuous phenotypes or by 
logistic regression for dichotomous phenotypes (Ehret and Caulfield 2013). High-
throughput genotyping using microarray chips enables the researcher to detect up to 
a million SNPs in thousands of subjects. GWAS is connected to linkage disequilibrium 
(LD) for functional variants (Padmanabhan, Newton-Cheh et al. 2012). For example, a 
study by Padmanabhan et al. showed that rs13333226 associates with hypertension 
and chronic kidney disease (Padmanabhan, Melander et al. 2010). 
Several GWAS have recognised the CYP17A1 locus as associated with hypertension 
(Levy, Ehret et al. 2009, Newton-Cheh, Johnson et al. 2009). 17α-Hydroxylase 
deficiency is an autosomal recessive defect of the CYP17A1 gene causing depletion of 
glucocorticoid and sex steroids with simultaneous mineralocorticoid (DOC) excess 
(Goldsmith, Solomon et al. 1967, MM Grumbach 2003). Patients present with 
hypertension and hypokalaemia (Yanase, Simpson et al. 1991, Miller and Auchus 
2011). Recently, the focus GWAS has brought to bear on the CYP17A1 locus has 
resulted in the identification of common SNPs with functional effects that may 
explain its association with blood pressure (Diver, MacKenzie et al. 2016). 
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1.7 The nature, synthesis and regulatory role of 
microRNA. 
1.7.1 microRNA 
MicroRNA (miRNA) are small single-stranded non-coding RNAs (ncRNA), 18–22 
nucleotides (nt) long, which regulate target messenger RNA (mRNA) levels post-
transcriptionally through cleavage or translational repression (Bartel 2004). miRNA 
bind to a specific 3’untranslated region (3’UTR) located on the target mRNA or, less 
commonly, to a protein-coding (CDS) or 5’UTR sequence. They are estimated to 
regulate the transcription of approximately 30% of the human protein-coding genome. 
The first miRNA to be recognized was the nematode Caenorhabditis elegans small 
non-coding RNA (ncRNA), lin-4, in 1993. This was shown to be an important agent in 
its its development.  Many more have since been discovered in many species and they 
were officially named miRNAs in 2001 by Ruvkun (Ruvkun 2001, Jeffrey 2008). By 
2014, 2469 novel human miRNAs had been identified and 1098 of these had been 
validated experimentally (Friedlander, Lizano et al. 2014). The discovery of miRNA 
regulation of mRNA transcription has been a huge breakthrough. Over the last 20 
years, the number of miRNA studies has grown exponentially, studying mechanisms, 
function and relevance to disease. The following sections outline the structure, 
synthesis and action of miRNAs, mainly in the human and with particular reference to 
adrenocortical function. 
1.7.2 miRNA structure. 
The biogenesis of miRNAs differs from that of other RNAs since they derive from 
transcripts that fold back on themselves to form a distinctive hairpin structure 
due to sequence complementary (Bartel 2004). See Figure 1-15. 
1.7.3 miRNA biogenesis. 
miRNA biogenesis is summarised in Figure 1-16 and in the following sections. 
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1.7.3.1 In the nucleus.  
miRNAs are encoded by DNA which may be situated in introns or exons, or else be 
scattered among intergenic sequences (Jeffrey 2008). miRNAs are transcribed from 
the genome by RNA polymerase II or RNA polymerase III to form a primary-miRNA (pri-
miRNA) transcript (Lee, Kim et al. 2004, Borchert, Lanier et al. 2006). Pri-miRNA is 
several kilobases long and contains at least one hairpin-like structure, or often several 
stem-loop structures (a polycystronic pri-miR). Polycystronic pri-miRNAs are called 
clusters; they will be discussed later. A pri-miRNA contains one stem structure 
consisting of a polyadenylated tail (poly(A)) at the 3’ end and a 7-methyl-guanylate 
cap at the 5’ end (Cai, Hagedorn et al. 2004).  
Regulation of pri-miRNA transcription involves adenosine deaminase action on RNA 
(ADAR). This deaminase catalyses conversion of adenosine nucleotides to inosine in an 
editing process known as A-to-I (Luciano, Mirsky et al. 2004). The editing process can 
affect miRNA processing by preventing dsRNA from being recognized and cleaved by 
Dicer (Scadden 2005), which would impair miRNA maturation (Kawahara, Megraw et 
al. 2008). pri-miRNA processing in mammalian cells requires heme. Unprocessed pri-
miRNAs  are quickly degraded via an as-yet unknown pathway so that they do not 
accumulate in the nucleus (Weitz, Gong et al. 2014). 
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Figure 1-15 : miRNA stem-loop structure. 
miRNA consists of a miRNA duplex (red & grey), lower and upper stems (green & blue) and a terminal loop (blue colour). The miRNA duplex is 
further processed to form two separate mature miRNAs. The miRNA structure shown is based on the miR-17 stem-loop sequence.
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Figure 1-16: miRNA biogenesis from genomic DNA illustration.  
The biogenesis starts with pri-miRNA transcription from genomic DNA. The stem-loop sequence of the pri-miRNA is cleaved by Drosha with DGCR8 to form pre-miRNA. The pre-
miRNA is then exported to the cytoplasm by Exportin-5 through nucleoporin. It is further processed to a mature miRNA sequence by Dicer-2 with AGO2 and TRBP assistance. The 
mature miRNA is incorporated by the RISC complex and binds mRNA targets to cause translational repression or mRNA degradation. Modified from (Sethi, Kulkarni et al. 2013).
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The stem-loop sequence of pri-miRNA is cleaved at the stem junction with the 
hairpin structure by RNAse III Drosha to form precursor-miRNA (pre-miRNA). 
Drosha requires the DiGeorge syndrome critical region in gene 8 (DGCR8) which 
is a double-stranded RNA-binding protein in Homo sapiens. (This function is 
served by Pasha in Drosophila melanogaster and C. elegans (Denli, Tops et al. 
2004, Han, Lee et al. 2004, Lee, Kim et al. 2004).) Drosha and DGCR8, which are 
highly conserved in animals, form the large microprocessor complex. The C-
terminal domain of DGCR8 interacts with the middle domain of Drosha to 
stabilize the complex (Yeom, Lee et al. 2006). There are 3 alternative models 
describing how Drosha identifies a pri-miRNA: 
(a) Drosha identifies its cleavage site on the 5’ end of pri-miRNA due to 
significant enrichment of 2–4 nt symmetrical internal loops near the 
cleavage site (Warf, Johnson et al. 2011).  
(b) Drosha recognizes the cleavage site by its position: ~11 bps from the 
stem-loop junction of the miRNA. DGCR8 may act as a molecular anchor that 
measures the distance (Han, Lee et al. 2006).  
(c) Drosha crops by reference to the start of the terminal loop of the pri-
miRNA. Even a slight variation in the structure of the terminal loop will 
impair miRNA processing in the nucleus (Zhang and Zeng 2010). 
Apart from Drosha/DGCR8, there are other proteins included in the 
microprocessor complex such as SMAD proteins (Blahna and Hata 2012), the 
DEAD-box helicases p68 (known as DD5X) and p72 (DDX17) (Fukuda, Yamagata et 
al. 2007), heterogeneous nuclear ribonucleoproteins and the Ewing's sarcoma 
family of proteins which contains a RNA recognition motif (RRM) and a zinc-
finger domain (Gregory, Yan et al. 2004). This microprocessor complex then 
cleaves the pri-miRNA to a shorter 60–70nt hairpin known as precursor-miRNA 
(pre-miRNA), a double-stranded RNA hairpin molecule, consisting of a 2-
nucleotide 3’ overhang with an hydroxyl group and a 5’ phosphate group with a 
region of imperfect base-pairing (Cullen 2004). The pre-miRNA is exported to the 
cytoplasm for further processing. 
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1.7.3.2 Nucleus-cytoplasm transportation 
The nuclear envelope (NE) separates the nucleus from the cytoplasm. Pre-
miRNAs are exported from the nucleus into the cytoplasm through the central 
channel of nuclear pore complexes (NPCs), termed nucleoporins, in the nuclear 
envelope. Pre-miR transport depends on Exportin 5 (Exp5) or importin β, a 
specific receptor that recognizes NPCs and interacts with the small Ran GTPase, 
a co-factor that controls the direction of miRNA transport. Exp5 belongs to the 
karyopherin family whose members play a significant general role in the nuclear 
export of noncoding RNAs including tRNAs, snRNAs and rRNAs (Lei and Silver 
2002). Exportin-5 recognizes RNAs containing a minihelix structure, a cis-acting 
export element that consists of a double-stranded stem which has more than 14 
nucleotides and bears a base-paired 5’ end and an approximate 3–8 nucleotide 
protruding 3’ end (Gwizdek, Ossareh-Nazari et al. 2004). The exportin-5-Ran 
GTPase complex exports the pre-miRNA to cytoplasm through the nucleoporins. 
1.7.3.3 Cytoplasmic processing 
Once in the cytoplasm, pre-miRNA is further processed by RNase III Dicer to 
mature miRNA, approximately 22 nucleotides long. Dicer is a highly conserved 
RNase which acts on specific double-stranded RNA (dsRNA) to generate small 
regulatory RNAs (srRNAs), which include miRNAs. Dicer has 2 main domains, C-
terminal and N-terminal, which each have specific properties and functions 
(Figure 1-17). The C-terminal domain comprises a large helicase domain which 
can differentiate between a perfect duplex and a hairpin structure in RNA 
(Doyle, Badertscher et al. 2013), and acts as an autoinhibitor, needed for 
production of small RNAs. This is followed by a small domain of unknown 
function (DUF283). Plant studies suggest that DUF may mediate protein-protein 
interaction with Dicer cofactors and may be involved in dsRBD folding and the 
PAZ domain, a conserved nucleic acid binding structure that plays a vital role in 
the docking of the 2nt 3’overhang dsRNA into the Dicer.(Sawh and Duchaine 
2012). The N-terminal consists of RNAse IIIa and IIIb together with the double-  
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stranded RNA binding domain (dsRBD) which differentiates between pre-miRNA 
and dsRNA substrate (Wostenberg, Lary et al. 2012); this may stabilize the 
interaction between Dicer and its substrate RNA (Zhang, Kolb et al. 2004). 
Deletion of human dsRBD significantly reduces Dicer’s ability to cleave RNAs (Ma, 
MacRae et al. 2008). The distance between the PAZ and RNase III domains is a 
‘molecular ruler’ which Dicer uses to generate RNAs of an exact length (Figure 
1-17) (Sawh and Duchaine 2012).  
miRNA interacts with TRBP and Argonaute 2 (AGO2), one of the components of 
the RNA-inducing silencing complex (RISC) to cleave pre-miRNA and form mature 
miRNA. TAR RNA-binding protein (TRBP) consists of three-double stranded RNAs, 
and is an important component of the Dicer-containing complex. TRBP associates 
with Dicer and AGO2 to form a complex catalysing the cleavage process of pre-
miRNA. A study has shown that TRBP knockdown lead to destabilization of Dicer 
and represses miRNA synthesis (Chendrimada, Gregory et al. 2005). 
 
Figure 1-17: Dicer structure. Adapted from (Sawh and Duchaine 2012).   
 
1.7.3.4 Argonaute Loading  
The process of Argonaute loading of small RNAs differs between species 
(Hutvagner and Simard 2008). The main function of Argonaute is miRNA 
maturation. It is a highly conserved protein complex consisting in mammals of 
four components: AGO1, -2, -3 and -4. However, only AGO2 has a cleavage 
function and is relevant to siRNA regulation (Liu 2004). It consists of four 
domains: the N- terminal, PAZ, Mid and PIWI. The PAZ domain binds to the 3’ 
end of miRNAs  and can distinguish small regulatory RNAs such as miRNA from 
degraded RNAs by their characteristic 3’-overhang (Hutvagner and Simard 2008). 
The PIWI domain acts as a binding pocket for the 5’ end of miRNA (Pillai, 
Bhattacharyya et al. 2007). Argonaute forms a complex with the RISC-loading 
complex (RLC) through an interaction between Dicer-2 and AGO2. It cleaves the 
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passenger strand of the small-interference RNA (siRNA) (Hutvagner and Simard 
2008) leaving the guide strand to form the active complex referred to as the 
miRNA-containing ribonucleoprotein particle (miRNP) (Ender and Meister 2010). 
The selection of RNA strand depends on the thermodynamic stability of the 5’ 
end of the small RNA. This is known as the ‘asymmetry rule’. The less stable 5’-
end will be incorporated into the miRNP and the opposite strand, referred to as 
miRNA* (miRNA star) or the passenger strand, is degraded (Hutvagner and Simard 
2008, Ender and Meister 2010). There are many databases available which 
predict the probability and strength of miRNA:mRNA interaction on the basis of 
thermodynamic properties, including Ingenuity Pathway Analysis. 
1.7.3.5 miRNA Target Repression or Destruction 
Mature miRNAs can either induce the degradation of specific mRNAs or repress 
their translation (Wang, Liang et al. 2008). They achieve this as part of an RNA-
induced silencing complex (RISC), which binds partially to a complementary site 
located within the 3’UTR of its mRNA target. Although most of metazoan miRNA 
targets the  3’UTRs of mRNA (Bartel 2009), targeting can also occur at the 5’UTR 
and open reading frames (ORFs) (Kloosterman, Wienholds et al. 2004). The most 
important factor determining mRNA destabilization or repression is the strength 
of complementarity between the miRNA and the mRNA target. Perfect 
complementarity leads to endonucleolytic cleavage, mediated by AGO2, whereas 
a mismatched bond in the central region of the miRNA leads to translational 
repression (Ender and Meister 2010).  
1.7.3.5.1 Translational Repression 
 
miRNA can repress translation at the initiation step or at the post-initiation 
phase (Petersen, Bordeleau et al. 2006). Several mechanisms have been 
suggested to explain how miRNA regulates mRNA translation, including the 
dissociation of eIF4 from the 5’terminal m7G cap of mRNA, blocking of the 60S 
ribosome subunit, interference of the eIF4 complex’s function and repression of 
the elongation step (Petersen, Bordeleau et al. 2006, Filipowicz, Bhattacharyya 
et al. 2008, Carthew and Sontheimer 2009). Another study reported that AGO 
proteins compete with eIF4E to binding the 5’cap and repress translation 
(Kiriakidou, Tan et al. 2007). 
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1.7.3.5.2  mRNA Degradation 
 
Disruption of the binding of GW182 to e IF4G (Eukaryotic Translation Initiation 
Factor 4 Gamma) and the PABP (poly-A binding protein) can inhibit translation 
initiation and preventing circularisation (Gu and Kay 2010). At the 3’UTR of 
target mRNA, miRNA recruits Argonaute to interact with GW182 which mediates 
deadenylation and shortens the poly(A) tail. GW182 and the AGO1 complex 
recruit deadenylase, which is necessary for the removal of the m7G cap to 
disrupt translation. This is further illustrated by a study showing GW182 
depletion improves mRNA stability (Pillai, Bhattacharyya et al. 2007). Other in 
vivo and in vitro studies report that miRSC recruits NOT, (CAF1 Chromatin 
Assembly Factor 1) and CCR4 (Chemokine (C-C Motif) Receptor 4) to remove the 
3’ poly(A) tail from target mRNA (deadenylation) (Behm-Ansmant, Rehwinkel et 
al. 2006, Wu, Fan et al. 2006). This is followed by a decapping process 
performed by DCP1 (Decapping MRNA 1), DCP2 (Decapping MRNA 2) along with 
EDC4 (Enhancer of MRNA decapping 4) and DDX6 (DEAD (Asp-Glu-Ala-Asp) Box 
Helicase 6) (Figure 1-16). Decapped mRNAs are then removed by XRN1 
(exonuclease) in the cytoplasm (Behm-Ansmant, Rehwinkel et al. 2006, Wu, Fan 
et al. 2006). 
1.7.4 miRNA Clusters 
miRNA clusters are derived from capped and polyadenylated pri-miRNA 
prescursors (Cai, Hagedorn et al. 2004). The majority of miRNAs are encoded 
within intergenic regions but some are encoded within mRNA introns or in ncRNA 
genes (Rodriguez, Griffiths-Jones et al. 2004). There is much evidence to suggest 
that clustered miRNAs are transcribed as polycistrons from long primary 
transcript miRNAs, producing one or more hairpin precursors that show great 
sequence similarity. (Tanzer and Stadler 2004, Altuvia, Landgraf et al. 2005). 
One study showed that if 3000nt is used as a distance threshold, 37% of human 
miRNAs are in such clusters. The percentage increases to almost 50% if the 
distance threshold is set at 10000 nt. The miRNA clusters have a highly 
conserved pattern, suggesting that the expression of the constituent miRNAs is 
co-regulated (Altuvia, Landgraf et al. 2005). miRNA are more clustered than 
other non-coding RNA like snoRNA and tRNA (Altuvia, Landgraf et al. 2005). 
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A microarray profiling study showed that proximal pairs of miRNAs in clusters are 
usually co-expressed. miRNAs encoded less than 50kb apart are usually derived 
from the same transcript. The correlation of expression is reduced significantly 
if this distance exceeds 50 kb. However, there are some miRNAs clusters 
spanning distances of more than 50 kb that can still be highly correlated; these 
include miR-7-miR-9 (>750 kb) and miR-128-miR-138 (8 Mb) (Baskerville and 
Bartel 2005). Another study, using the expressed sequence tag method, also 
showed that distant miRNAs such as miR-100, let-7 and miR-125 may reside on 
the same transcript (Altuvia, Landgraf et al. 2005).  
miRNAs within a cluster may exert a concerted action. The polycistronic miRNA 
cluster, miR-17-92, has a strong correlation with a variety of tumours in humans 
and animals, including Burkitt’s lymphoma (Woods, Thomson et al. 2007), 
colorectal carcinoma (Tsuchida, Ohno et al. 2011), lung carcinoma (Hayashita, 
Osada et al. 2005) and ovarian cancer (Fan, Liu et al. 2010) and contributes to 
the regulation of angiogenesis. Here, VEGF, an angiogenic chemokine, induces 
cluster expression and leads to a reduction in the levels of the angiogenic 
molecule, thrombospondin-1 levels (Suárez, Fernández-Hernando et al. 2008). In 
Drosophila melanogaster, miRNA clusters tend to target the same genes (Grün, 
Wang et al. 2005). Interestingly, one study reported that TFs regulating a 
particular miRNA gene tend also to regulate its mRNA target (Wang, Li et al. 
2011). Thus, clustered miRNAs might regulate a common pathway by targeting 
the same individual gene or by targeting several genes in the same pathway.   
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1.7.5 miRNA in the Circulation 
miRNA is transcribed and regulated within in the cell. However, it can also be 
detected extracellularly, particularly in the blood (Valadi 2007, Pegtel, 
Cosmopoulos et al. 2010, Diehl, Fricke et al. 2012, Raposo and Stoorvogel 2013, 
Eldh, Olofsson Bagge et al. 2014, Huang and Chen 2014, Melo, Sugimoto et al. 
2014). miRNA can be transported into the circulation in a heterogeneous group 
of cell-released microvesicles, including exosomes, microparticles and apoptotic 
membranes (Figure 1-18). Exosomes are lipid bilayers that transport protein, 
lipids or nucleic acids, including miRNA and mRNA, from the cell cytosol into the 
extracellular compartment (Valadi 2007). They are small, ranging from 50–90 
nm, endocytic in origin and arise from the fusion of multivesicular endosomes 
(MVE) with plasma membrane (Harding, Heuser et al. 1984). Almost all cell types 
produce exosomes through the fusion of MVE with cell membranes from a variety 
of sources, including B cells, T cells, mast cells, platelet, oligodendrocytes, 
Schwann cells, intestinal cells and tumour cells (Raposo, Nijman et al. 1996, 
Raposo, Tenza et al. 1997, Blanchard, Lankar et al. 2002, Valadi 2007, Raposo 
and Stoorvogel 2013, Sluijter and van Rooij 2015). Pre-miRNAs in a complex with 
Dicer, AGO2 and TRBP are present in exosomes of cancer cells and mediate 
silencing of mRNA in the specific target cell transcriptome (Melo, Sugimoto et al. 
2014). miRNAs are protected by exosomes from degradation by RNAse which is 
abundant in the blood (Pegtel, Cosmopoulos et al. 2010). miRNAs within 
exosomes are therefore stable in the circulation and might provide a convenient 
biomarker in clinical diagnosis. 
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Figure 1-18:  Cell death through apoptosis or necrosis processes.  
These processes release long DNA strands, RNA transcripts and the miRNA-AGO complex within apoptotic bodies.  miRNA also can be excreted from viable cells 
through exosomes. Adapted from (Schwarzenbach, Nishida et al. 2014).
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1.7.6 miRNA in Adrenal Tumours 
Most adrenal tumours are clinically silent and therefore diagnosis and treatment 
are frequently delivered at a later stage of the disease when effective treatment 
is likely to have a poorer outcome. At present, there is no reliable method of 
differentiating benign from malignant tumours except the identification of 
distant metastases (Gimm, DeMicco et al. 2012). The principal treatment for 
unilateral APA is laparoscopic adrenalectomy. Most patients are diagnosed 
through extensive investigation, including computed tomography (CT) imaging, 
adrenal venous sampling (AVS) and histological examination of excised tissue, all 
of which require expensive specialist medical expertise. A simple screening 
method facilitating early diagnosis would be valuable. miRNA might provide the 
basis for such a method (Igaz, Igaz et al. 2015). 
1.7.6.1 miRNA in adrenocortical carcinoma 
Differential expression of miRNAs has been reported between normal adrenal 
tissue and both benign and malignant adrenocortical tumours, as shown in Table 
1-6 and Table 1-7 (Soon, Tacon et al. 2009, Özata, Caramuta et al. 2011, 
Patterson, Holloway et al. 2011, Schmitz, Helwig et al. 2011, Chabre, Libé et al. 
2013, Patel, Boufraqech et al. 2013, Szabo, Luconi et al. 2014). It is reasonable 
to surmise that these differentially-expressed miRNAs may be involved in 
tumourigenesis and/or tumour function. In adrenocortical carcinoma (ACC), miR-
483-3p and miR-483-5p which are overexpressed have been proposed as 
oncogenic miRNAs (oncomiRs) (Soon, Tacon et al. 2009, Patterson, Holloway et 
al. 2011, Chabre, Libé et al. 2013). Inhibition of both miRNAs in vitro decreased 
cell proliferation (Özata, Caramuta et al. 2011). The miR-483 gene is located on 
chromosome 11, within the second intron of the IGF2 gene, which is highly 
expressed in ACC (Bertherat and Bertagna 2009). Increased expression of IGF-2 
could possibly stimulate cellular proliferation rate and tumour development 
(Veronese, Lupini et al. 2010). This hypothesis is supported by the results of an 
in vitro study that showed IGF-2 inhibition by IGF-1 receptor blockade reduces 
cell proliferation (Barlaskar, Spalding et al. 2009). However, miR-483 
overexpression is not exclusive to adrenocortical tumours and is also 
overexpressed, for example, in colon, breast and liver carcinomas and in Wilms’ 
tumours (Veronese, Lupini et al. 2010). 
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In addition to miR-483 upregulation, miR-503 (Soon, Tacon et al. 2009, Özata, 
Caramuta et al. 2011), miR-210 (Özata, Caramuta et al. 2011, Szabo, Luconi et 
al. 2014, Velázquez-Fernández, Caramuta et al. 2014), miR-675 (Schmitz, Helwig 
et al. 2011) and miR-21 (Özata, Caramuta et al. 2011) are all overexpressed in 
ACC. High expression of miR-503 is significantly associated with shorter survival 
in ACC patients (Özata, Caramuta et al. 2011), parathyroid carcinoma (Corbetta, 
Vaira et al. 2010) and retinoblastoma (Zhao, Yang et al. 2009). miR-210 plays a 
vital role in angiogenesis (Zeng, He et al. 2014), cell proliferation (Zuo, Wen et 
al. 2015) and is associated with poor cancer survival (Hong, Yang et al. 2012). 
miR-21 is highly expressed in most human tumours, including ACC (Özata, 
Caramuta et al. 2011). A pharmacological miR-21 antagonist might therefore 
benefit sufferers from many cancers, especially those for which there is as yet 
no specific treatment (Sicard, Gayral et al. 2013). 
In contrast, miR-195 (Soon, Tacon et al. 2009, Özata, Caramuta et al. 2011, 
Patterson, Holloway et al. 2011, Chabre, Libé et al. 2013, Velázquez-Fernández, 
Caramuta et al. 2014), miR-335 (Soon, Tacon et al. 2009, Schmitz, Helwig et al. 
2011, Chabre, Libé et al. 2013) and miR-497 (Özata, Caramuta et al. 2011, 
Chabre, Libé et al. 2013, Velázquez-Fernández, Caramuta et al. 2014) are all 
downregulated in ACC compared to NA and ACA. miR-195 induces cell cycle 
arrest by targeting the cell cycle genes, Cdc25I and Ccnd, in skeletal muscle 
stem cells (Sato, Yamamoto et al. 2014) and acts as a tumour suppressor in 
hepatocellular carcinoma cells (HCC) by blocking the G1/S transition through 
several targets, including CCND1, CDK6 and E2F3, thereby suppressing the Rb-
E2F signalling pathway(Xu, Zhu et al. 2009). miR-335 is downregulated in human 
HCC and inhibits HCC proliferation and migration through ROCK1 regulation(Liu, 
Li et al. 2015). miR-497 also suppresses cell proliferation by decreasing the S 
phase of cell cycle and inhibiting cell migration and tissue invasion in pancreatic 
malignancy (Xu, Wang et al. 2014).  
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Table 1-6: Previous studies analysing miRNA expression in ACC and ACA. 
(ACC: adrenocortical carcinoma, ACC: adrenocortical adenoma). 
Author miRNA expression 
(ACC vs ACA) 
Up-regulated Down-regulated 
Szabo et al 2014 miR-100 
miR-181b 
miR-184 
miR-210  
miR-483-5p 
 
Patel et al 2013 miR-34a 
miR-483-5p 
 
Chabre et al 2013 miR-139-5p  
miR-148b  
miR-376a  
miR-483-5p  
miR-503  
miR-508-3p  
miR-509-3p 
miR-513a-5p  
miR-514  
miR-93 
miR-195  
miR-199a-3p  
miR-199a-5p 
miR-335  
miR-376a  
miR-497 
Patel et al 2013 miR-34a 
miR-483-5p 
 
Patterson et al 2011 miR-1246 
miR-1308 
miR-483-5p 
miR-642 
miR-665 
let-7a 
let-7d 
let-7f 
let-7g 
miR-100 
miR-125a-5p 
miR-125b 
miR-126 
miR-1290 
miR-193b 
miR-195 
miR-214 
miR-26a 
miR-26b 
miR-29a 
miR-34a 
miR-600 
miR-768-5p 
Schmitz et al 2011  miR-139-3p 
miR-335 
miR-675 
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Table 1-7: Previous studies analysing miRNA expression in ACC and ACA. 
(ACC: adrenocortical carcinoma, ACC: adrenocortical adenoma). 
Author miRNA expression 
(ACC vs ACA) 
Up-regulated Down-regulated 
Deniz M özata et al 
2011 
let-7a 
let-7d 
let-7e 
let-7f 
let-7g 
let-7i 
miR-106b 
miR-10b 
miR-1202 
miR-125a-5p 
miR-127-3p 
miR-1275 
miR-136 
miR-140-5p 
miR-15b 
miR-1975 
miR-21 
miR-210 
miR-29a 
miR-29b 
miR-320b 
miR-320c 
miR-320d 
miR-331-3p 
miR-361-5p 
miR-376c 
miR-410 
miR-424 
miR-432 
miR-483-3p 
miR-483-5p 
miR-487b 
miR-503 
miR-506 
miR-513a-5p 
miR-513b 
miR-513c 
miR-514 
miR-720 
miR-886-3p 
miR-101 
miR-151-3p 
miR-195 
miR-1974 
miR-1977 
miR-199a-3p 
miR-199a-5p 
miR-202 
miR-214 
miR-29c* 
miR-30a 
miR-494 
miR-497 
miR-557 
miR-572 
miR-877* 
miR-99a 
 
Soon et al 2009 miR-339-5p 
miR-130b 
miR-483-5p 
miR-106b 
miR-148b 
miR-93 
miR-135a 
miR-320a 
miR-503 
miR-450a 
miR-542-3p 
miR-143 
miR-181b 
miR-542-5p 
miR-335 
miR-195 
miR-557 
miR-708 
miR-29* 
miR-617 
miR-647 
let-7c 
miR-202 
Tombol et al 2009 miR-184 
miR-503 
miR-210 
miR-511 
miR-214 
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1.7.6.2 miRNA in aldosterone regulation and adrenocortical adenoma (ACA) 
In primary aldosteronism (PA), the adrenal gland secretes inappropriately high 
levels of aldosterone. Aldosterone excess increases cardiovascular morbidity and 
mortality independent of elevated blood pressure.  
Aldosterone-regulating miRNAs have already been identified in several studies. 
Romero et al showed that miR-21 increases aldosterone secretion (Romero, 
Plonczynski et al. 2008) suggesting it may be repressing the expression of genes 
that themselves inhibit aldosterone biosynthesis (As miRNA is only capable of 
repression, miR-21 cannot directly stimulate CYP11B2 mRNA synthesis). 
However, Robertson et al. demonstrated that miRNA-24 directly inhibits 
CYP11B2 (and CYP11B1) mRNA expression, thereby significantly altering 
aldosterone production in vitro (Robertson, MacKenzie et al. 2013). 
Several microarray studies, have been validated by subsequent qPCR studies, 
showing differences in miRNA expression between normal adrenal (NA) and 
adrenocortical adenoma (ACA) tissue, as shown in Table 1-8 (Soon, Tacon et al. 
2009, Tömböl, Szabó et al. 2009, Özata, Caramuta et al. 2011, Patterson, 
Holloway et al. 2011, Robertson, MacKenzie et al. 2013, Velázquez-Fernández, 
Caramuta et al. 2014, He, Cao et al. 2015). In qPCR studies, mir-139-5p is more 
highly expressed in APA than in NA and has been proposed as a marker to 
differentiate APA from non-functioning adenomas (NFA) (Velázquez-Fernández, 
Caramuta et al. 2014). mir-210 was significantly more highly expressed in ACA 
than in NA in two independent studies (Özata, Caramuta et al. 2011, Velázquez-
Fernández, Caramuta et al. 2014). miR-210 has been shown to be important in  
other carcinoma such as laryngocarcinoma (Zuo, Wen et al. 2015) and has been 
proposed as potential biomarker in glioma prognosis and diagnosis (Shang, Hong 
et al. 2014).  
Significant downregulation of miR-375 and miR- 7 in ACA compared to NA has 
been reported in 3 validated independent studies (Soon, Tacon et al. 2009, 
Tömböl, Szabó et al. 2009, He, Cao et al. 2015). miR-375 targets metadherin 
(MTDH), also known as Astrocyte Elevated Gene-1, which is involved in the 
tumorigenesis of various tumours, including those of breast (Li, Zhang et al. 
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2008), prostate, kidney, bladder (Wang, Wei et al. 2014) and thyroid (Li, Wang 
et al. 2014). MTDH protein is upregulated in APA while endogenous 
downregulation of the MTDH gene by mir-375 suppresses Akt-Ser473 
phosphorylation (He, Cao et al. 2015), a reaction which is implicated in cell 
growth, proliferation and survival (Bayascas and Alessi).   
Aldosterone downregulates miR-335-5p, miR-290-5p and miR-1983 and also 
enhances epithelial sodium channel (ENaC) transport in mouse cortical collecting 
duct (mCCD) epithelial cells (Edinger, Coronnello et al. 2014); aldosterone’s 
effect may be partially accomplished by this mechanism.   
There is now strong evidence that aldosterone production is at least partly 
controlled by miRNAs. The full extent of microRNA involvement merits further 
study. 
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Table 1-8: Previous studies analysing miRNA expression in ACA vs NA. 
(ACA: adrenocortical adenoma, NA: Normal Adrenal). 
Author miRNA expression 
(ACA vs NA) 
Up-regulated Down-regulated 
He, Juan et al 2015 miR-29b 
miR-29c 
miR-7 
miR-375 
 
Velázquez-Fernández et al 
2014 
miR-10b 
miR-139-5p 
miR-186 
miR-195 
miR-21 
miR-210 
miR-30e 
mir-34a 
miR-497 
miR-520d-3p 
 
Robertson et al 2013 miR-34c-3p miR-10b 
miR-24 
Patterson et al 2011 
 
miR-100 
Deniz M özata et al 2011 miR-195 
miR-21 
miR-210 
miR-497 
 
Soon et al 2009  miR-7 
Tombol et al 2009  miR-375 
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1.7.7 miRNA in clinical trials 
1.7.7.1 Miravirsen (miR-122 antagonist) in hepatitis C 
miR-122 is highly expressed in hepatocellular cells and plays a critical role in 
hepatitis C virus (HCV) RNA stability by binding to two specific target sites at the 
5’ UTR of the HCV genome (Henke, Goergen et al. 2008). This generates an 
oligomeric miR-122-HCV complex that protects the HCV genome from 
degradation and increases its affinity for its target (Janssen, Reesink et al. 
2013). The binding sites for miR-122 are conserved across HCV subtype and 
genotypes (Janssen, Reesink et al. 2013). 
In 2010, Miravirsen, a specific mir-122 blocker, was introduced by Santaris 
Pharma for phase II clinical trials for hepatitis C treatment via a subcutaneous 
route. Miravirsen is a construct of locked nucleic acid (LNA) ribonucleotides that 
is complementary to miR-122. It is the first miRNA antagonist to be used in a 
clinical trial. The complementary binding of Miravirsen and miR-122 reduces HCV 
replication in chimpanzees (Lanford, Hildebrandt-Eriksen et al. 2010) and 
humans (Janssen, Reesink et al. 2013). Miravirsen targets the stem structure of 
miR-122 precursors and disrupts the processing of pri-122 and pre-miR-122 by 
inhibiting Drosha and Dicer (Gebert, Rebhan et al. 2014). In the phase 2 clinical 
study, commenced at several international centres, Miravirsen decreased the 
HCV load in the majority of patients and no adverse events were reported during 
the 18-week trial (Janssen, Reesink et al. 2013). However, a recent study 
reported that the mir-122 antagonist’s ability to inhibit HCV replication is 
severely reduced in the presence of any HCV mutation at the 5’UTR, even 
alteration of a single nucleotide (Israelow, Mullokandov et al. 2014). Therefore, 
future Miravirsen and miR-122-based medication for HCV may need to be 
customized according to the HCV sequence. 
1.7.7.2 MRX-34 (miR-34a mimic) in liver cancer and liver metastases  
miR-34a is a tumour suppressor. It is either lost or downregulated  in many 
malignancies (Bouchie 2013). It stimulates G1 cell cycle arrest, senescence, 
apoptosis and acts as a tumour silencer because of the irregular CpG methylation 
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of its promoter (Lodygin, Tarasov et al. 2008). miR-34 regulates many cancer-
related genes, including BCL2, CDK4/6, WNT 1/3, NOTCH-1 and β-catenin, and 
plays an important role in the p53 tumour suppressor pathway (Beg, Borad et al. 
2014).  
In 2013, Mirna Therapeutics, a biotechnology company in Texas, pioneered the 
Phase 1 clinical study of the first miR-34a mimic (MRX34) in patients with 
unresectable primary liver cancer or metastases with liver involvement 
(Christoph 2013). MRX-34, a miR-122 mimic, is a double-stranded RNA that can 
be given by the intravenous route. It is delivered within the special licensed 
liposome, Smarticles (Bouchie 2013) to avoid degradation by RNase in 
bloodstream. The study followed the standard protocol for oncology study design 
with two phases: dose-escalation and enrichment (Christoph 2013). The aim was 
to restore normal endogenous mir-122 tumour suppressor function (Bouchie 
2013). MRX34 prescription showed a manageable safety profile in these patients.  
1.8 Conclusion 
Corticosteroid hormones are important in blood pressure regulation and there is 
evidence that their biosynthesis is regulated in part by microRNA. Now, in order 
to clarify which miRNAs regulate this system, I will analyse the microRNA 
profiles of normal adrenal (NA) and aldosterone-producing adenoma (APA) 
tissue, and also of adrenocortical cells stimulated to produce aldosterone in 
order to identify key changes. By investigating such differences in vivo and in 
vitro, in combination with bioinformatic analysis, I intend to identify microRNAs 
that affect systems relevant to APA pathology, including steroidogenesis and 
cholesterol biosynthesis. 
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1.9 Aims 
1. To analyse changes to the microRNA profile when aldosterone production 
is altered in APA tissue and in stimulated H295R adrenocortical cells. 
2. To use bioinformatic analysis to predict those miRNAs most likely to affect 
and regulate the system. 
3. To experimentally validate these bioinformatic findings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Materials and Methods 
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2.1 Cell Culture 
2.1.1 H295R 
H295R cells were originally derived from a 48-year-old woman who presented 
with malignant adrenocortical carcinoma (Gazdar, Oie et al. 1990). Three 
separate strains (H295R strain 1, 2 and 3) and the monoclonal HAC15 cell line 
were later derived from this original line and were provided to us courtesy of 
Professor William Rainey (Medical College of Georgia, GA, U.S.A). Each has its 
own distinctive culture conditions and slight variations in their characteristics 
(Wang and Rainey 2012). 
2.1.2 Culturing Technique 
Cell culture was performed in monolayer under sterile conditions in tissue 
culture flasks, with specific medium and supplement at 37oC in a humidified 
chamber (5% CO2, 95% air). The cells were cultured until approximately 70-80% 
confluent, then the medium was removed and the cells washed with phosphate 
buffered saline (PBS) solution. To detach cells from the flask surface, Trypsin-
EDTA 0.25% (Ambion ®, Life Technologies, Paisley) was added for 5 minutes. 5 
ml DMEM-F12 medium was then added to inactivate the trypsin and the cells 
were centrifuged at 1500g for 5 minutes. The supernatant was removed and the 
cell pellet was re-suspended in new complete growth medium and aliquoted into 
a new flask (T150). Cells were fed every 3-4 days. 
Cells were maintained in Dulbecco’s modified Eagle medium (DMEM) with F12 
supplement (Invitrogen, Paisley, U.K). Specific medium for each strain is 
specified in Table 2-1: 
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Table 2-1: H295R Strains, HAC 15 and their medium specification. 
Cell Type Medium Serum/ Serum Replacement 
Agent 
Antibiotics 
 
H295R Strain 1 DMEM-F12 containing HEPES  
buffer, L-Glutamine and 
pyridoxine HCl medium 
(Life Technologies, Paisley, U.K) 
5% NuSerum (VWR Jenscon, 
Leicestershire, U.K) 
1% of 1 IU penicillin, 100 μg/ml Streptomycin 
(Invitrogen, Paisley, U.K) 
0.5 ml Gentamicin (Life Technologies, Paisley, U.K) 
H295R Strain 2 DMEM-F12 containing HEPES  
buffer, L-Glutamine and 
pyridoxine HCl medium 
(Life Technologies, Paisley, U.K) 
1% insulin-transferrin –selenium 
(ITS) (BD Biosciences, Paisley, U.K) 
2.5% Ultroser G (Corning, France) 
1% of 1 IU penicillin, 100 μg/ml Streptomycin 
(Invitrogen, Paisley, U.K) 
0.5 ml Gentamicin (Life Technologies, Paisley, U.K) 
H295R Strain 3 DMEM-F12 containing HEPES  
buffer, L-Glutamine and 
pyridoxine HCl medium 
(Life Technologies, Paisley, U.K) 
10% Cosmic Calf Serum (Thermo 
Fisher Scientific, Erembodegem, 
Belgium) 
1% of 1 IU penicillin, 100 μg/ml Streptomycin 
(Invitrogen, Paisley, U.K) 
0.5 ml Gentamicin (Life Technologies, Paisley, U.K) 
HAC 15 DMEM-F12 containing HEPES  
buffer, L-Glutamine and 
pyridoxine HCl medium 
(Life Technologies, Paisley, U.K) 
1% insulin-transferrin –selenium 
(ITS) (BD Biosciences, Paisley, U.K) 
2.5% Ultroser G (Corning, France) 
1% of 1 IU penicillin, 100 μg/ml Streptomycin 
(Invitrogen, Paisley, U.K) 
0.5 ml Gentamicin (Life Technologies, Paisley, U.K) 
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2.1.3 Cryopreservation 
The cells could be cryopreserved for long-term storage by pelleting, as in section 
2.1.2, then resuspending the cells in complete growth medium supplemented 
with 10% dimethyl sulphoxide (DMSO) (Thermo Fisher Scientific, Loughborough, 
U.K) to prevent ice crystal formation. Cell suspensions were then aliquoted and 
transferred to cryovials and frozen at -80oC using isopropanol and Nalgene Cryo-
Container (Thermo Fisher Scientific, Loughborough, U.K) before being placed in 
liquid nitrogen for long-term storage. 
2.1.4 Cell Resuscitation  
Cells from liquid nitrogen were thawed on ice and slowly brought to room 
temperature before transfer to a 37oC water bath. The cell suspension in the vial 
was aliquoted to a universal container with 10 ml fresh growth medium. This was 
centrifuged at 1500 g for 5 minutes and the medium containing DMSO removed. 
The cell pellet was then resuspended with 5 ml fresh medium and transferred to 
a T25 flask (Corning) and cultured as described in section 1.2. 
2.1.5 Cell Counting 
Cell suspension, as prepared in 2.1.2, was used for cell counting with a Bright 
Line Haemocytometer (Sigma Aldrich, Poole, U.K). The cell pellet was 
resuspended with 10 ml medium and 20 μl of this cell suspension placed on the 
haemocytometer under a coverslip, applied by capillary action across the 
chamber. The number of cells was assessed under a light microscope by counting 
and averaging the number of cells in each 1mm square. Each small square of the 
haemocytometer represents a total volume of 1 mm3. 
1 mm3 = 0.001 cm3 
1 mm3 x 1000 = 0.001 x 1000 cm3 = 1 cm3 = 1 ml  
As 1 cm3 is equivalent to 1 ml, the following calculation is adapted to calculate 
the cells concentration per ml: 
Cell number/ ml = average cell count per square x 103   x original volume 
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On the basis of this count, a set number of cells was used to seed new plates. 
For a 6-well plate, 5 x 105 cells were added to each well, while for 24-well 
plates, 8 x 104 cells were added. 96-well plates had 2 x 104 cells pipetted into 
each well. 
2.2 Stimulation of Cells 
2.2.1 Angiotensin II (Angio II), 100 nM, Dibutyryl-cyclic adenosine 
monophosphate(dbcAMP), 1 mM and Potassium Chloride 
(KCl), 20 mM 
As part of the studies, it was necessary to stimulate cells with various factors 
known to influence steroidogenesis. To prepare cells for stimulation, they were 
seeded to plate wells, as above, and incubated at 37°C (5% CO2) for 24 hours. 
Later, medium was removed and replaced with complete growth medium also 
containing the relevant factor and incubated at 37°C for a further 0, 6, 12 or 24 
hours, as required. The factors used were: 
- Angiotensin II (Angio II) (Tocris Bioscience, Bristol, U.K): 100 nM 
- Dibutyryl-cyclic adenosine monophosphate (dbcAMP) (Sigma-Aldrich, 
Dorset, England): 1 mM 
- Potassium chloride (KCl) (BDH AnalaR®, Poole, England): 20 mM 
2.3 Pre-miRTM and Anti-miRTM Transfection of Cells 
2.3.1 Lipofectamine Transfection 
Transfection of attached H295R cells with specific pre-miRTM and anti-miRTM 
(Ambion ® Life Technologies, Paisley, U.K) was performed using Lipofectamine 
reagent.  Cells were trypsinised and diluted to 16.67 x 104 cells/ml in a 6-well 
plate in normal medium and incubated at 37°C incubation for 24 hours. Later, 
transfection reagent master mix was prepared by mixing 8 μl of Lipofectamine 
2000 transfection agent (Ambion ® Life Technologies, Paisley, U.K) with 192 μl 
of OptiMEM® (Ambion ® Life Technologies, Paisley, U.K) for 10 minutes. 
Separately, the pre-miRTM or anti-miRTM were prepared by adding 24 μl of each 
of the miRNA to 176 μl OptiMEM® medium. 200 μl of the miRNA/ OptiMEM® was 
then added to 200 μl of the Lipofectamine 2000/OptiMEM® and incubated for 
another 20 minutes. 400 μl of this mixture was added to each well plate, 
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followed by 2600 μl of fresh cell medium. This was rocked gently to mix reagent 
then incubated at 37°C for 3 hours. The transfected cells were washed with 1 ml 
DPBS and prepared for cell lysis and RNA extraction. 
2.3.2 siPORTTM NeoFX Transfection 
Transfection of H295R cells in suspension was conducted using siPORTTM NeoFX 
(Applied Bioscience, Warrington, U.K). The cells were trypsinised as in section 
2.1.2 and counted as in section 2.1.5. Using 6-well plates, the cells were diluted 
to a concentration of 2 x 105/ ml using fresh medium and the suspension was 
incubated at 37°C until required. The master mix of transfection reagent was 
prepared by adding 9 μl siPORTTM NeoFX to 291 μl OptiMEM®. Separately, 24 μl 
of specific pre-miRTM or anti-miRTM was added to 276 μl OptiMEM® for 10 
minutes. 300 μl of miRNA/ OptiMEM® was then added to 300 μl of the 
Lipofectamine 2000/OptiMEM and incubated for another 20 minutes. 600 µl of 
this mixture was added to each well plate, followed by 2400 μl cell fresh 
medium. This was rocked gently to mix reagent then incubated at 37°C for 24 
hours. The transfected cells were washed with 1 ml DPBS prior to cell lysis and 
RNA extraction. 
2.4 Proliferation Assay 
2.4.1 CellTiter 96® Aqueous Non-Radioactive Proliferation Assay 
Using MTS Promega Assay 
The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, 
Madison, U.S.A) is used to assess cell proliferation, using a colorimetric method 
to determine the number of proliferating viable cells. The assay is composed of 
a solution of a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS(a)] 
and an electron-coupling reagent (phenazine methosulfate; PMS). In tissue 
culture medium, the MTS is bioreduced by cells into formazan rendering it 
soluble. Using 96-well plates, the absorbance of the formazan can be measured 
directly at 490 nm. 
Following cell stimulation (Section 1.6), medium was removed completely and 
100 μl of fresh culture media was added to each well of the 96-well plate 
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followed by 20 μl of MTS assay. The plate was incubated at 37°C for 1 to 4 
hours, with the colorimetric reaction progress being measured after 1, 2 ,3 and 4 
hours of incubation on the plate reader. 
2.4.2 Bromodeoxyuridine Cell Proliferation Assay (BrdU) 
Bromodeoxyuridine (BrdU) is used to detect and assess cell population that are 
actively synthesizing new DNA. BrdU is a thymidine analogue that is incorporated 
into newly synthesized DNA in the Synthesis (S) phase of the cell cycle. 
Subsequently, an anti-BrdU antibody binds incorporated BrdU and is conjugated 
with Goat Anti Mouse IgG HRPantibody, which catalyses the conversion of 
chromogenic substrate tetramethylbenzidine (TMB) from a colourless to blue or 
yellow solution.  
After 2-24 hours of BrdU incubation, fixative/denature solution was added to 
cells. Cells were seeded in 24-well plates at 8 x 104 cells per well. 400μl of 
culture medium, with cells, was added to each well and incubated for 24 hours. 
Cells were then washed with DPBS and serum-starved medium was added.C ells 
were incubated for a further 48 hours before addition of 10 nM Angio II or 100nM 
Angio II with 1 mM of BrdU for 48 hours. 
BrdU Label dilution was prepared by adding the label to culture medium in 
1:2000 ratio. 80 μl of BrdU Label dilution was then pipetted into each well and 
incubated for 24 hours. The BrdU Label was then removed and 800 μl Fixative/ 
Denaturing Solution added to each well and left for 30 minutes at room 
temperature. All liquid was removed from the well and 100 x Anti-BrdU Antibody 
1:100 in Antibody Dilution Buffer solution was prepared. 400 μl of the Anti-BrdU 
Antibody was added to each well and incubated at room temperature for one 
hour. 1x Wash Buffer was prepared by adding 25 ml of 20X concentration 
solution to 475 ml deionized water and each well washed three times. Conjugate 
was prepared by diluting reconstituted (in 1x PBS) Peroxidase Goat Anti-Mouse 
IgG HRP Conjugate in Conjugate Diluent, which was passed through a 0.2-micron 
filter. 400 μl of conjugate solution was pipetted into each well and incubated for 
30 minutes at room temperature. Wells were washed with 1x Wash buffer, then 
the entire plate was flooded with dH2O, which was removed by inversion. In the 
dark, 400 μl of Substrate Solution was added to each well and left at room 
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temperature for 15 minutes. 400 μl of Stop Solution was then added to each well 
(without removing the Substrate Solution) and its absorbance measured within 
30 minutes using the Spectrophotometric Plate Reader at 450 nm. 
2.5 Lysing Cells with Qiazol 
Qiazol Lysis Agent is a monophasic solution of phenol and guanidine thiocyanate 
that disrupts cells through lysis of fatty tissues and releases RNA; lysis reagent 
also inhibits RNases. Prior to lysis, cell medium was removed from wells and 
cells washed with DPBS before adding 700 μl of Qiazol Lysis Reagent. 
2.6 RNA Extraction and DNase Treatment Using 
miRNeasy Mini Kit (QIAGEN, Crawley, UK) 
The miRNeasy Mini Kit (QIAGEN, Crawley, UK) was used to isolate total RNA, 
including the microRNA fraction, from cells. The standard kit protocol was 
followed, including the optional DNase treatment, as follows. After cell lysis 
with Qiazol Lysis Agent, the cell culture plate was placed at -80°C overnight to 
complete homogenization (cell lysate can be stored at -80°C for several 
months). Subsequently, the homogenate was thawed at room temperature for 5 
minutes to promote dissociation of nucleoprotein complexes then transferred to 
1.5 ml RNase-free tubes. 140 μl chloroform was added to the homogenate, which 
was shaken vigorously for 15 seconds, then left at room temperature for 2 
minutes. Centrifugation for 15 minutes at 12000 x g at 4°C separated the 
samples into 3 phases. The upper colourless aqueous phase contains RNA; the 
interphase contains DNA and the lower, red organic phase contains proteins and 
lipid. The upper phase was pipetted into a new 1.5 ml RNase-free tube. 525 μl of 
100% ethanol was added and mixed thoroughly. 700 μl of the sample was then 
loaded on to an RNeasy mini spin column and centrifuged for 15 second at 8000 x 
g at room temperature; the flow-through was discarded and the step repeated 
for the remainder of the sample.  
DNase treatment was then performed. 350 μl of RWT Buffer was pipetted on to 
the RNeasy Mini spin column and centrifuged for 15 seconds at 8000 x g; the 
flow-through was discarded. 10 μl DNase I stock solution was mixed with 70 μl 
Buffer RDD and gently mixed by inversion. 80 μl of this DNase I incubation mix 
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was pipetted directly on to the RNeasy Mini spin column membrane and left at 
room temperature for 15 minutes. 350 μl Buffer RWT was pipetted on to the 
RNeasy Mini spin column and centrifuged for 15 seconds at 8000 x g. 
After on-column DNase digestion, 500 μl RPE Buffer was added to the RNeasy 
Mini spin column and centrifuged at 8000 x g for 15 seconds; flow-through was 
discarded. This step was repeated with a longer centrifugation for 2 minutes to 
dry the spin column and ensure no carry over of ethanol. The RNeasy Mini spin 
column was placed in a new 2 ml collection tube and centrifuged at full speed 
for 1 minute then transferred again to a new 1.5 ml RNase-free tube. Finally, 30-
50 μl RNase-free water was added directly to the RNeasy Mini spin column 
membrane and centrifuged for 1 minute at 8000 x g to elute the RNA. 
2.7 Nucleic Acid Quantification 
To determine the quantity and purity of nucleic acid, a Nanodrop ND-100 
spectrophotometer with ND-1000 v3.10 software (Labtech International LTD, 
Lewes, East Sussex, UK) was used. Initially the Nanodrop setting was set up to 
measure RNA. 2 μl of RNase free water was loaded to the Nanodrop base 
pedestal and the arm was lowered. It was blanked prior to sample measurement 
using Rnase-free water. The nucleic acid concentration is calculated as following 
using the Beer-Lambert Law of absorption: 
RNA concentration (µg/ ml) = (A260 reading – A320 reading) x 40 
The ratio of absorption at 260 nm and 280 nm (A260/280) is an indicator of RNA 
purity; ratios of 1.8 to 2 indicates high RNA purity.  
2.8 Agarose Gel Electrophoresis 
Agarose gels (1%) were prepared to analyse PCR product. 1 g Ultrapure agarose 
(Invitrogen, Paisley, U.K) was added to 100 ml of 1 x TBE buffer. The mixture 
was heated to dissolve the powder in a microwave oven at full power for 1–2 
minutes then allowed to cool slightly before addition of 1 μl of ethidium bromide 
solution (10 mg/ml; Sigma-Aldrich, Poole, U.K) in a fume hood. This was then 
poured into a tray with a 20-well comb (Teflon comb) and left to set. The 
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resulting gel was immersed in 1 X TBE buffer in an electrophoresis tank and the 
comb removed. 5 μl dye (0.02 % bromophenol blue, 0.02 % xylene cyanol and 2.5 
% glycerol) was added to 5 μl sample before loading the sample into a well. 5 μl 
of 1 kb DNA size ladder (Promega, Madison, WI, USA) was added to assess the 
resolution of molecular size. Gels were run for 50 minutes at 90 volts. The DNA 
fragments were visualised under UV light on a transilluminator machine (Bio-Rad 
Laboratories, Hemel Hampstead, U.K) and analysed by Multi-Analyst software v 
1.1 (Bio-Rad) at 302 nm. 
2.9 Reverse Transcription 
Reverse Transcription (RT) of single-stranded RNA to complementary DNA (cDNA) 
was achieved using the miScript II Reverse Transcription Kit (QIAGEN, Crawley, 
U.K). The supplied 10x miScript Nucleics Mix contain dNTPs, rATP, oligo-dT 
primers and internal synthetic RNA control (miRNA reverse transcription control 
(miRTC)). The 5x miScript HiFlex Buffer promotes conversion of miRNA or mRNA 
into cDNA for realtime PCR quantification (Sections 2.10 and 2.11). 
For each sample 150-200 ng of DNase-treated RNA was mixed with 2 μl of 
Reverse Transcriptase Mix, 4 μl of 5x miScript HiFlex Buffer and 2 μl of 10x 
miScript Nucleics. The total volume of 20 μl was made up with RNase-free water 
in a 96-well PCR plate. A negative reverse transcriptase (-RT) control was 
included for each sample as control to assess the specificity of qRT-PCR reaction 
to detect genomic DNA. The plate was sealed with clear polyolefin StarSeal (PCR 
seal) and centrifuged prior to reaction run. 
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The reaction was run on Multi Block System Satellite 0.2 Thermo Cooler (Thermo 
Fisher Scientific, U.K), see Table Table 2-2.   
Table 2-2: Reaction cycle of miScript Reverse-trasncription. 
Step Time (minutes) Temperature 
Reverse Transcription 120 37oC 
Inactivation of RT mix 5 95oC 
 Hold 10oC 
 
After the samples were run, 80 μl of RNase-free water was added to each and 
they were stored at -20oC until required. 
2.10 Quantitative Real-Time Polymerase Chain Reaction 
(Universal Probe Library) 
Detection of messenger RNA (mRNA) was performed by quantitative realtime 
PCR (realtime qPCR) in a 384-well PCR plate (Thermo Fisher Scientific, U.K) 
using TaqMan® Gene Expression Master Mix containing AmpliTaq Gold® DNA 
Polymerase, Uracil-DNA Glycosylase (UDG), UP (Ultra Pure), deoxyribonucleotide 
triphosphates (dNTPs) with deoxyuridine triphosphate (dUTP), ROX Passive 
Reference dye and buffer. The Universal Probe Library (UPL) probe system 
(Roche Applied Science, Indianapolis, USA) was used, consisting of 165 pre-
validated probes. These Locked Nucleic Acid (LNA) PCR probes are labelled with 
fluorescein (FAM) at the 5’end and a dark quencher dye at the 3’ end and offer 
greater specificity than SYBR-green-based assays. Each assay consists of a UPL 
probe combined with a specially-designed primer pair (Eurofins MWG Operon, 
Ebersberg, Germany), as shown in Table 2-7. 
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The realtime PCR reaction mix is prepared as shown in Table Table 2-3. 
Table 2-3: Taqman reaction components. 
Reagent Volume/ Reaction 
TaqMan® Gene Expression Master Mix 5.0µl 
UPL Probe 0.1µl 
Primer (Forward) 0.4µl 
Primer (Reverse) 0.4µl 
Nuclease-Free Water 2.1µl 
cDNA (template RNA) 2.0µl 
 
8 μl of Taqman master mix was added to 2 μl cDNA in the well of a 384-well 
plate. 3 technical replicates were set up for each RT positive (RT+) cDNA 
samples and 3 technical replicates for the RT negative sample. cDNA was 
prepared as described in Section 1.9. Negative water blank for control reactions 
were also included. The plate was sealed, centrifuged (1000g, 1 minute at room 
temperature) and run on QuantStudio™ 7 Flex Real-Time PCR Systems (Applied 
Biosystem by Life Technologies, Carlsbad, CA, USA) using SDS software 
QuantStudio™ 7 Flex Real-Time PCR System Software (Applied Biosystem by Life 
Technologies, Carlsbad, CA, USA). The cycling protocol is shown in Table 2-4. 
Table 2-4: Reaction cycle of Taqman qRT PCR. 
Step Time  Temperature Cycles 
Enzyme activation 10 minutes 95oC 1 
Denaturation 15 seconds 95oC 40 
Annealing and extension 1 minute 60oC 40 
 
2.11 SYBR Green Quantitative Real-Time Polymerase 
Chain Reaction  
The detection of mature miRNA was analysed using miScript SYBR Green PCR Kit 
(QIAGEN, Crawley, U.K.) and 10X miScript Primer Assays (see Table 2-8). 
Supplied lyophilised primer Assay was mixed with 550 µl of TE buffer (pH 8) and 
stored at -20oC. Reactions were prepared as shown in Table 2-5.  
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Table 2-5: SYBR Green reaction components.  
Reagent Volume/Reaction 
QuantiTect SYBR Green PCR Master Mix (2X) 10µl 
10X miScript Universal Primer 2.0µl 
10X miScript Primer Assay 2.0µl 
Nuclease-Free Water 4.0µl 
cDNA (template RNA) 2.0µl 
 
8μl of SYBR Green master mix was added to 2 µl of cDNA in each well. 3 
technical replicates were set up for RT positive (RT+) cDNA samples and 3 
technical replicates for the RT negative sample. cDNA was prepared as described 
in Section 1.9. The mixture was centrifudged for 1000 g, 1 minute at room 
temperature. It was run on QuantStudio™ 7 Flex Real-Time PCR Systems (Applied 
Biosystem by Life Technologies, Carlsbad, CA, USA) using SDS software 
QuantStudio™ 7 Flex Real-Time PCR System Software (Applied Biosystem by Life 
Technologies, Carlsbad, CA, USA) with cycle as mentioned below: 
Table 2-6: Reaction cycle of SYBR Green qRT PCR. 
Step Time  Temperature (oc) Cycles 
Enzyme activation 15 minutes 95 1 
Denaturation 
Annealing 
Extension 
15 seconds 
30 seconds 
30 seconds 
94 
55 
70 
 
40 
 
Melt curve 
15 seconds 
15 seconds 
15 seconds 
95 
60 
95 
 
1 
 
2.12 Analysis of qPCR Results 
Amplification of PCR product increases fluorescence from PCR probe or SYBR 
Green dye, as measured by the QuantStudio™ 7 Flex Real-Time PCR cycler.  The 
Ct (cycle threshold) is the PCR cycle number at which a predetermined level of 
fluorescence is achieved. The Ct is inversely proportional to the starting amount 
of target template and this is used for qPCR analysis. For these studies, the ΔΔCt 
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system of quantitative analysis was used. This employs a ‘housekeeping’ gene as 
a constant benchmark, measured alongside the gene/miRNA of interest. 
Therefore,  
ΔCt = Ct sample – Ct housekeeper 
GAPDH (for Taqman) and RNU-48 (for SBR Green) were used as ‘housekeeping 
genes’, acting as normalising controls for RNA concentration and correcting for 
minor discrepancies during pipetting. Both housekeepers were validated for 
consistent expression and reproducibility. 
The ΔΔCt can then be calculated from these as follows: 
ΔΔCt = ΔCt sample – ΔCt reference 
And the fold change (RQ) in mRNA or miRNA calculated as: 
Fold change = 2-(ΔΔCt) 
2.13 Microarray Analysis  
For miRNA profile studies of adrenal tissues (normal adrenal and APA tissues) 
and H295R cells (basal and stimulated H295R), the total RNA was prepared by Dr 
Stacy Robertson (adrenal tissues) and Dr Louise Diver (H295R cells). The group 
size for the adrenal tissue study was dictated by the availability of suitable 
clinical samples. We initially received 4 control samples (normal adrenal) and 
were able to subsequently match these with 4 aldosterone-producing adenoma 
samples. The four non-diseased control samples were more difficult to obtain 
and determined our sample size.  
The RNAs were sent for microarray analysis by LC Sciences (Houston, Texas, 
U.S.A.) using miRNA μParaflo® technology microarray (version 10.1). Briefly, 
RNA was labelled with fluorescent dye and hybridised overnight on a specific 
microfluidic chip containing probes for 723 human miRNAs and control RNA. The 
chip was scanned using a GenePiz 4000B laser scanner and analysed using Array-
Pro image software. The raw data were subtracted to background and 
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underwent data adjustment including data filtering, log2 transformation, gene 
centering and normalisation. The manufacturers recommend a signal cut-off of 
500 AU as the optimal threshold below which any miRNA should be regarded as 
absent; we employed this threshold for our studies. The need for such a 
threshold arises from the non-specific, background fluorescence, which is an 
unavoidable feature of this method, and requires the imposition of an arbitrary 
cut-off point for all measurements. 
2.14 miRBase Database Release 19: August 2012 
The mirBase Database is the primary online repository for all known miRNAs and 
provides comprehensive miRNA nomenclature, sequence data, annotation and 
predicted gene target information. The most recent version is Release 21: June 
2014 that contains 28645 entries of hairpin precursor miRNAs, 35828 mature 
miRNAs from 223 species (miRBase 2014), including 2588 mature human miRNAs 
(Kozomara A 2014). miRBase is accessible online at http://www.mirbase.org/.  
miRBase started from an initial 218 entries of miRNA and has been developed to 
almost 30000 entries 12 years later. The miRNA names use the prefix “miR” 
followed by unique and specific identifying number that are assigned 
sequentially regardless organism. The similar identifying numbers are given to 
identical or almost identical miRNA sequence. Almost all miRNAs precursor 
produced mature miRNA from either the 5’ end or 3’ hair-pin strand, the 
annotation of mature miRNA will be added ‘5p’ or ‘3p’, based on the origin they 
are cleaved from (Ambros, Bartel et al. 2003). 
2.15 Ingenuity Pathway Analysis (IPA) 
Ingenuity Pathway Analysis (IPA) software provides predicted target genes for 
miRNAs using miRNA Target Filter database. The database is derived from peer-
reviewed scientific literature (Ingenuity Expert Finding, Ingenuity ExpertAssist 
Finding), miRecords, Tarbase and TargetScan Human. The miRNA target filter 
can be filtered through several mechanism including disease type, organ type, 
pathway affected and confidence level as described in the following:  
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The filter system is based on 3 confidence levels;  
1) Experimentally observed miRNA-mRNA interaction (result based on 
validated experiment). 
2) Highly predicted miRNA-mRNA interaction. 
3) Moderately predicted miRNA-mRNA interaction. 
2.16 Statistical Analysis 
The reason we did the microarray is to screen for changes in miRNAs expression. 
All the unadjusted p-value data from LC Sciences were analysed using False 
Discovery Rate (FDR) Calculator to adjust the p-value. Ideally, the miRNAs with 
significant adjusted p-value would be taken forward for further analysis. 
However, if the FDR value is not significant, there are 2 options. Firstly, 
terminate any further investigation or secondly choose the most significant hits 
from the microarray analysis. In my thesis, the analysis of FDR values was done 
by Dr John McClure. Based on FDR calculation, the p-values provided by LC 
Sciences were not significant. As advised by Dr John McClure, I have chosen to 
analyse the most significant miRNAs based on the p-value and the miRNAs that 
have relevant biological input (with p < 0.05). In addition, I have done further 
experiment to validate these screening results by qRT PCR. 
Unless specified otherwise, the data shown are presented as mean ± standard 
error of the mean (SEM), with qRT PCR data expressed as RQ ± SEM or 1/dCt ± 
SEM. For in vitro experiments, at least 3 biological samples were performed with 
a minimum of 3 technical replicate were performed, unless stated otherwise. 
We are not just using a simple T-test here because we have adjusted the p-value 
for multiple testing using FDR. None of the results were significant, so we 
proceeded to analyse the most significant hits of the microarray results using 
unadjusted p-value. Differences with a p value < 0.05 were regarded as 
statistically significant. Statistical calculations were performed using GraphPad 
Prism Version 5 (GraphPad Software, Inc, San Diego, CA).  
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2.17 Ethical Board 
The four normal adrenal tissue samples were obtained from patients (adult) 
undergoing nephrectomy with local ethical approval from the University of 
Birmingham. The other four samples of APA tissues (FFPE) were acquired from 
the Biobank of University of Glasgow and were held in accordance of Human 
Tissue Act with the local ethical review board permission. The samples were 
then handled by Dr Stacy Robertson for RNA extraction and other related 
protocols. We were unable to access to the clinical data for these samples for 
reasons of ethics and privacy.
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Table 2-7: List of TaqMan Gene Expression Assay 
Gene Primer (Forward) Primer (Reverse) UPL Probe # 
GAPDH GCTCTCTGCTCCTCCTGTTC ACGACCAAATCCGTTGACTC 60 
CYP11B1 ACTAGGGCCCATTTTCAGGT GGCAGCATCACACACACC 68 
CYP11B2 GCACCTGCACCTGGAGATG CACACACCATGCGTGGTCC 57 
CYP17A1 CTATGCTCATCCCCCACAG TTGTCCACAGCAAACTCACC 67 
HMGCR GACGCAACCTTTATATCCGTTT TTGAAAGTGCTTTCTCTGTACCC 85 
HTR4 AATGGATCCACACATGTACTAAGG GGTGACACTGACTCTCCCACT 86 
FDX1 CTTTATAGGTCACCCGGAAGG CTGGAGTGGCGGAGAGAC 11 
KCNJ5 GGAAGCTCCGATCTCAACAA CCTGGTTCATGGCATTCCTA 33 
WNT4 GCAGAGCCCTCATGAACC CACCCGCATGTGTGTCAG 74 
LDLR CCACGGTGGAGATAGTGACA CTCACGCTACTGGGCTTCTT 53 
 
Table 2-8: List of SYBRGreen miRNA Assay used 
miRNA Assay miRNA Sequence Assay Product Code 
hsa-miR-24-3p 5'UGGCUCAGUUCAGCAGGAACAG 3’ MS00006552 
hsa-miR-21-5p 5'UAGCUUAUCAGACUGAUGUUGA 3’ MS00006552 
hsa-miR-125a-5p 5' UCCCUGAGACCCUUUAACCUGUGA MS00003423 
hsa-miR-335 5' UCAAGAGCAAUAACGAAAAAUGU 3’ MS00003976 
hsa-miR-106a-5p/ miR-17-5p 5' CAAAGUGCUUACAGUGCAGGUAG 3’ MS00029274 
hsa-miR-154-3p 5' AAUCAUACACGGUUGACCUAUU 3’ MS00031479 
hsa-miR-19a-3p 5' UGUGCAAAUCUAUGCAAAACUGA 3’ MS00003192 
hsa-miR-20b-5p 5' CAAAGUGCUCAUAGUGCAGGUAG 3’ MS00003206 
hsa-miR-766-3p 5' ACUCCAGCCCCACAGCCUCAGC 3’ MS00005439 
  
111 
 
 
 
 
 
 
 
 
 
3 Microarray Analysis of microRNA in Normal 
Human Adrenal (NA) and Aldosterone-Producing 
Adenoma (APA) Tissues 
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3.1 Introduction 
Microarray analysis is one of the techniques that can be implemented to detect 
the expression of miRNAs. Microarray allows the analysis of thousands of genes 
simultaneously in one experiment: a time- and cost-efficient investigation. 
Microarray can be classified (Abdullah-Sayani, Bueno-de-Mesquita et al. 2006) 
into the following types : 
1. Expression profiling 
2. Comparative genomic hybridization (CGH) 
3. Single nucleotide polymorphism analysis (SNP) 
4. Resequencing arrays (RA) 
Expression profiling and CGH are used to compare gene expression in normal vs 
disease states for tumour classification and prognostic purposes. SNP analysis is 
used to detect specific polymorphisms or mutations, helping to determine 
genetic predisposition to certain diseases and the discovery of DNA-based drug 
candidates. RA is utilised to sequence the genome for somatic mutation 
identification in cancer. In addition to the numerous ‘wet’ laboratory 
experimental analyses available for miRNA investigation (e.g microarray, qRT 
PCR, deep-sequencing and others), in silico analysis can also be utilised to 
facilitate the prediction of genes targeted by miRNA relatively quickly and cost-
effectively, before commencing the more expensive and time-consuming other 
techniques.  
In this chapter, the miRNA Target Filter in IPA was employed to determine 
putative targets for miRNAs of interest. miRNA Target Filter combines several 
bioinformatic miRNA tools: TargetScan, TarBase, miRecords and Ingenuity® 
Knowledge Base (IPA 2016). The ‘seed’ site refers to the second to seventh 
nucleotides of the miRNA from the 5’ end. Bartel et al reported that seed site 
base-pairing is one of the robust measure for many target miRNA target 
database, where it increases the reliability and reducing the false positive 
prediction (Bartel 2009). Tarbase and miRecords identify the experimentally 
validated miRNA-mRNA interaction from miRBase and published articles while 
Ingenuity ® Knowledge Base demonstrates thousands of miRNA-related finding 
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from published articles which are manually curated by Ingenuity Scientific 
experts (IPA 2016). 
The mRNA targets predicted by the TargetScan algorithm refers to the conserved 
7mer and 8mer seed match site of each miRNA (IPA 2016). 7-8mer (7mer-A1, 
7mer-m8 and 8mer) seed matches associate with the strongest targeting 
efficiency (Figure 3-1) and are used to predict  metazoan conserved miRNA 
targets (Friedman, Farh et al. 2009). In order of increasing strength of base-
pairing, a 7mer-A1 site has a seed match with an adenosine base in the mRNA 
sequence complementary to miRNA nucleotide 1 (Figure 3-1). Next strongest is a 
7mer-m8 site, composed of a seed match supplemented by a Watson-Crick 
match at miRNA nucleotide 8. The most stable bonding between mRNA and 
miRNA results from an 8mer comprising a seed match at both miRNA nucleotide 
8 and an A at nucleotide 1.  
 
Figure 3-1: miRNA-mRNA site base-pairing. Each nucleotide (N) is numbered as 1 to 8 from 
the 5’ end of the miRNA.  
Blue nucleotides are the core seed site of the miRNA and black nucleotides mark the start (N1) and 
end (N8) of the site. Green nucleotides are the complementary sites in the mRNA sequence. Red A 
denotes adenosine and the purple nucleotide at position 8 increase the recognition strength of the 
target by miRNA. Modified from (Friedman, Farh et al. 2009). 
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3.2 Aims 
1) To establish and identify significant differences between the miRNA 
profiles of normal adrenal (NA) and aldosterone-producing adenoma (APA) tissue 
using microarray analysis methods. 
2) To utilise bioinformatic analysis methods (Ingenuity Pathway Analysis; 
miRNA target Filter) to identify experimentally validated or predicted mRNA 
targets of miRNAs differentially-expressed between NA and APA tissue, which 
are likely to be relevant to adrenal function and APA pathology. 
3.3 Result 
3.3.1 miRNA expression in microarray 
Total RNA was extracted from 4 different samples of normal human 
adrenocortical (NA) tissue and 4 different samples of human aldosterone-
producing adenoma (APA). The RNA quantity was determined using the Nanodrop 
(Section 2.7) and the quality assessed by Agilent Bioanalyser chip. RNA samples 
were then sent for miRNA profile analysis by microarray microfluidic chip (LC 
Sciences, Houston, Texas). LC Sciences also conducted their own quality control 
procedures on the RNA samples. 
The large dataset from LC Sciences is further selected based on the 
manufacturer recommendation. According to the recommendations of the 
microarray manufacturer (LC Sciences, Houston, Texas), a 500 arbitrary unit 
(AU) cut-off point was applied as the detection threshold for individual miRNAs. 
The microarray analysis generated a list of miRNAs present in one or both tissue 
types (i.e. miRNAs >500 AU) and also of miRNAs differentially expressed between 
tissue types (i.e. miRNAs present in only one tissue type at >500 AU, or miRNAs 
present in both tissue types at >500AU but at significantly different levels 
(p<0.05). Figure 3-2 shows positive correlation of mean fluorescence intensity of 
miRNA expression between normalised NA and APA, suggesting the majority of 
miRNA levels remain highly consistent between the two tissues.  
Of the 723 screened miRNAs, 77 were detected at levels >500 AU in NA and/or 
APA. Of these, 50 were expressed in both NA and APA, 12 were present in NA 
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only and 15 in APA only (Figure 3-3). Of the 50 miRNAs present in both tissues, 
20 were differentially expressed (p<0.05; Figure 3-4). Of the total 47 miRNAs 
differentially expressed (i.e. present in only one tissue or present in both and 
differentially expressed (p<0.05)), 23 were more highly expressed in NA tissues 
(Figure 3-5) and 24 miRNAs were more highly expressed in APA (Figure 3-6). 
 
Figure 3-2: Scatter plot showing levels of individual miRNAs in stimulated normal adrenal 
(NA) vs aldosterone-producing adenoma (APA), as analysed by microarray. R2=0.8706.  
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3.3.2 miRNA expression more than 500 Arbitrary Units (AU) 
 
Figure 3-3: Venn diagram showing the number of expressed miRNAs present (>500 AU) in 
NA and/or APA. 
 
Figure 3-4: Venn diagram of differentially-expressed miRNAs i.e. those detected in only one 
tissue type (AU>500 in NA or APA) or present in both at significantly different levels 
(AU>500 in APA and NA; p<0.05).  
Note that fewer miRNAs are listed compared to Figure 3-3; this is because this figure contains only 
miRNAs of AU >500 and with p<0.05 between both tissues.
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More highly expressed miRNAs in NA
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Figure 3-5: Microarray data showing the 23 miRNAs consistently expressed at high levels in NA samples relative to APA. 
*miRNAs >500AU in NA but not APA; †miRNAs present in both tissues but at significantly different levels (p<0.05).
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Figure 3-6: Microarray data showing the 24 miRNAs consistently expressed at high levels in APA samples relative to NA. 
*miRNAs >500AU in APA but not NA; †miRNAs present in both tissues but at significantly different levels (p<0.05). 
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3.3.3 miRBase analysis of the differentially-expressed miRNAs in 
NA and APA. 
miRBase is the main online repository providing standardised nomenclature for 
miRNAs, sequences, annotation and mRNA target prediction. Starting from an 
initial 218 miRNA entries in 2002, it has developed to include almost 30,000 
entries as of 2014. The latest version is miRBase Release 21: June 2014. It 
contains 28,645 entries of hairpin precursor miRNAs, including 35,828 mature 
miRNAs from 223 species (miRBase 2014). The miRNA naming convention uses 
the prefix ‘miR’ followed by a unique and specific identifying number (e.g. miR-
768) that is assigned sequentially regardless of organism. Similar identifying 
numbers are given to identical or almost identical miRNA sequences (e.g. miR-
125a and miR-125b). Almost all miRNA precursors produce mature miRNA from 
either the 5’ end or the 3’ hair-pin strand; mature miRNA are annotated as ‘5p’ 
or ‘3p’ on the basis of this (e.g. miR-768-5p) (Ambros, Bartel et al. 2003). Each 
species has a specific prefix designation (for example, in humans ‘hsa’ is added 
prior to the miRNA name i.e hsa-miR-17). 
The microarray data were analysed using the current miRBase release (Release 
21: June 2014). Of the differentially-expressed miRNAs, two (miR-768-3p and 
miR-768-5p) were excluded from further analysis as these had been reclassified 
by miRBase as ‘dead miRNA’ entries due to their overlap with the annotated 
snoRNA, HBII-239 (miRBase 2014), meaning they are unlikely to be real 
functional miRNAs.  
According to microarray, the most abundantly expressed miRNAs are the let-7 
miRNAs: let-7a-5p (average fluorescence intensity 23866, p=0.0019), let-7b-5p 
(average fluorescence intensity 19235, p =0.0082), let-7c (average fluorescence 
intensity 20486, p =0.0089) and let-7d-5p (average fluorescence intensity 14091, 
p =0.029). These miRNAs are uniformly up-regulated in APA tissue (Figure 3-6). 
The most significant difference in miRNA expression between tissues is that of 
miR-29c-3p (p=0.000043), which is upregulated in NA relative to APA (Figure 
3-5). 
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3.3.4 miRNA Clusters Expression in NA and APA Tissues 
As classified by miRBase Release 21, a group of miRNAs located on the same 
chromosome and within 10 kb of one another are termed a miRNA cluster 
(Zhang, Azhar et al. 2012, miRBase 2014). There is evidence that the miRNAs 
derived from clusters tend to have similar function and associate with similar 
disease states (Lu, Zhang et al. 2008). In my study, members of 27 different 
miRNAs clusters were identified in NA or APA tissue (Figure 3-7 to Figure 3-14). 
Expression levels of different members of the same miRNA cluster often follow 
similar patterns. For example, Cluster let-7a-1, located on chromosome 9 
(Figure 3-11 A), contains let-7a-5p and let-7d-5p, which were both significantly 
upregulated in APA samples, as shown in Figure 3-11 and Figure 3-15. A further 
member of this cluster, let-7f-5p, shows a similar pattern of expression 
(upregulated in APA), but it is not differentially significant. Even though let-7d-
3p was judged significantly different between the two phenotypes (high in APA), 
the expression level in both tissues was <500 AU, so it is technically not 
expressed in either tissue (Figure 3-11). Similarly, no expression of the 
remaining cluster members, let-7a-3p and let-7f-1-3p, was detected from the 
microarray. In Cluster let-7a-3 (Figure 3-16), two miRNAs show consistent 
expression: let-7a-5p and let-7b-5p.  
Furthermore, two miRNAs from Cluster miR-134 (miR-134 and miR-382) are 
consistently upregulated in APA (Figure 3-17). These miRNAs are located at 
chromosome 14.  
Two members of Cluster miR-29b-1 (miR-29a-3p, miR-29b-3p; both p<0.05, >500 
AU) (Figure 3-18) are highly expressed in NA. The other 2 miRNAs in the cluster 
(miR-29a-5p and miR-29b-1-5p) show a consistent pattern of expression (the 
mean fluorescence intensity of the miRNAs are higher in NA), but the p-value is 
>0.05 (Figure 3-8). Cluster miR-29a/ 29b-1 is located on chromosome 7. 
Cluster miR-29b-2 (consists of miR-29b-3p, miR-29c-3p both p<0.05, >500 AU) 
(Figure 3-19) is down-regulated in APA tissues. Mature miR-29b-3p originates 
from 2 distinct miRNA precursors: stem-loop mir-29b-2 which is located at 
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chromosome 1 and stem-loop mir-29b-1 which is located at chromosome 7. The 
sequence of mature miR-29b-3p remains the same 
(UAGCACCAUUUGAAAUCAGUGUU) despite differences in miRNA precursor loops 
(miRBase 2014). 
Another cluster that shows a similar expression pattern is Cluster miR-15a 
(Figure 3-7), where miR-15a-5p and miR-16-5p show a similar trend towards 
upregulation in NA tissues, although this is not significant. 
Cluster miR-24-1 and Cluster miR-24-2 each feature members that are 
overexpressed in NA and in APA (Figure 3-8). The mature form of miR-24-3p is 
synthesized from two different primary miRNAs; miR-24-1 in chromosome 9 and 
miR-24-2 from chromosome 19. 
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Figure 3-7: miRNA Clusters (NA>APA) detected from microarray analysis. Cluster miR-125a 
(A), cluster miR-15a (B) and cluster miR-195 (C)).  
Blue bars indicate miRNAs that are expressed in NA and red bars indicate APA (*p<0.05).
A B 
C 
123 
 
Cluster miR-24-1
h
s
a
-m
iR
-2
3
b
-3
p
h
s
a
-m
iR
-2
3
b
-5
p
h
s
a
-m
iR
-2
4
-3
p
h
s
a
-m
iR
-2
4
-1
-5
p
h
s
a
-m
iR
-2
7
b
-3
p
h
s
a
-m
iR
-2
7
b
-5
p
h
s
a
-m
iR
-3
0
7
4
-3
p
h
s
a
-m
iR
-3
0
7
4
-5
p
0
2000
4000
6000
8000
10000
NA
APA
* *
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
Cluster miR-24-2
h
s
a
-m
iR
-2
3
a
-3
p
h
s
a
-m
iR
-2
3
a
-5
p
h
s
a
-m
iR
-2
4
-3
p
h
s
a
-m
iR
-2
4
-2
-5
p
h
s
a
-m
iR
-2
7
a
-3
p
h
s
a
-m
iR
-2
7
a
-5
p
0
2000
4000
6000
8000
NA
APA
*
*
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
Cluster miR-29a/ miR-29b-1
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Cluster miR-29c/ miR-29b-2
h
s
a
-m
iR
-2
9
b
-3
p
h
s
a
-m
ir
-2
9
b
-2
-5
p
h
s
a
-m
iR
-2
9
c
-3
p
h
s
a
-m
iR
-2
9
c
-5
p
0
1000
2000
3000
4000
NA
APA
*
*
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
 
Figure 3-8: miRNA Clusters (NA>APA) detected from microarray analysis (Cluster miR-24-1 
(A), Cluster miR-24-2 (B), Cluster miR-29b-1 (C) and miR-29b-2 (D)).  
Blue bar indicates miRNAs that are expressed in NA and red bars indicate APA (*p<0.05). 
A B 
C D 
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Figure 3-9: miRNA Clusters (NA>APA) detected from microarray analysis (Cluster miR-30b 
(A), Cluster miR-30c (B), Cluster miR-376c (C) and miR-379 (D)).  
Blue bars indicate miRNAs that are expressed in NA and red bars indicate APA (*p<0.05).
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Figure 3-10: miRNA Clusters (NA>APA) detected from microarray analysis (Cluster miR-
424).  
Blue bars indicate miRNAs that are expressed in NA and red bar indicates APA (*p<0.05).
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Figure 3-11: miRNA Clusters (APA>NA) detected from microarray analysis (Cluster let-7a-1 
(A), Cluster let-7a-2 (B), Cluster let-7a-3 (C) and Cluster let-7c (D)).  
Blue bars indicate miRNAs that are expressed in NA and red bars indicate APA (*p<0.05).
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Figure 3-12: miRNA Clusters (APA>NA) detected from microarray analysis (Cluster miR-
103ab-1 (A), Cluster miR-103ab-2 (B), Cluster miR-122 and (C) Cluster miR-134 (D)).  
Blue bars indicate miRNAs that are expressed in NA and red bars indicate APA (*p<0.05).
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Figure 3-13: miRNA Clusters (APA>NA) detected from microarray analysis (Cluster miR-34c 
(A), Cluster miR-451 (B) and Cluster miR-432 (C)).  
Blue bars indicate miRNAs that are expressed in NA and red bars indicate APA (*p<0.05).
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Figure 3-14: miRNA Clusters (APA>NA) detected from microarray analysis (Cluster miR-509-
1 (A), Cluster miR-509-2 (B), Cluster miR-92a-1 (C) and Cluster miR-92a-2 (D)).  
Blue bars indicate miRNAs that are expressed in NA and red bars indicate APA (*p<0.05).
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Figure 3-15: Cluster let-7a-1 consists of 6 miRNAs; 2 of the miRNAs are above 500 AU and 
differentially expressed.  
The blue bars represent normal adrenal (NA) and the red bars represent adrenal producing 
adenoma (APA). The dotted line indicates the 500 AU cut-off point, *p-value <0.05. 
Cluster let-7a-3
hsa-let-7a-5p hsa-let-7b-5p
0
10000
20000
30000
NA
APA
*
*
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
Figure 3-16: Cluster let-7a-3 consists of 6 miRNAs; 2 of the miRNAs are above 500 AU and 
differentially expressed.  
The blue bars represent normal adrenal (NA) and the red bars represent adrenal producing 
adenoma (APA). The dotted line indicates the 500 AU cut-off point, *p-value <0.05. 
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Figure 3-17: Cluster miR-134 consists of 16 miRNAs. Only 2 miRNAs (miR-134 and miR-382) 
showed similar pattern of expression and they are above 500 AU in APA.  
The others are mostly not expressed in microarray (<500 AU). The blue bars represent normal 
adrenal (NA) and the red bars represent adrenal producing adenoma (APA). The dotted line 
indicates the 500 AU cut-off point, *p-value <0.05. 
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Cluster miR-29b-1
hsa-miR-29a-3p hsa-miR-29b-3p
0
2000
4000
6000
NA
APA
*
*
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
Figure 3-18: Cluster miR-29b-1 consists of 4 miRNAs; 2 of the miRNAs are above 500 AU.  
2 of the miRNAs are above 500 AU and differentially expressed. The blue bars represent normal 
adrenal (NA) and the red bars represent adrenal producing adenoma (APA). The dotted line 
indicates the 500 AU cut-off point. *p-value <0.05. 
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Figure 3-19: Cluster miR-29c/29b-2 consists of 4 miRNAs; 2 of the miRNAs are above 500 
AU and differentially expressed.  
The blue bars represent normal adrenal (NA) and the red bars represent adrenal producing 
adenoma (APA). The dotted line indicates the 500 AU cut-off point, *p-value <0.05. 
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3.3.5 Ingenuity® Systems Pathway Analysis (microRNA target 
Filter) 
Having analysed the presence and differential expression levels of miRNAs 
between tissue types, further analysis of possible biological function was 
conducted using Ingenuity® Systems Pathway Analysis software (IPA; Ingenuity 
Systems, Redwood City, CA USA; http://www.ingenuity.com). This enables 
plausible messenger RNA targets of the differentially-expressed miRNAs to be 
determined in order to assess their possible molecular and cellular functions. 
47 Differentially-expressed miRNAs (p<0.05, >500 AU), as identified from the 
microarray data, were uploaded to the IPA system. Subsequently, using miRNA 
Target Filters, 34 miRNAs were automatically selected (Figure 3-20) while 13 
miRNAs are not included in the IPA analysis. The 13 miRNAs were excluded 
either due to no interaction being detected between the miRNA and mRNA or 
because the miRNAs were not listed in the database. These 34 miRNAs included 
those that share the same seed sequences (as shown in Table 3-1 and Table 3-2), 
which are termed ‘synonymous miRNA’.  These filtered miRNAs were then 
analysed using various software resources such as Ingenuity Expert Finding, 
Ingenuity Expert Assist Finding, miRecords, Tarbase and TargetScan Human. 
When predicting possible targets for miRNAs, different levels of rigour can be 
applied to the results. For example, it can be requested that only 
experimentally validated miRNA-mRNA interactions demonstrated in a previously 
published study be included in the results. Alternatively, highly and/or 
moderately predicted mRNA targets can also be included; although less rigorous, 
these predictions produce a greater number of ‘hits’ than the obviously more 
limited list of validated interactions.  
Data may also be filtered by specific disease type (e.g. endocrine, 
cardiovascular and cancer), by specific pathway (e.g. hormone/ sterol 
biosynthesis, apoptosis, cell growth, proliferation and development) and by 
organ system (e.g. adrenal gland). When all these filters are applied, the 
number of mRNA targets predicted for the 34 miRNAs under investigation reduce 
dramatically from 11,933 to 116 (Figure 3-20).  
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The next sections will focus on particular genes (i.e CYP11B2, HMGCR and 
others) and the pathways relevant to APA pathogenesis that are identified by IPA 
as being apparently targeted by multiple miRNAs. 
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Figure 3-20: Summary of differentially-expressed miRNA analysis in NA vs APA, conducted using Ingenuity Pathway Analysis (IPA).  
Using the IPA miRNA Target Filter, the number of miRNAs under investigation was reduced from 47 to 34. Applications of further filters then reduced the predicted 
number of target mRNAs for these 34 miRNAs from 11,933 to 116.
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Table 3-1: Synonymous miRNAs expressed in NA (>500 AU) i.e. miRNAs having similar seed sequence and therefore sharing similar mRNA targets (IPA). 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (miRBase Acession) 
Seed Sequence Number of targeted mRNA from 
different genes 
hsa-miR-10a-5p  ACCCUGU 780 
hsa-miR-125a-5p hsa-miR-125b-5p CCCUGAG 1531 
hsa-miR-126a-3p  CGUACCG 111 
hsa-miR-139-5p  CUACAGU 690 
hsa-miR-148a-3p  CAGUGCA 1197 
hsa-miR-15a-5p hsa-miR-16-5p AGCAGCA 2020 
 hsa-miR-195   
 hsa-miR-424   
hsa-miR-21-5p  AGCUUAU 615 
hsa-miR-24-3p  GGCUCAG 1394 
hsa-miR-26b-5p hsa-miR-26a-5p UCAAGUA 1095 
hsa-miR-27a-3p hsa-miR-27b-3p UCACAGU 1654 
hsa-miR-29b-3p hsa-miR-29a-3p AGCACCA 1492 
 hsa-miR-29c-3p   
hsa-miR-30c-5p hsa-miR-30a-5p GUAAACA 1592 
 hsa-miR-30b-5p   
hsa-miR-335-5p  CAAGAGC 637 
hsa-miR-376c-3p  ACAUAGA 667 
hsa-miR-379-5p  GGUAGAC 448 
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Table 3-2: Synonymous miRNAs expressed in APA (>500 AU) i.e. miRNAs having similar seed sequence and therefore sharing similar mRNA targets (IPA). 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (miRBase Acession) 
Seed Sequence Number of targeted mRNA from 
different genes 
hsa-let-7a-5p hsa-let-7b/c/d-5p GAGGUAG 1396 
hsa-miR-103-3p hsa-miR-107 GCAGCAU 1255 
hsa-miR-140-3p  ACCACAG 792 
hsa-miR-149-3p  GGGAGGG 2606 
hsa-miR-320a hsa-miR-320b AAAGCUG 1073 
hsa-miR-34a-5p  GGCAGUG 1477 
hsa-miR-34c-3p  AUCACUA 302 
hsa-miR-361-5p  UAUCAGA 561 
hsa-miR-375-3p  UUGUUCG 263 
hsa-miR-382-5p  AAGUUGU 447 
hsa-miR-432  CUUGGAG 491 
hsa-miR-451a  AACCGUU 190 
hsa-miR-483-5p  AGACGGG 461 
hsa-miR-509-3p  GAUUGGU 346 
hsa-miR-574-3p  ACGCUCA 199 
hsa-miR-574-5p  GAGUGUG 564 
hsa-miR-92a-3p hsa-miR-92b-3p AUUGCAC 1139 
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3.3.5.1 Experimentally Validated Targets of clustered differentially-
expressed miRNAs. 
IPA analysis identified 3 miRNAs clusters containing differentially-expressed 
constituents to be of particular interest. 
The first is cluster let-7a-1 which contains, among others, the differentially 
expressed miRNAs let-7a-5p and let-7d-5p (Figure 3-11). Both of these miRNAs 
are significantly downregulated in NA compared to APA. let-7f-5p also shows a 
similar downregulation pattern in NA, but it is not significant. IPA analysis lists 
132 experimentally-validated mRNA targets for members of this cluster, 131 of 
them human. Interestingly, these validated targets include DICER1, which 
expresses the key component of miRNA processing. Overexpression of let-7 
significantly reduces expression of DICER1 at the mRNA and protein levels; 
furthermore, downregulation of DICER1 itself reduces let-7 expression 
(Tokumaru, Suzuki et al. 2008). let-7a and let-7c have also been shown 
experimentally to target HMGA2 (High-mobility group A2), an early embryonic 
gene that is up-regulated in many advanced cancers and whose expression 
correlates with poor prognosis (Shell, Park et al. 2007, Peng, Laser et al. 2008). 
The other two clusters, cluster miR-29b-1 (Figure 3-18) and cluster miR-29b-2 
(Figure 3-19), both contain miRNAs that are upregulated in NA relative to APA 
and have similar seed sequences (i.e. are synonymous), as shown in Table 3-1. 
These clusters share 57 experimentally-validated targets according to the IPA 
database. Among the targeted genes are COL1A1, COL1A2, COL3A1 and COL5A3, 
which are involved in atherosclerosis signalling. These are discussed later in this 
chapter. 
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Table 3-3: Cluster let-7a and let-7b miRNAs share the same experimentally-validated mRNA targets as a result of their synonymous seed sites. 
Source: IPA database.   
Validated targets for cluster let-7a and let-7b 
1GF2BP2 
AARSD1 
ACP1 
ADGRG1 
AGO4 
AKAP8 
ANAPC1 
ATAD3B 
ATP6V1F 
ATP6VOA1 
AURKB 
BCL2L1 
BCL7A 
BMP2K 
BSG 
CALCOCO2 
CAPG 
CARHSP1 
CASP3 
CCND1 
CDC25A 
CDIPT 
CDK6 
CDKAL1 
CHMP2A 
COIL 
COL1A2 
COMMD9 
CSDE1 
CSNK1D 
DAD1 
DHX57 
DICER1 
DOCK5 
DRD3 
DSP 
DUSP12 
DUSP23 
EIF3J 
EIF4G2 
F2 
FADS2 
FAM105A 
FAM96A 
FANCD2 
FNDC3A 
GAK 
GEMIN7 
GRPEL2 
GTPBP3 
GYS1 
HMGA1 
HMGA2 
HMOX1 
HYOUT 
IFIT5 
IFRD1 
IGF2BP1 
IGF2BP3 
IPO4 
ITGB3 
KCNJ16 
KLK10 
KRAS 
KRT19 
 
LIN28A 
MARS2 
MED28 
MLLT1 
MRM1 
MRPS24 
MRPS33 
MTPN 
MTRR 
MYC 
NEDD4 
NF2 
NRAS 
NXN 
PGRMC1 
POLD2 
POLR2C 
POM121C 
PPP1R7 
PRDM1 
PRIM1 
 
PRRC2A 
PTGS2 
PXDN 
RABGAP1L 
Ras 
RBM19 
RDH10 
RHO6 
RHOB 
RPP38 
RRP8 
RTCA 
SCYL1 
SEPT3 
SIGMAR1 
SLC1A4 
SLC25A1 
SLC25A13 
SLC25A24 
SLC25A32 
SLC38A1 
 
SMC1A 
SMOX 
SNAP23 
SPCS3 
SPRYD4 
SYPL1 
TAF9B 
TAGLN 
TGFBR1 
THBS1 
TLR4 
TMEM2 
TPM2 
TRIM71 
TRMT1 
TTC9C 
TUSC2 
UGT8 
UHRF1 
VIM 
VPS39 
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Table 3-4: Clusters miR-29b-1 and miR-29b-2 miRNAs share the same experimentally-validated mRNA targets as a result of their synonymous seed sites. 
Source: IPA database. 
Validated target for cluster miR-29b-1 and miR-29b-2 
ACVR2A 
ARPC3 
BACE1 
CAV2 
CD276 
CDC42 
CDK6 
CNOT8 
COL15A1 
COL1A1 
COL1A2 
COL3A1 
COL4A1 
COL4A2 
COL5A2 
COL5A3 
DCP2 
DNMT3A 
DNMT3B 
DUSP2 
FAM3C 
FBN1 
FRAT2 
GAS7 
GMFB 
GPR37 
HDAC4 
HMGN3 
INSIG1 
KCTD3 
KLF4 
LAMC1 
LOXL2 
MAPRE2 
MCL1 
MLF1 
MYBL2 
NASP 
NAV3 
PIK3R1 
PPIC 
PPM1D 
PTEN 
PURA 
RERE 
SHROOM2 
SP1 
SPARC 
SRSF10 
TCL1A 
TDG 
TET1 
TGFB3 
Tpm1 
TRIM9 
TUBB2A 
YY1 
ZFP36L1 
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3.3.5.2 HMGCR, a potential miRNA target 
One of the most striking results of IPA analysis concerns the HMGCR gene. 
HMGCR targeting by miRNA was chosen to be one of the main focuses of 
investigation in this thesis. This is due to its function as a limiting enzyme for 
cholesterol synthesis, and the fact that cholesterol is the main substrate for 
steroidogenesis. 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase 
(HMGCR) is a rate-limiting enzyme for cholesterol biosynthesis. It is involved in 
various canonical pathways including Retinoid-X-Receptor/ Liver-X-Receptor 
(LXR/ RXR) signalling (Figure 3-23), Adenosine Monophosphate-Activated Protein 
Kinase (AMPK) signalling (Figure 3-24) and the Mevalonate Pathway (Figure 3-25). 
Targeting of HMGCR in the mevalonate cascade may have therapeutic 
applications by inhibiting cholesterol biosynthesis. As cholesterol is the main 
substrate for steroidogenesis, there are obvious implications for APA function.  
Seven of the differentially-expressed miRNAs are predicted to target HMGCR: 
miR-125a-5p, miR-27a-3p, miR-27b-3p, miR-29a-3p, miR-29c-3p and miR-335-5p 
(Figure 3-22). Each is downregulated in APA (Figure 3-21). 
miR-27a-3p (chromosome 19) and miR-27b-3p (chromosome 9) share the seed 
sequence UCACAGU, while miR-29a-3p (chromosome 7), miR-29b-3p 
(chromosome 7 & 1) and miR-29c-3p (chromosome 1) share the seed sequence 
AGCACCA (Table 3-1).  
Two differentially-expressed clusters are involved in targeting HMGCR: Cluster 
miR-29a-3p/ miR-29b-3p and Cluster miR-29b-3p/ miR-29c-3p.  
miR-125a-5p is potentially the most interesting of these miRNAs. miR-125a-5p 
(previously miR-125a in earlier miRBase versions) is transcribed from 
chromosome 19 as part of a cluster with let-7e, miR-125a, and miR-99b (Figure 
3-7). TargetScan Human predicts mature miR-125a-5p (seed CCCUGAG) targets 
human HMGCR mRNA (aggregate PCT=0.289, total context + score= 0.211) and 
also CYP11B2 mRNA (aggregate PCT=0.06, total context + score= 0.377), 
suggesting it may be able to simultaneously target the mevalonate pathway and 
the mineralocorticoid pathway, as shown in Figure 3-25. 
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Figure 3-21: Microarray expression of miRNAs targeting HMGCR.  
All of the miRNAs were downregulated in APA compared to NA tissues (*p<0.05). 
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Figure 3-22: Seven differentially-expressed miRNAs are predicted to target HMGCR.  
Note that only 4 direct interactions are shown in this diagram, as IPA groups the three synonymous 
miRNAs together.
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Figure 3-23: miRNAs targeting HMGCR in LXR/ RXR Pathway.  
All of the miRNAs are highly upregulated in NA tissue (p<0.05, >500 AU).
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Figure 3-24: miRNAs targeting HMGCR in AMPK (Adenosine monophosphate-activated protein kinase) Signalling.  
All of the miRNAs are highly upregulated in NA tissue. 
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Figure 3-25: miR-125a-5p is targeting HMGCR in Mevalonate Pathway and targeting CYP11B2 in the Mineralocorticoid Biosynthesis Pathway. 
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3.4 Discussion 
The microarray analysis presented here shows 23 miRNAs to be expressed at 
significantly higher levels in NA relative to APA, including miR-125a-5p, miR-
27a/b-3p, miR-29a/b/c-3p and miR-30a/b/c-5p (Figure 3-5). Conversely, 24 
miRNAs were significantly upregulated in APA relative to NA (Figure 3-6). The 
summary of miRNA expression in APA vs NA is as shown in Chapter 1 (Table 1-8). 
For miRNA expression in ACC vs ACA see Table 1-6 and Table 1-7. Some of these 
results are not in agreement with the Velázquez-Fernández study where, for 
example, mir-29c-3p was found to be downregulated in NA and miR-320a was 
downregulated in APA (Velázquez-Fernández, Caramuta et al. 2014). On the 
other hand, there are areas of agreement between the two studies, including 
the finding that miR-92a and mir-361-5p are more highly expressed in APA 
relative to NA (Velázquez-Fernández, Caramuta et al. 2014). The differences of 
these results may due to non-homogenous cell populations in the APA and NA 
samples. Furthermore, the samples used in Velázquez-Fernández et al. 2014 
were obtained from snap-frozen tissues and were analysed by a different 
microarray platform i.e. Agilent Technologies’ human microarray (Velázquez-
Fernández, Caramuta et al. 2014). 
Although the 47 differentially-expressed miRNAs identified here represent just a 
small fraction of the 723 miRNAs detectable by microarray, the number and 
variety of possible mRNA targets for these 47 is so potentially large that careful 
use of bioinformatic tools is required in order to focus on the pathways most 
likely to be relevant in the development and pathogenesis of APA. Filtering of 
data by IPA led to the highlighting of miR-125a, miR-335, cluster miR-29b and 
cluster let-7a. 
miR-29c is clustered in miR-29b group. The downregulation pattern of miR-29c in 
APA is in accordance with the low expression of miR-29c in nasopharyngeal 
carcinomas (NPC). The low level of miR-29c is correlated with high levels of 
COL1A1, COL1A2 and COL3A1. miR-29c inhibits the luciferase activity at the 
3’UTR of the mentioned genes (Sengupta, den Boon et al. 2008). However in 
another study, miR-29 was found to be upregulated in aortic dilation (Boon, 
Seeger et al. 2011) and aortic aneurysms (Maegdefessel, Azuma et al. 2012). It is 
correlated with significant downregulation of many extracellular matrix 
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components (Boon, Seeger et al. 2011, Maegdefessel, Azuma et al. 2012). One 
study suggests that anti miR-29 could improve vascular integrity during aneurysm 
(Boon, Seeger et al. 2011) and markedly increase elastin expression in Williams-
Beuren syndrome (characterized with aortic stenosis) (Zhang, Huang et al. 
2012). miR-29a, miR-29b and miR29-c inhibit the expression of COL1A1, COL1A2, 
COL3A1, COL4A1 and numerous extracellular matrix protein. These genes and 
proteins can lead to cardiac, liver, renal and pulmonary fibrosis. It is suggested 
that anti miR-29 could be used as a therapeutic method for aneurysm, 
vulnerable plaque and pro-elastin/pro-collagen therapies (Van Rooij and Olson 
2012). This study is supported by another experiment where miR-29b was shown 
to suppress alpha 1 collagen (COL1A1) mRNA and protein level through 3’UTR 
binding in human stellate culture cells. COL1A1 is involved in liver fibrogenesis. 
This study proposed miR-29b as a therapeutic tool for antifibrotic therapy 
(Ogawa, Iizuka et al. 2010). In diabetic-induced rat, mir-29a, miR-29b and mir-
29c are upregulated in microarray of the Goto-Kakizaki (GK) rat compared to 
healthy controls. Validation with Northern blotting shows upregulation of the 3 
paralogs miRNA in muscle, fat and liver of diabetic rat, all of which are the 
target tissues of insulin action. Increased miR-29a/b/c might cause insulin 
resistance by repressing insulin-stimulated glucose uptake (He, Zhu et al. 2007). 
Members of the let-7 family (let-7a-5p, let-7b-5p, let-7c and let-7d-5p) were 
consistently upregulated in APA tissues (Figure 3-6). In one study, let-7a and let-
7d were downregulated in ACC compared to ACA (Patterson, Holloway et al. 
2011). However, Özata et al reported a different finding, where let-7a and let-
7d were both increased significantly in ACC compared with ACA (Özata, 
Caramuta et al. 2011). In other tumours, members of let-7 family were 
significantly suppressed in primary malignant melanoma compared to the control 
(benign melanocytic nevi). let-7b overexpression in melanoma samples via in 
vitro analysis downregulated the expression of cyclins D1, D3, A and cyclin-
dependent kinase 4 (CDK4) at 3’UTR region. let-7b inhibited cell-cycle progress 
and stopped the growth of melanoma cells (Schultz, Lorenz et al. 2008). let-7e 
directly suppresses Cyclin D1, resulting in the inhibition of G(1) cell cycle 
progress in a breast carcinoma cell line (Mitra, Das et al. 2011). let-7d is 
upregulated in transition of breast ductal carcinoma in situ (DCIS) to invasive 
ductal carcinoma (IDC) (Volinia, Galasso et al. 2012). In the chemical-induced 
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hepatocarcinogenesis rat model, several circulating miRNAs are highly elevated; 
e.g. let-7a, let-7f. Both of these miRNAs are even detected at the early stages of 
hepatocarcinogenesis, indicating that they might be useful as predictive tools to 
monitor development of carcinogenesis (Sukata, Sumida et al. 2011). 
miR-125a-5p shares the same seed sequence with miR-125b-5p shown in Table 
3-1. It is downregulated in APA compared to NA (Figure 3-5). Patterson et al, 
showed a downregulation pattern of expression of miR-125a-5p and mir-125b in 
ACC compared to ACA (Patterson, Holloway et al. 2011). Özata et al found the 
opposite, where the miR-125a-5p was upregulated in ACC compared to ACA 
(Özata, Caramuta et al. 2011). In the urinary system, the expression of miR-125b 
was significantly decreased in bladder cancer tissue and bladder cancer cell 
lines. This in vitro experiment showed that miR-125b inhibits the formation of 
cancer colonies and suppresses bladder tumour in mice. Among miR-125b targets 
are E2F3 and Cyclin A2, both essential for cell cycle transition (G1/ S phase). 
miR-125b inhibits the expression of E2F3 and Cyclin A2. This experiment 
suggested that miR-125b may be involved in cell cycle regulation via the E2F3-
Cyclin A2 signalling pathway and that downregulation of miR-125b may be a 
contributing factor to tumorigenesis (Huang, Luo et al. 2011). Furthermore, miR-
125a-5p inhibits migration and invasion of lung carcinoma. Epidermal growth 
factor receptor (EGFR) activation significantly repressed miR-125a-5p. EGFR 
regulates progression of epithelial malignancy. These data suggest that miR-
125a-5p might be a metastasis suppressor (Wang, Mao et al. 2009). In another 
study, miR-125b was significantly suppressed in malignant melanoma cell lines 
and downregulates c-Jun protein. C-Jun is the main regulator for melanoma 
progression (Kappelmann, Kuphal et al. 2013). miR-125b is located close to the 
deletion genomic region (epicentre of 11q23) in chronic lymphocytic leukaemias 
(CLLs). The aggressive and slow type of human CLL showed low expression of 
miR-125b. In in-vitro analysis, miR-125b increases the downregulation of T53 
mRNA in MEC2 cells (cell line derived from B-chronic lymphocytic leukaemia) 
(Tili, Michaille et al. 2012). On the other hand, miR-125b is abundantly 
expressed in squamous cell carcinoma (SCC). It directly repressed the MAP 
kinase gene and Vps4B (vacuolar protein-sorting 4 homolog B) that prolong the 
activation of epidermal growth factor receptor (EGFR) signalling that 
subsequently leads to cell proliferation, cell migration and adhesion (Zhang, Ge 
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et al. 2014). miR-125a is overexpressed in the hyperglycaemic hepatocyte of the 
Goto-Kakizaki (GK) rat and in adipose tissue (Herrera, Lockstone et al. 2009). 
HMGCR is a rate-limiting enzyme for cholesterol biosynthesis. HMGCR is also 
involved in the LXR/ RXR Pathway (Figure 3-23) and in AMPK (Adenosine 
monophosphate-activated protein kinase) signalling (Figure 3-24) through the 
Mevalonate Cascade (Figure 3-25). HMGCR expression is negatively mediated by 
sterols and non-sterol metabolites originating from mevalonate. The enzyme is 
suppressed by cholesterol derived from internalization of LDL via the LDLR. 
Inhibition of HMGCR induces the expression of LDLR in hepatocytes which leads 
to increased plasma LDL catabolism and subsequent decrease in plasma 
cholesterol level. This will eventually reduce the formation of atherosclerosis. 
HMGCR is targeted by statin, which lowers the cholesterol level. Statin is a 
potent cholesterol lowering drug that lowers cardiovascular mortality in 
hypercholesterolemia patients (Gould, Rossouw et al. 1998). The decrease in 
intracellular cholesterol stimulates SREBP, increasing LDLR and hence 
upregulating LDL uptake from plasma and reducing cholesterol in the circulation. 
miR-125a-5p is predicted to target HMGCR and CYP11B2 mRNAs. It is suggested 
that miR-125a-5p might be a therapeutic tool to decrease cholesterol level and 
to repress the production of aldosterone in APA. 
miR-335 has a total of 637 target mRNAs predicted by IPA analysis. Among these 
is HMGCR. Similar to miR-125a-5p, this miRNA is downregulated in APA tissues. 
In 2009, miR-335 was reported to be downregulated in ACC compared to ACA 
(Soon, Tacon et al. 2009). This study is supported by Schmitz et al. and Chabre 
et al., who found miR-335 to be low in ACC compared to ACA (Schmitz, Helwig 
et al. 2011, Chabre, Libé et al. 2013). Overexpression of miR-335 not only 
inhibits human mesenchymal stem cell (hMSCs) proliferation, migration and 
differentiation but also decreases their adipogenic and osteogenic potential 
(Tome, Lopez-Romero et al. 2011). Furthermore, in breast cancer, miR-335 
supresses tumour reinitiation and metastasis (Png, Yoshida et al. 2011).  
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3.5 Conclusion 
In conclusion, the studies in this chapter have identified from microarray 
profiling that regulation of certain miRNA clusters are consistently differentially 
regulated in similar in APA relative to normal adrenal tissue and share similar 
experimentally-validated targets. Furthermore, my analysis predicts several 
targets of these dysregulated miRNAs to be involved in corticosteroid and 
cholesterol biosynthesis pathway. In order to validate the putative targets and 
miRNAs involved, it is necessary to conduct in vitro analysis; results of this will 
be presented in Chapter 5. However, it was first necessary to optimise the 
selected in vitro cell model, and this is described in Chapter 4. 
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4 Optimisation of H295R Cells 
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4.1 Introduction 
The NCI-H295 cell line was developed from human adrenocortical carcinoma and 
is capable of corticosteroid biosynthesis (Gazdar 1990). However, this original 
strain grew very slowly and only loosely attached to surfaces. Therefore, new 
subtypes were developed by flushing out floating cells and culturing the 
remaining attached cells. The different subtypes and their culturing conditions 
are as described in Chapter 2. This chapter describes a series of studies 
conducted to characterise and compare the different cell strains in order to 
choose the most suitable model for my subsequent studies. 
This chapter also describes attempts to validate some of the microarray and 
bioinformatic result from Chapter 3 (Normal adrenal vs APA) and Chapter 6  
(Basal H295R vs Stimulated Cells; Angio II (100 nM), dbcAMP (1 mM) and KCl (20 
mM)). 
4.2 Aim 
The aim of my study is to combine bioinformatic and laboratory-based 
approaches (in vitro analysis) to investigate the role of miRNAs in the aetiology 
of APA and assess their role in the regulation of steroid production and 
cholesterol pathway. The chapter aim is therefore adrenocortical cell 
characterization  
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4.3 Results 
4.3.1 Adrenocortical Cell Characterization  
4.3.1.1 H295R Cell Line Morphology. 
 
Figure 4-1: Morphology of H295R Strain 1, 2, 3 and HAC 15 under compound microscope. 
 
The four strains were termed H295R-S1, H295R-S2 and H295R-S3 (Le, Liu et al. 
2013), based on the differing serum supplements used for their culture, and HAC 
15, which was developed from an isolated clonal population of H295R cell lines; 
it was thought to be a novel line but subsequent array analysis showed it to be 
derived from contaminating H295R cells (Jeniel Parmar 2008). These lines 
respond well to K+ and Angio II treatment by increasing aldosterone production 
but show a modest effect on cortisol output in response to ACTH (Le, Liu et al. 
2013) by second messenger action, dbcAMP. This due to the extremely low 
expression of ACTH receptor in H295R cell lines. 
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4.3.1.2 CYP11B2 Gene Expression in Angiotensin II-Stimulated Cells 
  
  
Figure 4-2: CYP11B2 gene expression of Strain 1 (A), Strain 2 (B), Strain 3 (C) and HAC 15 
(D) after Angio II Stimulation (n=6 in each group).  
See Table 4-1 for fold change and Ct values. * indicates p<0.05. 
 
 
CYP11B2 gene expression was assessed under basal and stimulated conditions 
(Angiotensin II, 100nM, 24 hours). Prior to Angio II stimulation, the H295R cells 
were seeded for 24 hours to allow cells to adhere to the culture wells. In order 
to optimise the experimental method, Angio II was used as a positive control. 
Angio II, via Angiotensin Type I Receptor (AT1), has been shown to stimulate cell 
growth, regulates  gene expression of growth factors, cytokines and activates 
multiple intracellular signalling cascade and transcription factors (Kim and Iwao 
2000). Under Angio II stimulation, as shown in Figure 4-2 and Table 4-1, Strain 1 
showed the highest expression of CYP11B2 (25-fold) followed by strain 2 (5-fold) 
and strain 3 (2-fold). On the other hand, HAC 15 demonstrated downregulation 
of CYP11B2 gene expression, against expectations (Figure 4-2 D). 
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4.3.1.3 Passage number effect on CYP11B2 Gene Expression 
 
Figure 4-3: CYP11B2 gene expression of H295R Strain 1 according to passage number, 10 
to 20 (n=2 in each group).  
Expression is normalised to GAPDH. See Table 4-3 for fold change and Ct values. * indicates 
p<0.05. 
 
As Strain 1 consistently showed the highest and most significant rise in CYP11B2 
expression in stimulated cells, study of the effect of passage number on its 
responsiveness was performed. Cells were stimulated with 100 nM of Angio II for 
24 hours at passages 10, 17 and 20. Figure 4-3 and Table 4-3 show that Angio II 
responsiveness decreased with passage number (CYP11B2 fold-change decreased 
from 25 to 4 from passages 10 to 20), with the stimulation of CYP11B2 more 
pronounced in younger cells. 
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4.3.1.4 CYP11B2 Gene Expression in dbcAMP-, and KCl-Stimulated Cells 
  
Figure 4-4: CYP11B2 gene expression of H295R Strain 1 after dbcAMP (A) and KCl (B) 
stimulation (n=6 in each group).  
See Table 4-2 for fold-change and Ct values. * indicates p<0.05. 
 
H295R Strain 1 was further investigated for trophic responses by stimulating the 
cells with dbcAMP (1 mM) and KCl (20 mM) for 24 hours.  Both of these 
significantly increased CYP11B2 gene expression relative to basal conditions 
(Figure 4-4 and Table 4-2).  
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Table 4-1: CYP11B2 expression in different strains of H295R cells.  
Ct=cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Cell Strain n Basal               
Mean Ct (SD) 
CYP11B2           
Mean Ct (SD) 
ddCt Fold Change 
(Relative to basal=1) 
p-value 
H295R Strain 1 6 30.28 (0.52) 25.54 (0.31) -4.66 25.22 0.00 
H295R Strain 2 6 25.45 (0.38) 22.41 (0.22) -2.44 5.44 0.00 
H295R Strain 3 6 29.09 (0.40) 28.10 (0.22) -0.97 1.95 0.00 
HAC 15 6 25.73 (0.39) 25.97 (0.17) 0.49 0.71 0.00 
 
Table 4-2: CYP11B2 expression following stimulation (Angio II, dbcAMP and KCl) of H295R cells (Strain 1).  
Ct=cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Stimulation n Basal               
Mean Ct (SD) 
CYP11B2           
Mean Ct (SD) 
ddCt Fold Change 
(Relative to basal=1) 
p-value 
Angio 6 30.28 (0.52) 25.54 (0.31) -4.66 25.22 0.00 
dbcAMP 6 34.32 (0.69) 29.58 (0.28) -4.33 20.08 0.00 
KCl 6 34.32 (0.69) 27.66 (0.26) -6.44 88.85 0.00 
 
Table 4-3: CYP11B2 expression by passage number in H295R cells (Strain 1).  
Ct=cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Passage     
(H295R Strain 1) 
n Basal               
Mean Ct (SD) 
CYP11B2           
Mean Ct (SD) 
ddCt Fold Change 
(Relative to basal=1) 
p-value 
Passage 10 6 30.28 (0.52) 25.54 (0.31) -4.66 25.22 0.00 
Passage 17 6 29.45 (0.46) 26.10 (0.17) -3.30 9.87 0.00 
Passage 20 6 26.57 (1.09) 24.76 (0.58) -1.82 3.52 0.01 
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4.3.1.5 H295R Cell Proliferation in Response to Angiotensin II (100 nM) in 
MTS and BrdU 
  
Figure 4-5: H295R cell proliferation in response to Angio II stimulation (100nM) in MTS (A) 
and in BrdU (B). 
n=4 in each group. * indicates p<0.05. 
 
  
A B 
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Next, the cells were quiescent for 48 hours to arrest cell proliferation (as 
described in Chapter 2, Material & Method, Section 2.4). After 2 days without 
any serum supplement to the cells, they were stimulated with 100 nM Angio II to 
assess its effect on cell proliferation. There was a trend towards increased 
proliferation using the MTS assay for 24, 48 and 72 hours but this did not achieve 
significance (Figure 4-5 A). However, the proliferation of H295R was significant 
using the BrdU assay (Figure 4-5 B) at time points from 24 to 72 hours post-
stimulation. The optimal proliferation time point was noted as 48 hours.
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4.4 Discussion 
Gazdar et al established the human adrenocortical tumour cell line from a 
patient with invasive primary adrenocortical carcinoma patient (Gazdar, Oie et 
al. 1990). As previously noted, these NCI-H295R cells grew in floating clumps and 
had >96 hours doubling time. It was the first cell line established to produce 
steroids. However the cells were developed further for monolayer cultures 
(Rainey, Bird et al. 1994), to suit laboratory use and the doubling time shortened 
to 48 hours. This resulted in different strains, each with different serum 
supplementation required for cell growth (Wang, Rowland et al. 2012).  
In this chapter, a series of studies was conducted to characterise and compare 
the different strains in order to choose the most suitable model for subsequent 
in vitro studies. In order to optimise the experimental method, I used 
Angiotensin II (Angio II) as my positive control. Angio II, via Angiotensin Type I 
Receptor (AT1), has been shown to stimulate cell growth, regulate  gene 
expression of growth factors and cytokines, and activate multiple intracellular 
signalling cascade and transcription factors (Kim and Iwao 2000). In this study, it 
was clearly shown that Angio II stimulated CYP11B2 gene expression in Strains 1, 
2 and 3 (Figure 4-2), with the greatest stimulation being in Strain 1. This strain 
also showed upregulation of CYP11B2 following dbcAMP and KCl stimulation 
(Figure 4-4). The finding is supported by several studies indicating that the cell 
line is an effective model for steroidogenesis (Bird, Hanley et al. 1993, Xing, 
Edwards et al. 2011). H295R-Strain 1 is commercially available from the 
American Type Culture Collection (ATCC CRL-2128), grows in Nu-Serum type I 
(Wang and Rainey 2012) and is able to produce steroid under basal and 
stimulated conditions.  
The key factor in cell culture experiment is the quality of the cells. The cells 
determine the reliability and reproducibility result; if impaired, these will 
introduce great variability into the experiment. The H295R cell line showed 
reduced CYP11B2 responsiveness with increasing passage number (Figure 4-3). 
This is consistent with a de-differentiation of the cells from their steroidogenic 
phenotype as passage number increases. this is a well-recognised phenomenon; a 
previous study, using RAW 264.7 (ATCC® TIB-71™) cells, showed significant 
reduction in the quality of protein expression with high passage (Linda Jacobsen 
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2007). O’Driscoll et al compared low passage (18) and high passage (40) of MIN-6 
cells and found that there were significant differences of mRNA expression that 
involved in proliferation, adhesion and secretion (O’Driscoll L et al. Phenotypic 
and global gene espression changes in low and high passage MIN6 cells 
(O’Driscoll, Gammell et al. 2006).  
Study of selected miRNA effects on gene expression requires optimised 
transfection of the newly-characterised H295R cells. Transfection is defined as 
the process of deliberately introducing nucleic acid (e.g. RNA, miRNA) into cells. 
There are several methods of RNA delivery including microRNA injection, 
electroporation and lipid-mediated transfection, using agents such as 
LipofectamineTM 2000. LipofectamineTM 2000 had been chosen as the transfection 
agent for this model because it is effective for transfecting adhered cell, even 
though it is reported to cause cytotoxicity in some cell lines (Zhong, Wei et al. 
2008). However, many in vitro experiments report successful transfection of 
H295R cells with LipofectamineTM 2000 (Bouizar, Ragazzon et al. 2010, He, Cao 
et al. 2015, Udhane, Pandey et al. 2015). LipofectamineTM 2000 is a cationic 
liposome that forms a complex with nucleic acids, Lipofecatmine interacting 
with their negatively-charged sugar-phosphate backbones. The cationic state of 
the complex will overcome the electrostatic repulsion of the cell membrane and 
permit entry to the cell. This allows miRNA, for example, access to the cell’s 
intracellular processing mechanisms. Some studies support the ability of 
LipofectamineTM 2000 complex to penetrate the intact nuclear envelope (Dalby, 
Cates et al. 2004). 
In conclusion, my optimisation studies established H295R strain 1 at lower 
passage numbers as the best cell line to be used for validation of microarray 
data. This validation will be the focus of the next chapter. 
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5 Validation of NA vs APA Microarray Study 
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5.1 Introduction 
Microarray study has permitted the analysis of thousands of gene expression 
profiles for various diseases. In Chapter 3, we were able to determine miRNA 
profiles in NA vs APA tissue by microarray. Microarray has limited depth of 
analysis due to the relatively low amount of RNA used in this particular method. 
Normally only a small (microgram) amount of RNA is utilised for standard 
hybridisation and detection of gene expression in microarray analysis. Therefore, 
further analysis using higher concentration of RNA is needed for validation 
purposes. The optimal validation method is qRT-PCR. In this chapter, 2 key 
miRNAs were selected for further analysis: miR-125a-5p and miR-335-5p. Both of 
these were predicted to block HMGCR, a very important gene for cholesterol 
production. Interestingly, both of these miRNAs were shown to have similar 
effects to CYP11B2, despite only miR-125a-5p being a putative target for the 
aldosterone synthase gene, according to IPA. 
5.2 Aim 
To validate microarray results and IPA prediction by qRT-PCR. 
5.3 Result: Validation of the microarray and bioinformatic 
study of Normal Adrenal vs APA 
5.3.1 miR-125a-5p 
5.3.1.1 miR-125a-5p in Microarray and qRT PCR 
In microarray analysis of NA vs APA microRNA expression, miR-125a-5p was found 
to be downregulated in APA tissues (Figure 5-1 A). In order to examine whether 
this change in miR-125a-5p expression might be related to the dysregulated 
aldosterone biosynthesis of APA, aldosterone production was stimulated in vitro 
using the H295R adrenocortical cells model, incubated with dbcAMP to mimic 
the ACTH stimulation of aldosterone secretion by adrenocortical tissue in vivo 
(Saruta, Okuno et al. 1979). miR-125a-5p levels were then quantified in these 
cells by realtime SYBR Green qRT-PCR (see Chapter 2, Section 2.11). In a similar 
manner to the tissue, miR-125a-5p-5p was downregulated in the dbcAMP-
stimulated cells relative to the basal state (Figure 5-1 B; Table 5-1). This 
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suggests that changes in the expression of miR-125a-5p are a statistically 
significant phenomenon related to changes in aldosterone regulation.  
  
Figure 5-1: A: Microarray expression of miR-125a-5p (n= 3) in NA vs APA tissue. B: Similar 
reduction in miR-125a-5p observed in H295R cells stimulated with dbcAMP (n=6).  
* indicates p<0.05. 
 
Table 5-1: miR-125a-5p expression in Basal vs dbcAMP-stimulated cells (Strain 1).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
miRNA n Basal               
Mean Ct (SD) 
dbcAMP            
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-value 
miR-125a-5p 6 19.87 (0.19) 20.35 (0.10) 0.57 0.68 <0.01 
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5.3.1.2 miR-125a-5p Expression in Transfected Cells 
To further investigate the role of miR-125a-5p, H295R Strain 1 was transfected 
with pre-miR-125a or anti-miR-125a-5p. The transfection efficiency was assessed 
by SYBR Green qRT-PCR (see Chapter 2, Section 2.11). miR-125a-5p was found to 
be highly expressed following pre-miR-125a-5p transfection (311-fold increase; 
Table 5-2; Figure 5-2 A) and significantly downregulated following anti-miR-
125a-5p transfection (Figure 5-2 B).  
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Figure 5-2: miR-125a-5p expression in H295R cells following transfection with (A) pre-miR-
125a-5p or (B) anti-miR-125a-5p transfection (n=6 in each group).  
* indicates p<0.05. 
 
Table 5-2: miR-125a-5p expression following precursor-miRNA transfection. 
 Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
miRNA n Pre-Neg   
Mean Ct 
(SD) 
Pre-miRNA      
Mean Ct (SD) 
ddCt Fold Change  
(Relative to basal= 1) 
p-
value 
miR-125a-5p 6 15.94 (0.18) 8.47 (0.62) -8.28 311.42 <0.01 
 
Table 5-3: miR-125a-5p expression following anti-miRNA transfection.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
miRNA n Anti-Neg        
Mean Ct 
(SD) 
Anti-miRNA      
Mean Ct (SD) 
ddCt Fold Change  
(Relative to basal= 1) 
p-
value 
miR-125a-5p 6 15.91 (0.29) 24.28 (0.58) 8.08 0.00 <0.01 
 
The effects of these transfections on the cells’ expression of steroidogenesis-
related genes and targets predicted by IPA were then investigated. 
A B 
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5.3.1.3 CYP11B2 Gene Expression in Pre-miR-125a and Anti-miR-125a 
Transfection 
In IPA analysis, miR-125a-5p was predicted to bind CYP11B2 mRNA. This effect 
was tested in vitro by transfecting H295R cells with pre-miR-125a to significantly 
increase miR-125a-5p levels (see above). This resulted in a significant reduction 
in CYP11B2 mRNA (Figure 5-3 A and Table 5-4). Conversely, transfection with 
anti-miR-125a to reduce the miR levels significantly increased CYP11B2 mRNA 
levels (Figure 5-3 B and Table 5-5). These results are consistent with the IPA 
prediction of a direct action by miR-125a-5p on CYP11B2 mRNA. 
 
 
Figure 5-3: Effects on CYP11B2 mRNA levels in H295R Strain 1 cells following transfection 
with pre-miR-125a (A) or anti-miR-125a (B) (n= 3 in each group).  
* indicates p<0.05. 
 
Table 5-4: CYP11B2 gene expression in H295R cells (Strain 1) transfected with precursor-
negative miRNA (Pre-Neg) or precursor-miRNA-125a (Pre-miRNA-125a).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Pre-Neg  
Mean Ct (SD) 
Pre-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-value 
CYP11B2 3 26.58 (0.65) 30.10 (0.34) 2.56 0.17 0.00 
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Table 5-5: CYP11B2 gene expression in H295R cells (Strain 1) transfected with CYP11B2 anti-
negative miRNA (Anti-Neg) or anti-miRNA-125a.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Anti-Neg  
Mean Ct (SD) 
Anti-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change  
(Relative to 
basal= 1) 
p-value 
CYP11B2 3 29.53 (0.19) 28.22 (0.40) -1.93 3.81 0.01 
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5.3.1.4  HMGCR Gene Expression in Pre-miR-125a and Anti-miR-125a 
Transfection 
The IPA prediction of a direct regulatory effect of miR-125a-5p on HMGCR was 
also tested in this system. Despite showing trends toward decreased HMGCR 
mRNA following pre-miR-125a transfection (Figure 5-4 A) and an increase after 
anti-miR-125a transfection (Figure 5-4 B), these effects did not achieve 
significance.  
  
Figure 5-4: HMGCR mRNA levels in H295R Strain 1 cells following (A) pre-miR-125a 
transfection or (B) anti-miR-125a transfection (n=3 in each group). 
 
Table 5-6: HMGCR expression in H295R cells (Strain 1) transfected with precursor-negative 
miRNA (Pre-Neg) or precursor-miRNA-125a (Pre-miRNA-125a).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Pre-Neg  
Mean Ct (SD) 
Pre-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-value 
HMGCR 6 21.36 (0.30) 21.96 (0.55) 0.15 0.90 0.56 
 
Table 5-7: HMGCR expression in H295R cells (Strain 1) transfected with anti-negative 
miRNA (Anti-Neg) or anti-miRNA-125a.  
Ct=cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Anti-Neg  
Mean Ct (SD) 
Anti-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change  
(Relative to 
basal= 1) 
p-value 
HMGCR 6 21.33 (0.27) 21.74 (0.18) -0.03 1.02 0.82 
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5.3.2 miR-335-5p 
5.3.2.1 miR-335-5p Expression in Transfected Cells 
Similar to miR-125a-5p, above, miR-335-5p was identified by microarray as being 
downregulated in APA relative to NA tissue, and was also predicted by IPA to 
target CYP11B2 and HMGCR expression through direct action on their respective 
mRNAs. To investigate this further, H295R Strain 1 cell was this time transfected 
with pre-miR-335 and anti-miR-335. miR-335-5p was significantly increased 1431- 
fold following pre-miR transfection (Figure 5-5 and Table 5-8) in the precursor 
transfection but no changes were noted in transfection of anti-miR-335-5p. 
  
Figure 5-5: miR-335-5p levels in H295R cells following (A) pre-miR-335 transfection or (B) 
anti-miR-335 transfection (n= 3 in each group).  
* indicates p<0.05. 
 
Table 5-8: miR-335-5p expression following precursor-miRNA transfection.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
miRNA n Pre-Neg   
Mean Ct 
(SD) 
Pre-miRNA-335     
Mean Ct (SD) 
ddCt Fold Change 
(Relative to basal= 1) 
p-
value 
miR-335-5p 3 26.71 (0.37) 12.58 (0.64) -13.81 14317.20 <0.01 
 
Table 5-9: miR-335-5p expression following anti-miRNA transfection.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
miRNA n Anti-Neg        
Mean Ct (SD) 
Anti-miRNA-335      
Mean Ct (SD) 
ddCt Fold Change (Relative 
to basal= 1) 
p-
value 
miR-335-5p 3 26.66 (0.70) 27.51 (0.87) 0.80 0.58 0.32 
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5.3.2.2 CYP11B2 Gene Expression in Pre-miR-335 and Anti-miR-335 
Transfection 
miR-335-5p action on CYP11B2 mRNA was investigated in the transfected cells. 
This confirmed suppression of CYP11B2 mRNA levels following pre-miR-335 
transfection (Figure 5-6 A and Table 5-10). However, the same significant effect 
was also observed following anti-miR-335 transfection (Figure 5-6 B); this result 
contradicts the hypothesis, which predicted that anti-miR-335 should upregulate 
the miR-335-5p expression. 
  
Figure 5-6: CYP11B2 mRNA levels in H295R Strain 1 cells following transfection with (A) 
pre-miR-335 or (B) anti-miR-335 (n= 3 in each group).  
* indicates p<0.05. 
 
Table 5-10: CYP11B2 mRNA levels in H295R Strain 1 cells following transfection with 
precursor-negative miRNA (Pre-Neg) and precursor-miRNA-335 (pre-miR-335).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Pre-Neg  
Mean Ct (SD) 
Pre-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-value 
CYP11B2 3 24.30 (0.50) 27.46 (0.47) 3.40 0.09 <0.01 
 
Table 5-11: CYP11B2 mRNA levels in H295R Strain 1 cells following transfection with 
CYP11B2 anti-negative miRNA (Anti-Neg) and anti-miRNA-335 (anti-miR-335).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Anti-Neg  
Mean Ct (SD) 
Anti-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change  
(Relative to 
basal= 1) 
p-value 
CYP11B2 3 24.15 (0.42) 27.83 (0.36) 4.17 0.06 <0.01 
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5.3.2.3 HMGCR Gene Expression in Pre-miR-335 and Anti-miR-335 
Transfection 
In vitro analysis also confirms this predicted suppression of HMGCR mRNA levels 
following pre-miR-335 transfection (Figure 5-7 A and Table 5-12). However, again 
anti-miR-335 transfection (Figure 5-7 B) also results in suppression of the same 
mRNA. 
  
Figure 5-7: HMGCR levels in H295R Strain 1 cells following transfection with (A) pre-miR-335 
or (B) anti-miR-335 transfection (n= 3 in each group).  
* indicates p<0.05. 
 
Table 5-12: HMGCR mRNA levels in H295R Strain 1 cells following transfection with 
precursor-negative miRNA (Pre-Neg) and precursor-miRNA-335 (Pre-miR-335).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Pre-Neg  
Mean Ct (SD) 
Pre-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-value 
HMGCR 3 24.37 (0.35) 25.03 (0.46) 0.89 0.54 0.03 
 
Table 5-13: HMGCR mRNA levels in H295R Strain 1 cells following transfection with HMGCR 
anti-negative miRNA (Anti-Neg) and anti-miRNA-335 (anti-miR-335).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard deviation. 
Gene n Anti-Neg  
Mean Ct (SD) 
Anti-miRNA-125a  
Mean Ct (SD) 
ddCt Fold Change  
(Relative to 
basal= 1) 
p-value 
HMGCR 3 24.31 (0.19) 24.79 (0.06) 0.98 0.51 0.01 
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5.4 Discussion 
In this part of the study, selected miRNAs differentially expressed in NA vs APA 
and predicted to bind important steroidogenic mRNAs (see Chapter 3) were 
analysed further. miR-125a-5p levels had been reduced in APA tissue according 
to microarray analysis (Figure 5-1 A), and this finding was supported by its 
downregulation in dbcAMP-stimulated cells (Figure 5-1 B). This indirect method 
of comparison was necessary because there were no more APA or NA RNA 
samples available for direct realtime RT-PCR (qRT PCR) validation of the 
microarray results. Therefore, stimulated cells from the H295R Strain 1 
adrenocortical cell line were used instead. This is the best available model for 
these studies (see Chapter 4) but the expression of ACTH receptor is very low in 
these cells. Because of this, dbcAMP was used to mimic the stimulatory ACTH 
action on aldosterone production rather than ACTH itself. Cells stimulated with 
dbcAMP were intended to mimic the pathological condition in APA, where high 
levels of ACTH are detected. This is supported by Arnaldi et al, who observed 
overexpression of ACTH-receptor mRNA in APA but not in adrenocarcinoma 
(Arnaldi, Mancini et al. 1998). The summary of differential expression of miRNA 
in APA vs NA is shown in Chapter 1, Table 1-8. 
pre-miR-125a transfection of cells significantly reduced CYP11B2 mRNA, while 
inhibition of miR-125a-5p production increased transcript levels almost fourfold. 
This finding is supported by a previous pEZX-reporter plasmid study, where pre-
miR-125a was co-transfected into HeLa cells along with a reporter plasmid 
containing the CYP11B2 3’UTR; this significantly suppressed the reporter 
plasmid’s luciferase activity, offering further evidence of a direct interaction 
between this miRNA and CYP11B2 transcripts (Stacy Wood 2011). In another 
recent study, suppression of miR-125a-5p expression in colon cancer cell lines 
and colon cancer tissue inhibited their proliferation. This was the result of the 
microRNA targeting antiapoptotic genes (BCL2, BCL2L12 and MCL-1) (Tong, Liu 
et al. 2015). In hepatocellular carcinoma, miR-125a-5p is also reported to 
suppress the P13K/ AKT/mTOR signalling pathway that is involved in the 
migration and invasion of liver cancer cells (Tang, Li et al. 2015). 
Several miRNAs downregulated in APA, including the two studied in this chapter, 
are predicted by IPA to target HMGCR. Although there was no significant 
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evidence that miR-125a-5p targets HMGCR, pre-miR-335 did reduce levels of the 
mRNA in vitro. HMGCR is a rate-limiting gene in cholesterol production and so 
may be an important determinant of steroid biosynthesis. However, no 
validation studies have been done to evaluate whether reduction of HMGCR 
expression has a direct effect on adrenal steroidogenesis in vivo. Nevertheless, 
rat in vivo studies show that statins (especially simvastatin) result in 
downregulation of CYP17A1 expression in ovarian theca-interstitial cells 
(Sokalska, Stanley et al. 2014).  
miR-335-5p expression in cancer tissues has already received much attention. As 
reported by Schmitz et al, the significant upregulation of miR-335-5p observed in 
adrenocortical carcinoma (ACC) is proposed as a potential diagnostic tool to 
discriminate ACC from adrenocortical adenoma (ACA) (Schmitz, Helwig et al. 
2011). This is supported by Soon et al, who reported that the expression of miR-
335-5p is also suppressed in ACA relative to its ACC counterpart (Soon, Tacon et 
al. 2009). However, in breast carcinoma, overexpression of miR-335-5p positively 
correlates with expression of the tumour suppression gene BRCA1, inhibiting cell 
viability and stimulating apoptosis (Heyn, Engelmann et al. 2011). In this 
experiment, despite downregulation of CYP11B2 and HMGCR gene expression in 
the pre-miR-335 transfection, both were also supressed in anti-miR-335 
transfection. This may due to insufficient level of anti-miR-335 in the cell to 
negatively regulate miR-335-5p or may be due to an alternative pathway (or 
gene) modulating the function of anti-miR-335 and leading to decrease levels of 
CYP11B2 and HMGCR mRNA.  
However, despite the predictions of IPA, some of the targets were not validated 
by lab experiment. This may be due to incorrect prediction of the strength of 
complementary binding between miRNAs and mRNAs. IPA classifies base-pairing 
as highly-predicted (8mer) or moderately-predicted (7mer). Highly-predicted 
targets have a higher chance of forming base-pairs between miRNA and mRNA. 
Furthermore, the non-validated targets may be due to inefficiency of miRNA 
transfection, either due to poor cell line responsiveness or the efficacy of 
transfection protocol. In addition, to find the cell line that is a precise model for 
the tissue of interest is challenging. To date, the most suitable cell line used for 
steroid regulation is H295R cells, which is a human adrenocortical carcinoma cell 
line, not APA. This might lead to discrepancies in validation. 
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5.5 Conclusion 
In summary, this chapter has been able to experimentally validate some of the 
IPA predictions, in particular effects of miR-125a-5p and miR-335-5p. Both of 
these miRNAs have been predicted and validated to be involved in 
steroidogenesis and cholesterol biogenesis. This is a novel finding in steroid and 
cholesterol regulation. Further experiments are needed to extend this result so 
that it might contribute to the improvement of diagnosis and treatment of APA 
and other diseases relevant to steroid biosynthesis and cholesterol handling.  
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6 Analysis of microRNA in Basal, Angiotensin II, 
dbcAMP- and KCl-Stimulated H295R Cells. 
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6.1 Introduction 
As in Chapter 3, microarray analysis is again utilised here for miRNA expression 
analysis. I subjected H295R cells to three different types of aldosterone 
stimulation: angiotensin II (Angio II), potassium (in the form of KCl) and dibutyryl 
cAMP (dbcAMP), to mimic ACTH stimulation; non-stimulated basal cells were 
used as controls. After 24 hours, I isolated RNA and confirmed stimulation by 
qRT-PCR of CYP11B2 (aldosterone synthase) mRNA. The microRNA profile of each 
sample was then analysed by microarray and differentially-expressed miRNAs 
were identified. Finally, bioinformatic analysis was used to identify possible 
targets through which differentially-expressed miRNAs might affect steroid or 
cholesterol production. This was achieved using the Ingenuity Pathway Analysis 
(IPA) software.  
Subsequently I validated by qRT-PCR the significant changes in expression 
observed in microarray by using the more reliably quantitative method of qRT-
PCR. It was my intention to look at the consistently downregulated miRNAs that 
emerge from microarray as listed below: 
1. miR-106a-5p  
2. miR-154-3p  
3. miR-17-5p 
4. miR-196b-5p 
5. miR-19a-3p 
6. miR-20b-5p 
7. miR-766-3p 
 
 However, expression of one of these miRNAs was found to be marginal from 
microarray (i.e miR-196b-5p), so was excluded from further study. I present 
validation of the 6 remaining miRNAs under each of the 3 stimulatory conditions 
(Angio II, dbcAMP and KCl). IPA also prediscts that miR-17 will suppress the 
expression of LDLR; I investigate whether this miRNA significantly downregulates 
this predicted target. 
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6.2 Aim 
1. To identify significant differences in microRNA profile between cells 
stimulated for aldosterone production and their basal counterparts. 
2. To identify mRNA targets of key differentially-expressed microRNAs. 
3. To experimentally validate the consistently expressed miRNA from all 3 
stimulation groups – as assessed by microarray - using qRT-PCR. 
4. To experimentally validate expression of the putative target of miR-17, 
LDLR, by qRT PCR. 
6.3 Microarray results 
Total RNA was extracted from 3 biological samples (in each group) of non-
stimulated H295R cells (basal), Angiotensin II-stimulated cells (Angio II), 
dbcAMP-stimulated cells (dbcAMP) and KCl-stimulated cells (KCl). The RNA 
quantity was determined by Nanodrop (Section 2.7) and further assessed by 
Agilent Bioanalyser chip for quality analysis. The RNA samples were sent for 
miRNA profile analysis by microarray microfluidic chip (LC Sciences, Houston, 
Texas). Prior to that, all RNAs were subjected to quality control testing by the 
company. 
Similar to the data presented in Chapter 3, as recommended by the microarray 
manufacturer, a 500 arbitrary unit (AU) cut-off point was applied to the miRNA 
detection threshold. The microarray analysis identified a list of expressed 
miRNAs (i.e. miRNAs that register > 500AU in basal or stimulated cells) and 
differentially-expressed miRNAs (i.e. miRNAs expressed in both basal and 
stimulated cells at >500 AU, but at significantly different levels (p<0.05)). 2019 
miRNAs were screened in each of the cell groups. There is a strong positive 
correlation between miRNA expression in the basal group and each of the 3 
stimulated groups (Figure 6-1), suggesting the majority of miRNAs do not alter 
significantly under stimulation. 
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- Relative to basal, Angio II treatment resulted in differential expression of 
32 miRNAs, of which 12 were present in both Angio II and basal cells but 
at significantly different levels (p<0.05), 13 were present only in the basal 
group and 7 only in the Angio II group (Figure 6-5). 
- dbcAMP treatment altered 84 miRNAs, of which 53 were expressed in both 
groups at different levels (p<0.05), 19 in basal only and 12 in dbcAMP-
treated cells only (Figure 6-3).  
- KCl treatment altered 61 miRNAs, of which 45 were expressed in both 
groups at different levels (p<0.05), 5 in basal only and 11 in KCl-treated 
cells only (Figure 6-4). 
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Figure 6-1: Scatter plots showing relative miRNA levels in basal (non-treated cells) vs Angio 
II-, dbcAMP- and KCl-treated cells, as analysed by microarray. 
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Figure 6-2: Venn Diagram of the number of expressed miRNAs that were detected >500 AU 
in basal and/or Angio II-stimulated cells (H295R).  
miRNAs listed as ‘Both’ were detected in both basal and stimulated cells, but at significantly 
different levels (p<0.05). 
 
Figure 6-3: Venn Diagram of the number expressed miRNAs that were detected >500 AU in 
basal and/or dbcAMP-stimulated cells (H295R). 
miRNAs listed as ‘Both’ were detected in both basal and stimulated cells, but at significantly 
different levels (p<0.05). 
 
Figure 6-4: Venn Diagram of the number expressed miRNAs that were detected >500 AU in 
basal and/or KCl-stimulated cells (H295R).  
miRNAs listed as ‘Both’ were detected in both basal and stimulated cells, but at significantly 
different levels (p<0.05).  
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6.3.1 Differentially Expressed miRNAs in Basal vs Angiotensin II, 
dbcAMP and KCl; miRBase Annotation 
The latest miRBase Release 21: June 2014, contains 28,645 entries of hairpin 
precursor miRNAs, including 35,828 mature miRNAs from 223 species (miRBase 
2014). The miRNA names use the prefix “miR” followed by a unique and specific 
identifying number assigned sequentially regardless of organism. Similar 
identifying numbers are given to identical or almost identical miRNA sequences. 
As almost all miRNA precursors produce mature miRNA from either the 5’ or 3’ 
end of the hair-pin strand, ‘5p’ or ‘3p’ is added to the annotation (Ambros, 
Bartel et al. 2003). The microarray data were further analysed utilising the 
latest miRBase Release 21: June 2014.  
Quantitative data relating to the differentially-expressed miRs mentioned above 
are provided in Figure 6-5, Figure 6-6 and Figure 6-7, below. The most 
abundantly-expressed miRNA is miR-23b-3p. It is highly expressed in dbcAMP-
stimulated cells (average fluorescence intensity 19,005, p-value=0.0006) and is 
similarly up-regulated in both dbcAMP and KCl-stimulated cells (but not Angio II 
stimulated cells) relative to basal (Figure 6-6). 
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Figure 6-5: Microarray data showing differentially-expressed miRNAs in basal vs Angio II-treated cells (all miRNAs shown have AU>500). 
*miRNAs >500AU in APA or NA; †miRNAs present in both tissues but at significantly different levels (p<0.05). 
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Figure 6-6: Microarray data showing differentially expressed miRNAs in Basal vs dbcAMP-treated cells (all miRNAs shown have AU>500). 
*miRNAs >500AU in APA or NA; †miRNAs present in both tissues but at significantly different levels (p<0.05). 
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Figure 6-7: Microarray data showing differentially expressed miRNAs in Basal vs KCl-treated cells (all miRNAs shown have AU>500). 
*miRNAs >500AU in APA or NA; †miRNAs present in both tissues but at significantly different levels (p<0.05
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6.3.2 Consistent miRNA Expression Across the 3 Stimulatory 
Treatments (Angio II, dbcAMP and KCl) & The Cluster 
Involved 
Relative to basal, the 7 miRNAs consistently differentially expressed across Angio 
II, dbcAMP and KCl-stimulated cells are:  
1) hsa-miR-106a-5p  
2) hsa-miR-154-3p  
3) hsa-miR-17-5p 
4) hsa-miR-196b-5p 
5) hsa-miR-19a-3p 
6) hsa-miR-20b-5p 
7) hsa-miR-766-3p 
These are downregulated in each of the stimulated groups (Figure 6-8 to Figure 
6-10). miR-154-3p is clustered with 22 other miRNAs (not listed here), none of 
which are consistently expressed throughout the stimulated groups. On the other 
hand, neither miR-196b-5p nor miR-766-3p belong to any cluster.  
miR-106a-5p and miR-20b-5p are found within the same cluster, which is located 
on chromosome X. They have similar seed sequences for mRNA targets 
(AAAGUGC). Other miRNAs from the same cluster are miR-106-3p, miR-18b-3p, 
miR-18b-5p, miR-19b-3p, miR-19b-5p, miR-363-3p, miR-363-5p, and miR-92a-3p. 
Furthermore, miR-106a-5p, miR-19b-3p, miR-20b-5p have similar patterns of 
expression while mir-92a-3p exhibits an opposite trend, being upregulated by 
the 3 stimulations. However, miR-106a-3p, miR-18b-3p, miR-18b-5p, miR-363-3p 
and miR-363-5p are expressed below 500 AU. 
miR-17-5p and miR-19a-3p are from the same cluster on chromosome 13. They 
are encoded by the miR-17-92 gene inside a single polycistronic transcript along 
with 4 other miRNAs (miR-18a, miR-20a, miR-19b-1 and miR-92a-1). They have 
similar pattern of expression with other miRNAs within the same cluster; miR-
20a-5p and miR-19b-3p. In contrast, miR-92a-3p shows an opposite pattern 
where the miRNA is highly upregulated in the 3 stimulated groups. miR-17-3p, 
miR-18a-5p, miR-18a-3p, miR-19a-5p, miR-19b-1-5p and miR-92a-1-5p are not 
expressed in the samples (<500 AU). 
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Figure 6-8: Consistent pattern of miRNA expression in Angio II-stimulated cells relative to 
basal.  
The dotted line indicates the detection cut-off point of 500 AU (n=3 in each group). †miRNAs 
>500AU in APA or NA; *miRNAs present in both tissues but at significantly different levels 
(p<0.05). 
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Figure 6-9: Consistent pattern of miRNA expression in dbcAMP-stimulated cells relative to 
basal.  
The dotted line indicates the detection cut-off point of 500 AU (n=3 in each group). †miRNAs 
>500AU in APA or NA; *miRNAs present in both tissues but at significantly different levels 
(p<0.05). 
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Figure 6-10: Consistent pattern of miRNA expression in KCl-stimulated cells relative to 
basal.  
The dotted line indicates the detection cut-off point of 500 AU (n=3 in each group). †miRNAs 
>500AU in APA or NA; *miRNAs present in both tissues but at significantly different levels 
(p<0.05). 
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Figure 6-11: miRNA Clusters detected from microarray analysis (Cluster miR-106a/ miR-20b).  
* p<0.05 relative to basal.
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Cluster miR-17/ miR-19a
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Figure 6-12: miRNA Clusters detected from microarray analysis (Cluster miR-30b, Cluster miR-17/ miR-19a).  
* p<0.05 relative to basal.
190 
 
6.4 Ingenuity® Systems Pathway Analysis (microRNA 
target filter) 
Ingenuity® Systems Pathway Analysis (IPA; Ingenuity Systems, Redwood City, CA 
USA; http://www.ingenuity.com) software was utilised to determine 
differentially-expressed miRNAs and their putative targets along with their 
molecular and cellular functions. The sources of the miRNA Target Filter are 
Ingenuity Expert Finding, Ingenuity ExpertAssist Finding, miRecords, Tarbase and 
TargetScan Human.  
The filter system is based on 3 confidence levels;  
1) Experimentally observed miRNA-mRNA interaction (result based on 
validated experiment). 
2) Highly predicted miRNA-mRNA interaction. 
3) Moderately predicted miRNA-mRNa interaction. 
 
Comparing basal vs Angio II groups, 32 differentially-expressed miRNAs (>500 AU) 
from the microarray data were uploaded into the IPA system. Subsequently, 
using miRNA Target Filter, 22 miRNAs were automatically selected. These 22 
miRNAs include overlapping miRNAs that share the same seed sequence. (This 
will be fully explained in the next section.) Initially, utilising all 3 levels of 
confidence, the 22 miRNAs were predicted to target 9517 mRNAs. However, 
applying experimentally observed confidence levels sharply reduced the number 
of miRNAs to 9 and mRNAs to 108 (Figure 6-13). 
Similarly, comparing the basal vs dbcAMP groups, with 84 differentially-
expressed miRNAs, 61 were included by the IPA miRNA Target Filter with 13683 
mRNA targets predicted. When limited to experimentally observed findings, only 
28 miRNAs targeting 696 mRNAs were included for further analysis (Figure 6-14). 
Finally, 61 differentially-expressed miRNAs from the basal vs KCl groups were 
reduced to 42 miRNAs with 12391 target mRNAs in the database. Of these, 22 
miRNAs and 706 mRNAs were identified as experimentally validated by the 
database (Figure 6-15). 
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Figure 6-13: Summary of differentially expressed miRNA analysis using Ingenuity Pathway Analysis (IPA) for basal vs Angio II-treated cells.  
Using IPA miRNA Target Filter, the number of miRNAs decreases from 32 to 9 and the number of target mRNAs from 9517 to 108. The filter is based on 3 levels of 
confidence (experimentally observed, highly predicted and moderately predicted), as shown above. 
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Figure 6-14: Summary of differentially expressed miRNA analysis using Ingenuity Pathway Analysis (IPA) for basal vs dbcAMP-treated cells.  
Using IPA miRNA Target Filter, the number of miRNAs decreases from 84 to 28 and the number of target mRNAs from 13,683 to 696. The filter is based on 3 levels of 
confidence (experimentally observed, highly predicted and moderately predicted), as shown above. 
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Figure 6-15: Summary of differentially expressed miRNA analysis using Ingenuity Pathway Analysis (IPA) for basal vs KCl-treated cells.  
Using IPA miRNA Target Filter, the number of miRNAs decreases from 61 to 22 and the number of target mRNAs from 12391 to 706. The filter is based on 3 levels of 
confidence (experimentally observed, highly predicted and moderately predicted), as shown above. 
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6.5 Synonymous miRNAs, seed sequences and the 
number of targeted mRNAs (IPA Database). 
The miRNA seed sequence is vital in determining its complementary binding to 
target mRNA. Several annotated miRNAs have identical seed sequences. These 
overlapping miRNAs are termed ‘synonymous miRNAs’. A full list of synonymous 
miRNAs differentially expressed in this study is shown in the tables presented in 
the Appendix. 
For the purposes of clarity and understanding, in this chapter synonymous 
miRNAs are presented separated by an oblique symbol (/) e.g. the synonymous 
miRNAs miR-125b-5p and miR-125a-5p will be listed as ‘miR-125b-5p/miR-125a-
5p’. 
The miRNAs hsa-miR-17-5p, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-20a-5p, 
hsa-miR-20b-5p and hsa-miR-93-5p share the seed sequence, AAAGUGC, and 
therefore have the same predicted 1418 mRNA targets. However, despite their 
high homology, these miRNAs are derived from different clusters and different 
chromosomes.  
Some of these miRNAs are therefore not included in the IPA analysis using miRNA 
Target Filter. Examples are: hsa-miR-1185-1-3p, hsa-miR-136-3p, hsa-miR-139-
3p, hsa-miR-16-2-3p, hsa-miR-20a-3p, hsa-miR-218-1-3p, hsa-miR-335-3p, hsa-
miR-3617-3p, hsa-miR-376b-5p, hsa-miR-376c-5p, hsa-miR-493-5p, hsa-miR-5100, 
hsa-miR-5190, hsa-miR-539-3p, hsa-miR-6076, hsa-miR-7-1-3p, hsa-miR-937-5p. 
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6.6 IPA Target Filter Analysis: mRNA targets involved in 
steroidogenesis, cholesterol synthesis and related 
pathways 
6.6.1 CYP11B2, CYP11B1 & CYP17A1 
As shown in Figure 6-16, 4 miRNAs target the CYP11B2 gene: miR-1275, miR-
4323, miR-647 and miR-766-3p (Basal vs Angio II).  
In the basal vs dbcAMP group (Figure 6-17), 4 miRNAs are predicted to target 
CYP11B2 (miR-125a-5p, miR-1275, miR-647 and miR-766-3p). Four miRNAs – some 
different – are also predicted to target CYP11B2 from the basal vs KCl group 
(Figure 6-18); miR-125a-5p, miR-708-5p/miR-28-5p, miR-766-3p and miR-874-3p.  
Only the basal vs KCl group contains differentially-expressed miRNAs predicted 
to target the other steroidogenic genes CYP11B1 (miR-874-3p) and CYP17A1 
(miR-4730). 
6.6.2 HMGCR, ABCA1, LDLR & other related genes 
From the basal vs Angio II group (Figure 6-16), miR-548v is predicted to target 
HMGCR. Several other miRNAs (mir-140-5p, miR-17-5p, miR-106a-5p, miR-19a-
3p, miR-20b-5p and miR-19b-3p) are predicted to target ABCA1 and LDLR.  
Figure 6-17 shows miRNA-mRNA interactions in the basal vs dbcAMP groups. 
HMGCR is targeted by miR-125b-5p/miR-125a-5p, miR-145-5p, miR-29b-3p/miR-
29a-3p/miR-29c-3p, miR-365-3p/miR-365a-3p and miR-4324. ABCA1 is targeted 
by hsa-miR-130a-3p/miR-454-3p, mir-140-5p, mir-145-5p, miR-17-5p/miR-106a-
5p/miR-19a-3p/miR-20b-5p, miR-19b-3p and miR-23a-3p. LDLR has similar 
targeting miRNAs to ABCA1, plus miR-30c-5p, miR-344d-3p/miR-410, miR-4284 
and miR-4286. 
For the basal vs KCl groups (Figure 6-18), HMGCR is targeted by miR-125b-
5p/miR-125a-5p and miR-29b-3p/miR-29a-3p/miR-29c-3p. ABCA1 is targeted by 
miR-128-3p, hsa-miR-130a-3p/miR-454-3p, miR-17-5p/miR-106a-5p/miR-19a-
3p/miR-20b-5p, miR-19b-3p and miR-23a-3p. 
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Other possibly relevant mRNAs predicted to be targeted include KCNJ5, STAR, 
WNT4, WNT7B, ATP2B3, FDXR and several more, as shown in Figure 6-16 to 
Figure 6-18. 
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Figure 6-16: IPA miRNA target genes for the basal vs Angio II-treated group.  
The arrow from each miRNA indicates inhibition of the target gene.  
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Figure 6-17: IPA miRNA target genes for the basal vs dbcAMP-treated group.  
The arrow from each miRNA indicates inhibition of the target gene. 
199 
 
 
Figure 6-18: IPA miRNA target gene for the basal vs KCl-treated group.  
The arrow from each miRNA indicates inhibition of the target gene.  
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6.7 IPA Target Filter Analysis: experimentally-validated 
mRNA targets by cluster. 
6.7.1 Cluster miR-17-5p and miR-19a-3p (Chromosome 13). 
The miRNAs miR-17-5p and miR-19b-3p originate from a primary miRNA encoded 
at chromosome 13q31.3. Both of these miRNAs are significantly downregulated 
by all of the stimulations (Angio II, dbcAMP and KCl (Figure 6-19). However, 
despite originating from the same cluster, the seed sequences of these 2 miRNAs 
are distinct: AAAGUGC for miR-17-5p and GUGCAAA for miR-19a-3p (Figure 
6-19). miR-17-5p shares a similar seed sequence with hsa-miR-106a-5p, hsa-miR-
106b-5p, hsa-miR-20a-5p, hsa-miR-20b-5p and hsa-miR-93-5p. miR-19a-3p shares 
its seed sequence with miR-19b-3p (GUGCAAA). Based on IPA analysis, there are 
42 experimentally-validated targets for miR-17-5p and 11-experimentally 
validated targets for miR-19a-3p.  
From the Ingenuity Expert Finding literature database, human miR-17-5p has 
been shown to target CCND1 by quantitative RT-PCR, luciferase reporter gene 
assay (Yu, Wang et al. 2008) and Western blotting (Deshpande, Pastore et al. 
2009). PTEN is another mRNA targeted by miR-17-5p and miR-19a-3p (Lima, 
Busacca et al. 2011). miR-17 reduces activation-induced cell death and 
decreases inducible regulatory T-cell differentiation. The function of miR-17 is 
mediated by TGFβR2 and CREB1. The loss of miR-17-92 in CD4 T cells results in 
tumour evasion and this study suggests that regulation of miR-17 could enhance 
the effectiveness of T cell-based tumour therapy(Jiang, Li et al. 2011). miR-17-
5p is shown to directly target HBP1 (HMG-box transcription factor 1) in breast 
cancer cells (Li, Bian et al. 2011). E2F transcription factor 1 (E2F1), E2F 
transcription factor 2 (E2F2) and E2F transcription factor 3 (E2F3) are the 
validated targets for cluster miR-17-92. These are essential for cell cycle 
function, inducing the expression of genes involved in progression of G1 phase to 
S phase (Slaby, Svoboda et al. 2009). High cluster mir-17-92 level leads to 
downregulation of E2F1 protein, thus inhibiting apoptosis (Woods, Thomson et 
al. 2007). Janus kinase 1 (JAK1), is another validated target for miR-17; it plays 
a crucial role in vascular homeostasis and it is required for sprouting 
angiogenesis (Doebele, Bonauer et al. 2010).  
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miR-19a-3p targets CCDN1, as ascertained by luciferase reporter gene assay,  
Western blotting and quantitative RT-PCR (Qin, Wang et al. 2010). miR-19a has 
oncogenic activity through repression of PTEN, a tumour suppressor in the 
Emmu-myc model of mouse B-cell lymphoma (Olive, Bennett et al. 2009). miR-
19a is upregulated in human embryonic stem cells (hES) and inversely expressed 
relative to ERBB4 (erb-b2 receptor tyrosine kinase 4) mRNA; mutation of ERBB4 
has been associated with cancer(Tsai, Singh et al. 2010).  
Other experimentally-validated targets of the clustered miRNAs miR-17-5p and 
miR-19-3p are shown in Figure 6-19. 
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Figure 6-19: (Left) Microarray expression of mir-17-5p and miR-19a-3p across basal (blue), Angio II (red), dbcAMP (purple) and KCl treatments (green). All 
exhibit a consistent pattern throughout stimulation. * p<0.05 relative to basal. (Right) the primary miRNA structure of miR-17-5p and miR-19a-3p: yellow box 
indicates the seed sequence for both miRNA (AAAGUGC for miR-17-5p and GUGCAAA for miR-19a-3p). 
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Figure 6-20: miR-17-5p, miR-19a-3p and their experimentally-validated targets, derived from miRNA Target Filter Analysis (IPA). 
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6.7.2 Cluster miR-106a-5p and miR-20b-5p (Chromosome X). 
The miRNAs miR-106a-5p and miR-20b-5p originate from a primary miRNA 
located on chromosome X. Both miRNAs are significantly downregulated 
following stimulation with Angio II, dbcAMP and KCl (Figure 23). Furthermore, 
they share the same seed sequence (AAAGUGC), as does miR-17-5p. Both miRNAs 
share their seed sequence with hsa-miR-106b-5p, hsa-miR-20a-5p, hsa-miR-20b-
5p and hsa-miR-93-5p. Based on IPA analysis, there are 42 experimentally 
validated targets for miR-106a-5p and miR-20b-5p. 
In the transgenic mouse model for Alzheimer’s disease, miR-106b is shown to 
target TGFβ2 receptor (Wang, Liu et al. 2010). In chronic lymphocytic leukaemia 
(CLL), exogenous transfection with miR-106b demonstrates that ITCH is a direct 
target for this miRNA (Sampath, Calin et al. 2009). E2F1, E2F2 and E2F3 are 
modulated by the cluster members miR-106a-92 and miR-106b-25 (a miR-17-92 
cluster paralog) (Bueno, Gómez de Cedrón et al. 2010). miR-106b is upregulated 
in human gastric tumours and develops a negative-feedback loop to E2F1 gene 
expression (Petrocca, Visone et al. 2008) 
miR-20a facilitates the transition through G1 in normal diploid human cells and 
the inhibition of the miRNA leads to an accumulation of E2F1 transcription factor 
(Pickering, Stadler et al. 2008). ESR1 is targeted by miR-20b, as demonstrated by 
luciferase reporter gene assay (Akingbemi, Ge et al. 2003).  
miR-106a-5p and miR-20b-5p also share mRNA targets with miR-17-p (Figure 6-20 
and Figure 6-22). 
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Figure 6-21:(Left) Microarray expression of mir-17-5p and miR-19a-3p across basal (blue), Angio II (red), dbcAMP (purple) and KCl  treatments (green).  All 
exhibit consistent expression throughout stimulation. (Right) the primary miRNA sturucture of miR-17-5p and miR-19a-3p: the yellow box indicates the 
seed sequence for both miRNA (AAAGUGC for miR-106a-5p and mir-20b-5p, both share similar seed sequence with miR-17-5p). * p<0.05 relative to basal.
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Figure 6-22: miR-106-5p and miR-20b-5p and their experimentally-validated targets, derived from miRNA Target Filter Analysis (IPA). 
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6.7.3 IPA Canonical Signalling Involving cluster miR-17-5p/miR-
19a-3p miRNAs. 
The cluster miRNAs miR-17-5p/miR-19a-3p are predicted by IPA Canonical 
Pathways Signalling to target a few important pathways relevant to 
steroidogenesis, biosynthesis of cholesterol, apoptosis, angiogenesis and tumour 
development. 
Specifically, the IPA Canonical Pathways involved are: 
1. Aldosterone signalling in epithelial cells (Figure 6-23) 
2. LXR/ RXR activation (Figure 6-24) 
3. WNT/ β-catenin signalling (Figure 6-25) 
4. Apoptosis signalling (Figure 6-26) 
5. VEGF signalling (Figure 6-27) 
6. TGF-β signalling (Figure 6-28) 
6.7.3.1 Genes Targeted by miR-17/19 in Aldosterone Signalling in the 
Epithelial Cell Pathway 
miR-19b-3p/miR-19a-3p (and other mature microRNAs with seed GUGCAAA) 
target the Mineralocorticoid Receptor (MR). The NR3C2 (nuclear receptor 
subfamily 3, group C, member 2) gene encodes the mineralocorticoid receptor 
(MR) which facilitates aldosterone’s actions on salt and water balance. The MR 
protein acts as a ligand-dependent transcription factor that binds to 
mineralocorticoid response elements in order to stimulate target genes. 
Mutations of NR3C2 cause autosomal dominant pseudohypoaldosteronism type I, 
a disorder presenting with urinary salt wasting, early onset hypertension, 
severely exacerbated in pregnancy. MR mediates the biological action of 
aldosterone via water-salt homeostasis, stimulates inflammation, increases 
cardiovascular remodelling, causes endothelial dysfunction and impairs 
pancreatic insulin released (Ronconi, Turchi et al. 2012). 
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) 
targets RAF1 (Raf-1 proto-oncogene, serine/threonine kinase). RAF1 is a cellular 
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homolog of the viral raf gene (v-raf) and encodes MAP kinase 3 (MAP3K) which 
plays an important role in the cell cycle, apoptosis, cell differentiation and cell 
migration. By targeting RAF1, these miRNAs might reduce apoptosis and increase 
cell proliferation in tumours. These miRNAs are also predicted to bind with KRAS 
(Kirsten rat sarcoma viral oncogene homolog) which encodes a protein member 
of the small GTPase superfamily.  
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) also 
target SGK1 (serum/glucocorticoid regulated kinase 1) that encodes serine/ 
threonine protein kinase, involved in several cellular responses. The kinase 
activates some sodium, potassium and chloride channels (i.e renal sodium 
excretion). Upregulation of this gene may contribute to hypertension and 
diabetic nephropathy. Furthermore, it targets SLC9A1 that encodes the Na+/H+ 
antiporter from the solute carrier family 9 (plasma membrane transporter) 
expressed in kidney and intestine. The protein is essential for pH balance, cell 
migration and cell volume and tumour growth.  
miR-17-5p (and other mature microRNA with seed AAAGUGC) is predicted to 
target ICMT (isoprenylcysteine carboxyl methyltransferase), that encodes 
enzymes that modify isoprenylated C-terminal cysteine residues 
(posttranscriptionally). 
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6.7.3.2 Genes Targeted by miR-17/ 19 in the LXR/RXR Activation pathway 
Both miR-17 and miR-19 target LDLR, ABCA1 and IDOL. LDLR (low density 
lipoprotein receptor) encodes a cell surface protein receptor that is responsible 
for LDL endocytosis. LDL is then processed by lysosomes and degraded to 
produce cholesterol (under the control of HMGCR). The ABCA1 (ATP-binding 
cassette, sub-family A (ABC1), member 1) gene encodes a member of the ABC 
transporter family, that acts as a cholesterol efflux pump in the cellular lipid 
removal pathway. Mouse miR-19b-3p/miR-19a-3p (and other mature microRNAs 
with seed GUGCAAA) and mouse miR-17-5p (and other mature microRNAs with 
seed AAAGUGC) target mouse IDOL/MYLIP (myosin regulatory light chain 
interacting protein) in T-cell leukaemia (high expression of cluster miR-17-92 is 
detected in human T-cell leukaemia) (Landais, Landry et al. 2007). IDOL acts as 
an E3 ubiquitin ligase to elicit ubiquitination and degradation of LDLR. One study 
suggests that structure-based IDOL inhibitors might have therapeutic potential to 
treat cardiovascular disease by increasing LDLR abundance (Sorrentino, Scheer 
et al. 2011). IDOL increases degradation of LDLR by C-terminal domain 
ubiquitination, leading to limitation of cholesterol uptake. Cells deficient of 
IDOL exhibit high levels of LDLR protein and high rates of LDL uptake (Scotti, 
Hong et al. 2011).  
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) 
target the TNF (tumour necrosis factor) gene that encodes proinflammatory 
cytokines in the TNP superfamily. It is mainly secreted by macrophages and is 
involved in cell proliferation, lipid metabolism, coagulation, apoptosis and cell 
migration. 
miR-17-5p (and other mature microRNA with seed AAAGUGC) is predicted to 
target the ABCG4 (ATP-binding cassette, sub-family G (WHITE)), member 4) 
gene, which encodes another transporter, a member of the White subfamily 
mostly expressed in liver. No specific function has been described. 
  
210 
 
6.7.3.3 Genes Targeted by miR-17/ 19 in the WNT/ β-catenin Signalling 
pathway 
Both miR-17 and miR-19 target Cyclin D1 (product of the CCND1 gene). Cyclin D1 
is also a validated target of miR-17-5p as shown in breast cancer experiments 
(Yu, Wang et al. 2008). miR-17-5p also significantly suppresses cyclin D1 at its 
3’UTR in mantle cell lymphoma (MCL) (Deshpande, Pastore et al. 2009). Cyclin 
D1 forms a complex with CDK4 and CDK6 that is required for cell cycle G1/ S 
transition. Mutation of the gene is frequently observed in many tumours and may 
therefore contribute to tumorigenesis. CCND1 also has been shown to be a 
validated target for miR-19a in human umbilical vein endothelial cells (Qin, 
Wang et al. 2010). The miR-17-5p cluster downregulates cyclin D1 translation in 
human breast tumour cell lines. The cluster supressed cell proliferation and 
colony formation by inversely regulating CCND1 via a conserved 3’UTR miRNA-
binding site, leading to inhibition of S-phase of cell cycle (Yu, Wang et al. 2008). 
The overexpression of cyclin D1 is significant in mantle cell lymphoma. The level 
of cyclin D1 can be significantly reduced by the miR-17-92 cluster that directly 
binds to the 3’UTR of cyclin D1 (Deshpande, Pastore et al. 2009). One study 
showed that transfection of miR-19a significantly downregulates the cyclin D1 
gene and protein in endothelial cells. This leads to cell arrest at the G1/S 
transition (Qin, Wang et al. 2010).  
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) are 
predicted to target GJA1/CX43. GJA1 (gap junction protein, alpha 1, 43kDa), a 
member of the connexin family that encodes a component of the gap junction 
protein that provides a route for low molecular weight material diffusion from 
cell to cell. It is crucial in controlling heart contraction and embryonic 
development. Mutation is associated with heart malformation. The miRNA also 
targets NLK (nemo-like kinase), involved in ATP binding, kinase activity and 
transcription factor binding that are involved in hepatocellular carcinoma. It also 
targets MARK2/PAR-1. MARK2 (MAP/microtubule affinity-regulating kinase 2) 
that encode the Par-1 family of serine/threonine protein kinases. It is a vital cell 
polarity regulator in epithelial and neuronal cells and controls microtubule 
stability. 
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miR-17-5p (and other mature microRNAs with seed AAAGUGC) is predicted to 
target TCF4 (transcription factor 4) and PPARD. The PPARD (peroxisome 
proliferator-activated receptor delta) gene encodes the peroxisome proliferator-
activated receptor (PPAR). PPAR is a nuclear receptor and mediates various 
disorders, including cancer, atherosclerosis, diabetes and obesity. In a knockout 
mouse model, the protein was shown to be involved in lipid metabolism and cell 
proliferation. The TCF4 gene encodes a basic helix-hoop-helix transcription 
factor that plays an important role in the nervous system. PPAR is a nuclear 
hormone receptor that binds peroxisome proliferators and regulates the number 
and size of peroxisomes generated by cells. PPAR may be involved in diabetes, 
obesity, atherosclerosis and cancer. 
6.7.3.4 Genes Targeted by miR-17/ 19 in the Apoptosis Signalling pathway 
Both miR-17 and miR-19 target BCL2L11/BIM. The BCL2L11 gene (BCL2-like 11 
(apoptosis facilitator)) encodes a member of the BCL-2 family, which can act as 
pro- or anti-apoptotic regulators. Gene expression can be stimulated by nerve 
growth factor (NGF). It is involved in neuronal and lymphocyte apoptosis. 
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) is 
predicted to target APAF1 and RAF1. APAF1 (apoptotic peptidase-activating 
factor 1) encodes a cytoplasmic protein that initiates apoptosis. RAF1 (Raf-1 
proto-oncogene, serine/threonine kinase) is a cellular homolog of the viral raf 
gene (v-raf) and encodes MAP kinase 3 (MAP3K), playing an important role in the 
regulation of genes involved in the cell cycle, apoptosis, cell differentiation and 
cell migration. 
miR-17-5p (and other mature microRNA with seed AAAGUGC) is predicted to 
target MAP3K5/ASK1, BCL2, CASP2, CASP7 and MCL1. The MAP3K5 (mitogen-
activated protein kinase 5) protein is involved in MAPK kinase and c-Jun N-
terminal kinase activation. BCL2 encodes outer mitochondrial membrane 
proteins that block the death of some cells (e.g. lymphocyte apoptosis). The 
CASP2 (caspase 2, apoptosis-related cysteine peptidase) gene encodes a member 
of the cysteine-aspartic acid protease (caspase) family, involved in stress-
induced cell death pathways, the cell cycle and tumorigenesis oppression. The 
CASP7 (caspase 7, apoptosis-related cysteine peptidase) gene encodes cysteine-
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aspartic acid protease (caspase) family. This family plays an important function 
in the completion-phase of cell apoptosis. The MCL1 (myeloid cell leukaemia 1) 
gene encodes anti-apoptotic protein (member of BCL-2 family). 
6.7.3.5 Genes Targeted by miR-17/ 19 in the VEGF Signalling pathway 
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) is 
predicted to target ELAVL1/HUR, PTK2B/PYK2 and RAF1. ELAVL1 (ELAV-like RNA 
binding protein 1) encodes a member of the ELAVL family of RNA-binding 
proteins. The proteins contain multiple RNA recognition motifs and specifically 
bind to AU-rich elements (AREs) found in the 3’UTRs of miRNA. The gene is 
highly expressed in cancers. PTK2B (protein tyrosine kinase 2 beta) encodes 
tyrosine kinase in the cytoplasm that increases calcium influx and activates the 
MAPK signalling pathway. RAF1 (Raf-1 proto-oncogene, serine/threonine kinase) 
is a cellular homolog of viral raf gene (v-raf) and encodes MAP kinase 3 (MAP3K). 
It plays an important role in regulation of genes involved in the cell cycle, 
apoptosis, cell differentiation and cell migration. 
miR-17-5p (and other mature microRNA with seed AAAGUGC) is predicted to 
target BCL2, HIF1A and VCL. BCL2 encodes outer mitochondrial membrane 
proteins that block the death of some cells (e.g. lymphocyte apoptosis). The VCL 
(vinculin) gene encodes a cytoskeletal protein involved in cell-cell and cell-
matrix junctions. Impairment of VCL is the cause of dilated cardiomyopathy type 
1W. This disease is characterized by a dilated ventricle and systolic malfunction 
and lead to arrhythmias and congestive heart failure. The HIF1A (hypoxia 
inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)) 
gene encodes the transcription factor, hypoxia-inducible factor-1 (HIF-1), α-
subunit, which will bind with the β-subunit to form a heterodimer. HIF1A is 
involved in angiogenesis, increasing oxygen delivery and helping metabolic 
adaptation to hypoxia. 
6.7.3.6 Genes Targeted by miR-17/ 19 in the TGF-β Signalling pathway 
Both miR-17 and miR-19 target RUNX3, SMAD4, SMURF1 and ZFYVE9/SARA. The 
RUNX3 (runx-related transcription factor 3) gene encodes a member of the runx 
domain-containing family of transcription factors. By forming a complex with the 
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DNA sequence, 5'-PYGPYGGT-3' core (found in some promoters and enhancers), it 
can stimulate or inhibit transcription. The protein acts as a tumour suppressor 
and silencer of this gene, which is often related to cancer. The SMAD4 (SMAD 
family member 4) gene encodes a member of the SMAD family of signal 
transduction proteins. Mutations occur in pancreatic cancer and hereditary 
haemorrhagic telangiectasia syndrome. SMAD proteins are activated in response 
to TGF-Beta signalling and are subjected to post-transcriptional modification. 
The SMURF1 (SMAD specific E3 ubiquitin protein ligase 1) gene encodes a specific 
receptor-regulated SMAD protein (ubiquitin ligase) in the bone morphogenetic 
protein (BMP) pathway. This protein plays an essential role in cell motility, cell 
signalling and cell polarity. The ZFYVE9 (zinc finger, FYVE domain containing 9) 
gene encodes a double zinc finger motif-containing protein involved in the 
transforming growth factor-beta (TGFB) signalling pathway. The protein 
interacts with SMAD2 and SMAD3 and recruits SMAD2 to the TGFB receptor. The 
ZFYVE9 gene encodes a double zinc finger motif-containing protein involved in 
transforming growth factor-beta (TGFB) signalling pathway. The protein 
interacts with SMAD2 and SMAD3 and recruits SMAD2 to the TGFB receptor. 
miR-19b-3p/miR-19a-3p (and other mature microRNA with seed GUGCAAA) are 
predicted to target ARKADIA/RNF111, CRAF, GSC, PAI-1/SERPINE, 
TMEPAI/PMEPA1 and TGIF. RNF111 (ring finger protein 111) plays a critical role 
in embryonic mesoderm development; CRAF is involved in the cell cycle, 
migration, differentiation and apoptosis; GSC (goosecoid homeobox) encodes 
proteins of the bicoid subfamily of the paired (PRD) homeobox family. The 
protein acts as a TF; in mice it is involved in craniofacial and rib cage 
development during embryogenesis. SERPINE1 (serpin peptidase inhibitor, clade 
E (nexin, plasminogen activator inhibitor type 1), member 1) encodes the serine 
proteinase inhibitor (serpin) superfamily. The protein is an inhibitor of 
fibrinolysis (tissue plasminogen activator (tPA) and urokinase (uPA) inhibitor). 
High expression of the gene is associated with thrombophilia. TMEPAI/PMEPA1 
(prostate transmembrane protein, androgen induced 1) overexpression is 
involved in many types of cancer. TGIF1 (TGFB-induced factor homeobox 1) 
encodes a protein that is active as a transcriptional co-repressor of SMAD2 and 
may be involved in nuclear signal transmission. 
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miR-17-5p (and other mature microRNA with seed AAAGUGC) is predicted to 
target BCL2, SKI, SMAD6 and SMAD7. The SKI (SKI proto-oncogene) gene encodes 
the nuclear protooncogene protein. This protein represses TGF-beta signalling 
which may contribute to neural tube development and muscle differentiation. 
The SMAD6 (SMAD family member 6) gene encodes a protein that negatively 
regulates TGF-beta/activin-signalling. The SMAD7 (SMAD family member 7) gene 
encodes a nuclear protein that binds the E3 ubiquitin ligase SMURF2. It interacts 
with TGF-beta receptor type-1 (TGFBR1), leading to the receptor degradation. 
The gene is involved in colorectal cancer. BCL involves in inhibiting lymphocyte 
apoptosis. 
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Figure 6-23: Aldosterone Signalling in the Epithelial Cellular Pathway.  
miR-17-5p (and other miRNAs with seed AAAGUGC) targets ICMT while miR-19b-3p/miR-19a-3p (and other miRNAs with seed GUGCAAA) targets MR, cRaf, KRAS, 
SGK and SLC9A1 (Na+/H+ Antiporter).  
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Figure 6-24: The LXR/RXR Activation pathway.  
miR-17-5p (and other miRNAs with seed AAAGUGC) targets LDLR, ABCA1, IDOL and ABCG4 while miR-19b-3p/miR-19a-3p (and other miRNAs with seed 
GUGCAAA) targets ABCA1, LDLR, IDOL and TNF-α. 
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Figure 6-25: The WNT/ β-catenin Signalling Pathway.  
miR-17-5p (and other miRNAs with seed AAAGUGC) targets Cyclin D1, TCF4 and PPARδ while miR-19b-3p/miR-19a-3p (and other miRNAs with seed GUGCAAA) 
targets PAR-1, NLK, Cyclin D1 and CX43. 
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Figure 6-26: The Apoptosis Signalling pathway.  
miR-17-5p (and other miRNAs with seed AAAGUGC) targets ASK1, CASP2, BIM, p90RSK, BCL-2, MCL and CASP7 while miR-19b-3p/miR-19a-3p (and other 
miRNAs with seed GUGCAAA) targets c-RAF, BIM and APAF1.  
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Figure 6-27: The VEGF Signalling Pathway.  
miR-17-5p (and other miRNAs with seed AAAGUGC) targets HIF-1α (HIF1A), VCL and BCL-2 while miR-19b-3p/miR-19a-3p (and other miRNAs with seed 
GUGCAAA) targets HUR (ELAVL1), c-RAF (RAF1) and PYK2 (PTK2B). 
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Figure 6-28: The TGF-β Signalling Pathway.  
miR-17-5p (and other miRNAs with seed AAAGUGC) targets SMAD6, SKI, SARA (ZFYVE9), SMURF1, SMAD7, SMAD4, RUNX3 and BCL2 while miR-19b-3p/miR-
19a-3p (and other miRNAs with seed GUGCAAA) targets SMURF1, ARKADIA (RNF111), TMEPAI (PMEPA1), SARA (ZFYVE9), c-RAF (RAF1), TGIF (TGIF1), 
SMAD4, RUNX3, PAI-1 (SERPINE1) and GSC.  
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6.8 Result: Validation of microarray and bioinformatics 
study of miR-17-5p 
6.8.1 miR-17-5p 
6.8.1.1 miR-17-5p in Angio II-Stimulated Cells 
miR-17-5p expression was found by microarray to be significantly decreased in 
Angio II-stimulated cells (Figure 6-29 A). Quantitative validation of this effect was 
conducted by realtime qRT-PCR which, although showing a similar pattern of 
downregulation, did not achieve significance (Figure 6-29 B; Table 6-1). 
 
 
 
Figure 6-29: Levels of miR-17-5p as in basal vs. Angio II-stimulated cells, as detected by 
(A) microarray (n= 3) and (B) realtime qRT-PCR (n= 5).  
* indicates p<0.05. 
 
Table 6-1: miRNA expression in Basal vs Angio II-stimulated H295R cells (Strain 1), 
analysed by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
Angio II             
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-17-5p 5 23.63 (0.01) 24.06 (0.31) 0.33 0.80 0.20 
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6.8.1.2 miR-17-5p in dbcAMP Stimulated Cells 
Similarly, in dbcAMP-stimulated cells, a significant reduction of miR-17-5p had 
been observed by microarray but was not observed using realtime qRT-PCR 
(Figure 6-30; Table 6-2). 
  
Figure 6-30: Microarray expression of miR-17-5p (A) (n= 3) in Basal vs dbcAMP and the 
validation in qRT PCR (B) (n= 5) in Basal vs dbcAMP stimulated cells.  
* indicates p<0.05. 
 
Table 6-2: miRNA expression in Basal vs dbcAMP-stimulated H295R cells (Strain 1), 
analysed by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
dbcAMP            
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-17-5p 5 23.63 (0.34) 23.69 (0.23) 0.23 0.85 0.18 
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6.8.1.3 miR-17-5p in KCl Stimulated Cells 
However, the significant reduction in miR-17-5p observed by microarray in KCl-
stimulated cells was validated by realtime qRT PCR (Figure 6-31 and Table 6-3). 
  
Figure 6-31: Microarray expression of miR-17-5p (A) (n= 3) and validation by qRT PCR 
(B) (n= 5) of Basal vs KCl-stimulated cells.  
* indicates p<0.05. 
 
Table 6-3: miRNA expression in Basal vs KCl-stimulated H295R cells (Strain 1), 
analysed by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
KCl                      
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-17-5p 5 23.63 (0.34) 24.02 (0.21) 0.56 0.68 0.01 
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6.8.2 miR-20b-5p 
6.8.2.1 miR-20b-5p in Angio II Stimulated Cells 
Microarray had identified significant downregulation of miR-20b-5p in Angio II-
stimulated cells (Figure 6-32 A), but realtime qRT-PCR did not identify this 
reduction as significant (Figure 6-32 B).   
  
Figure 6-32: Microarray expression of miR-20b-5p (A) (n= 3) in Basal vs Angio II-treated 
cells and its validation by qRT PCR (B) (n= 6). 
* indicates p<0.05. 
 
Table 6-4: miRNA expression in Basal vs Angio II-stimulated H295R cells (Strain 1), 
analysed by realtime qRT-PCR.  
Ct=cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
Angio II             
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-20b-3p 6 25.88 (0.28)  26.11 (0.41)  0.22 0.86 0.25 
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6.8.2.2 miR-20b-5p in dbcAMP Stimulated Cells 
The reduction in miR-20b-5p observed by microarray in dbcAMP-stimulated cells 
(Figure 6-33 A) also was not found to be significant under realtime qRT-PCR 
(Figure 6-33 and Figure 6-34 B). 
  
Figure 6-33: Levels of miR-20b-5p in Basal vs dbcAMP-stimulated H295R cells (Strain 
1), as measured by (A) microarray (n= 3) and (B) realtime qRT-PCR (n= 5).  
* indicates p<0.05. 
 
Table 6-5: miRNA expression in Basal vs dbcAMP-stimulated H295R cells (Strain 1), 
analysed by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
dbcAMP            
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-20b-3p 6 25.88 (0.28) 25.98 (0.30) 0.18 0.88 0.24 
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6.8.2.3 miR-20b-5p in KCl Stimulated Cells 
The reduction in miR-20b-5p observed by microarray following KCl stimulation 
(Figure 6-34 A) was validated by realtime qRT-PCR (Figure 6-34 B and Table 6-6). 
 
  
 
Figure 6-34: Levels of miR-20b-5p following KCl stimulation of H295R cells (Strain 1) as 
measured by (A) microarray (n= 3) and (B) qRT-PCR (n= 6).  
* indicates p<0.05. 
 
Table 6-6: miR-20b-3p levels in Basal vs KCl-stimulated H295R cells (Strain 1) , 
analysed by realtime qRT-PCR.  
Ct=cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
KCl                      
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal=1) 
p-
value 
miR-20b-3p 6 25.88 (0.28) 26.26 (0.24) 0.57 0.67 <0.01 
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6.8.3 miR-766-3p 
miR-766-3p was reported to be significantly upregulated in Angio II-stimulated 
cells analysed by microarray. The result was validated by realtime qRT PCR, 
which also identified significant upregulation of miR-766-3p (Figure 6-35 B and 
Table 6-7). 
6.8.3.1 miR-766-3p in Angio II Stimulated Cells 
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Figure 6-35: Levels of miR-766-3p in basal vs Angio II-stimulated H295R cells (Strain 1) 
measured by (A) microarray (n= 3) and (B) realtime qRT-PCR (n= 5).  
* indicates p<0.05. 
 
Table 6-7: miRNA levels in Basal vs Angio II-stimulated H295R cells (Strain 1), analysed 
by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
Angio II             
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-766-3p 5 20.13 (0.14) 19.99 (0.26) -0.31 1.24 0.01 
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6.8.3.2 miR-766-3p in dbcAMP Stimulated Cells 
The upregulation of miR-766-3p in dbcAMP-stimulated cells could not be 
validated by realtime qRT-PCR (Figure 6-36; Table 6-8). 
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Figure 6-36: Levels of miR-766-3p in Basal vs dbcAMP-stimulated H295R cells (Strain 
1), as analysed by (A) microarray (n= 3) and (B) realtime qRT-PCR (n= 6).  
* indicates p<0.05. 
 
Table 6-8: miRNA levels in basal vs dbcAMP-stimulated H295R cells (Strain 1), analysed 
by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
dbcAMP            
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-766-3p 6 20.09 (0.16) 20.08 (0.03) 0.07 0.95 0.56 
 
  
miR-766-3p Microarray Expression
in Basal vs dbcAMP
Basal dbcAMP
0
500
1000
1500
2000
2500
Basal
dbcAMP
*
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
A B 
229 
 
 
6.8.3.3 miR-766-3p in KCl-Stimulated Cells 
Levels of miR-766-3p also saw a significant increase following KCl stimulation 
when analysed by microarray (Figure 6-37 A) but, despite a trend towards 
increased levels when analysed by realtime RT-PCR, this change could not be 
validated by this method (Figure 6-37 B; Table 6-9). 
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Figure 6-37: Levels of miR-766-3p in Basal vs KCl-stimulated H295R cells (Strain 1), as 
analysed by (A) microarray (n= 3) and (B) realtime RT-PCR (n= 6).  
* indicates p<0.05 
 
Table 6-9: miRNA levels in Basal vs KCl-stimulated H295R cells (Strain 1), as analysed 
by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
KCl                      
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal=1) 
p-
value 
miR-766-3p 6 20.09 (0.16) 20.08 (0.03) 0.07 0.95 0.56 
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6.8.3.4 Validation of other miRNAs in Stimulated H295R Cells 
miR-125a-5p as described previously, was significantly downregulated in dbcAMP-
stimulated cells (Table 6-11) but not in other groups (Table 6-10 and Table 6-12). 
Other validated expressed miRNAs in the cells are miR-154-3p and miR-19a-3p, 
however no significant difference of these miRNAs was observed in basal vs 
stimulated cells, as shown in Table 6-10 and Table 6-12. 
Table 6-10: miRNA expression in Basal vs Angio II-stimulated cells (Strain 1).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
Angio II             
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-125a-5p 6 19.87 (0.19) 20.01 (0.27) 0.06 0.96 0.62 
mir-154-3p 6 25.66 (0.39) 25.74 (0.28) -0.01 1.01 0.93 
miR-19a-3p 6 25.43 (0.61) 25.60 (0.34) 0.03 0.98 0.76 
 
 
Table 6-11: miRNA expression in Basal vs dbcAMP-stimulated cells (Strain 1).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
dbcAMP            
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-125a-5p 6 19.87 (0.19) 20.35 (0.10) 0.57 0.68 <0.01 
mir-154-3p 6 25.66 (0.39) 25.65 (0.31) 0.07 0.95 0.66 
miR-19a-3p 5 25.41 (0.64) 25.38(0.28) 0.03 0.98 0.92 
 
 
Table 6-12: miRNA expression in Basal vs KCl-stimulated cells (Strain 1).  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
miRNA n Basal               
Mean Ct (SD) 
KCl                      
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-
value 
miR-125a-5p 6 19.87 (0.19) 19.78 (0.18) 0.00 1.00 0.99 
mir-154-3p 6 25.66 (0.39) 25.49 (0.13) -0.09 1.07 0.62 
miR-19a-3p 5 25.41 (0.64) 25.57 (0.21) 0.34 0.79 0.08 
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6.8.3.5 LDLR expression following miR-17 Transfection 
In order to assess the effects of this significantly-altered miRNA on predicted 
target genes, H295R Strain 1 was transfected with pre-miR-17 for 24 hours, as 
described in Chapter 2, Section 2.3. A direct interaction between miR-17-5p and 
LDLR mRNA had been predicted by IPA. Following pre-miR-17 transfection, levels 
of this mRNA were found to be significantly reduced as shown in Figure 6-38 and 
Table 6-13. 
 
Figure 6-38: LDLR gene expression of H295R Strain 1 in pre-miR-17 transfection (n= 3).  
* indicates p<0.05. 
 
Table 6-13: LDLR mRNA levels following pre-miR-17 transfection of H295R cells (Strain 
1), analysed by realtime qRT-PCR.  
Ct= cycle threshold; ddCt= delta delta Ct; n= biological sample number; SD= standard 
deviation. 
Gene n Pre-Neg        
Mean Ct (SD) 
Pre-miRNA-17     
Mean Ct (SD) 
ddCt Fold Change 
(Relative to 
basal= 1) 
p-value 
LDLR 3 26.08 (0.30) 26.46 (0.24) 0.23 0.85 0.04 
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6.9 Discussion 
This chapter combined microarray, IPA analysis and further in vitro 
experimental work to analyse differences in miRNA expression between basal 
and stimulated cells (Angio II, dbcAMP and KCl), as measured by microarray 
analysis. This generated 3 lists of miRNAs significantly differentially 
expressed as a result of each type of stimulation (Figure 6-8 to Figure 6-10). 
Based on these patterns of expression, 7 miRNAs were found to be 
consistently altered throughout the 3 treatments. These 7 miRNAs were 
assembled into 2 main clusters as shown in Figure 6-11 and Figure 6-12. The 
2 clusters were then cross-referenced with IPA analysis in order to construct 
a list of relevant mRNA targets and pathways that are predicted to be 
affected. Some of these miRNAs were validated by qRT PCR. 
6.9.1 Microarray 
Cross-referencing of miRNAs to mRNAs enabled identification of several 
predicted regulatory targets. IPA employs three levels of filter in its 
prediction of target: experimentally-validated target, high-confidence target 
and moderate-confidence target. These 3 levels of confidence are based on 
TargetScan, TarBase, miRecords, and the Ingenuity® Knowledge Base. The 
predicted targets are obtained by utilising the TargetScan algorithm which 
recognises the presence of conserved 8mers and 7mers that match the seed 
sequence of each miRNA. TarBase content identifies the target by 
miRNA/mRNA matching from Tarbase itself and miRBase identifiers. For 
experimentally-validated interactions, miRecords is used to ascertain 
identify these from published articles. Lastly, the Ingenuity® Knowledge Base 
is derived from thousands of manually-curated published articles by 
Ingenuity’s own scientific experts. 
miRNAs predicted to target CYP11B2 include: 
 miR-1275 and miR-4323 (basal vs Angio group, Figure 6-16) 
 miR-125b-5p/miR-125a-5p, miR-1275, miR-647 and miR-766-3p (basal 
vs dbcAMP, Figure 6-17) miR-125b-5p/miR-125a-5p, miR-708-5p, miR-
766-3p 
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miR-874-3p are predicted to bind to CYP11B2 (basal vs KCl group, Figure 
6-18).  
Of these, miR-125b-5p/miR-125a-5p and miR-766-3p are consistently 
expressed in a similar pattern across the 3 stimulations (i.e. downregulated 
in each stimulated group). Only miRNAs in the KCl group are predicted to 
target CYP11B1 (miR-874-3p) and CYP17A1 (miR-4730). CYP11B2 & CYP11B1 
encode members of the cytochrome P450 superfamily of enzymes: namely 
aldosterone synthase and11-β-hydroxylase. They are the monooxygenase 
cytochrome P450 proteins located at the inner mitochondrial membrane, 
which catalyse various processes including cholesterol and steroid 
metabolism and drug metabolism. Mutation of CYP11B2 will cause 
corticosterone methyl oxidase deficiency and mutation of CYP11B1 will lead 
to congenital adrenal hyperplasia (due to 11-β-hydroxylase deficiency). 
Another important gene in steroidogenesis is CYP17A1, which encodes 
17alpha-hydroxylase, important for the synthesis of mineralocorticoids, 
glucocorticoids, androgens, oestrogens and progestin. Mutation of this gene 
is associated with adrenal hyperplasia and 17-alpha-hydroxylase/17,20-lyase 
deficiency. In an experimentally validated study, miR-24 was shown to 
directly target the 3’UTR of CYP11B2 (Robertson, MacKenzie et al. 2013). In 
another study, miR-766 was shown to bind the 735G-allele at the 3’UTR of 
human CYP11B2; the transfection of miR-766 reduces human aldosterone 
synthase mRNA and protein level in adrenocortical cell lines. As there is 
known linkage disequilibrium between the A/G polymorphism at the 735 
position and the single nucleotide polymorphism at -344, this might suggest 
that miR-766 downregulates human aldosterone synthase gene expression 
and reduces blood pressure in human subjects carrying the -344T allele 
(Maharjan, Mopidevi et al. 2014). miR-125a-5p and miR-125b-5p also has 
been shown to downregulate aldosterone synthase expression in pEZX-
reporter plasmid experiments (Stacy Wood 2011). 
In the dbcAMP- and KCl-stimulated groups, 2 miRNAs are predicted to target 
HMGCR: miR-125b-5p/miR-125a-5p and miR-29b-3p. HMGCR is a rate-limiting 
enzyme for cholesterol synthesis regulated via a negative feedback 
mechanism controlled by sterols, the product of the reaction that it 
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catalyses. HMGCR is suppressed by cholesterol derived from the influx and 
degradation of low density lipoprotein (LDL) via the LDL receptor (LDLR). 
Competitive inhibitors of HMGCR increase liver LDLR, which in turn escalate 
the LDL plasma catabolism and decrease cholesterol concentration in 
circulation, a key factor of atherosclerosis. HMGCR aberrations may lead to 
cardiovascular disorder (e.g. coronary artery disease, myocardial infarction 
due to atherosclerosis formation) and stroke. It has been reported that 
mesangial cells produced aldosterone locally. Atorvastation, an HMGCR 
inhibitor intensely impaired the glucose, Angio II and LDL to aldosterone 
production. It is suggested that this mesangial endocrine system that 
produce local aldosterone might have therapeutic effect for diabetic 
nephropathy by the action of HMGCR inhibitor (Nishikawa, Matsuzawa et al. 
2010). Therefore, inhibiting of HMGCR by miRNAs might have therapeutic 
effect on the abnormal aldosterone level.  
There are a number of miRNAs that putatively bind ABCA1, in particular, 
miR-17-5p and miR-19b-3p/miR-19a-3p. Both of these miRNAs are derived 
from the same cluster. ABCA1 (ATP-binding cassette, sub-family A, member 
1) is from the superfamily of ATP-binding cassette (ABC) transporters. The 
protein transports cholesterol efflux in the cellular lipid removal pathway. 
The family of ABC genes is divided into seven distinct subfamilies (ABCA1, 
MDR/TAP, MRP, ALD, OABP, GCN20 and White). Abnormalities in the ABCA1 
gene are associated with Tangier's disease and familial high-density 
lipoprotein deficiency. In an animal experimental study, it was shown that 
mouse ABCA1 protein increased expression of HMGCR mRNA in the liver 
(Basso, Freeman et al. 2003). 
miR-19a-3p and miR-17-5p are predicted to target LDLR. The LDLR (low 
density lipoprotein receptor) gene encodes cell surface proteins for 
receptor-mediated endocytosis. Low density lipoprotein (LDL) is normally 
bound to the receptor and taken into the cell. The protein is degraded by 
the lysosome and free cholesterol is made available for downregulation of 
the microsomal enzyme HMGCR, the rate-limiting step in cholesterol 
synthesis. Simultaneously, a reciprocal upregulation of cholesterol ester 
synthesis occurs. LDLR mutation is related to familial hypercholesterolemia. 
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LDLR abnormalities have been associated with atherosclerosis, obesity, 
hypercholesterolemia, hyperglycaemia, and insulin resistance. 
6.9.2 Validation 
Table 6-14: miRNA expression in microarray and qRT PCR. 
Down= downregulated, Up= upregulated, *= p value < 0.05. 
miRNA Microarray qRT PCR 
Angio 
II 
dbcAMP KCl Angio 
II 
dbcAMP KCl 
miR- 
17-5p 
Down* Down* Down* Down Down Down* 
miR-154-
3p 
Down* Down* Down* Down Down Down 
miR- 
19a-3p 
Down* Down* Down* Down Down Down 
miR-20b-
5p 
Down* Down* Down* Down Down Down* 
miR-766-
3p 
Up* Up* Up* Up* Down Down 
 
Validation of miRNAs of interest identified in the microarray study (Basal vs 
stimulated cells) was done by qRT PCR. These miRNAs were: miR-17-5p, miR-
154, miR19a-3p, miR-20b-3p and miR-766-3p. miR-17-5p; each was 
consistently downregulated throughout the stimulation in microarray 
analysis. The expression was validated and only KCl caused a significant 
difference of expression. miR-17-5p belongs to Cluster 17-92. The primer for 
SYBR Green assay of miR-17-5p is similar to miR-106a-5p. Therefore, further 
analysis should be carried out to determine the real effect of gene 
expression by miR-17-5p. Interestingly, IPA analysis revealed that both miR-
17-5p and miR-20a-5p shared the same seed sequence in target mRNA (see 
Table 8-11, Appendix). This is not so surprising as cluster mir-17/miR-19a 
(located at chr 13q31.3) is a paralogue cluster to miR-106a/ miR-20b (chr 
Xq26.2) (Mogilyansky 2013).  
miR-17-5p is predicted by IPA to target LDLR and this effect was confirmed 
by qRT-PCR. LDLR is a vital transport mechanism for intracellular cholesterol 
homeostasis. Cholesterol is the main substrate of steroidogenesis, so 
targeting LDLR may reduce the level of cholesterol in the cytoplasm leading 
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to an effect on steroid secretion. No previous study has established the 
effect of LDLR level on aldosterone production intracellularly. However, 
miR-17-92 is widely expressed in various cancers and is known as the first 
‘oncomir’ (He, Thomson et al. 2005). miR-17 and its cluster are also known 
for their role in suppressing proapoptotic genes E2F1 (O'Donnell, Wentzel et 
al. 2005, Petrocca, Visone et al. 2008). Interestingly, in studying miRNA 
expression in human aging, miR-17, miR-106, miR-19b and miR-20a were 
each reported to be downregulated in cell aging models (CD8(+) T cells, 
renal proximal tubular epithelial cells and fibroblast of skin) (Hackl, Brunner 
et al. 2010). miR-17-p and mir-106a also were reported to be involved in 
promoting adipogenesis and inhibiting osteogenesis by targeting BMP2 (Li, Li 
et al. 2013). 
miR-20b-5p, like miR-17-5p, was consistently downregulated by all 3 
stimulations of H295R cells in vitro, but qRT-PCR validation only achieved 
significance during KCl stimulation. From the IPA database, mir-20b-5p 
shares a similar seed sequence with mir-17-5p, miR-106a-5p and other 
miRNAs, as shown in Table 8-11 (Despite sharing similar seed sequences, the 
PCR primers used for amplification of mir-20b-5p differs from that for miR-
17-5p). In human oral squamous carcinoma cells (clone E10), exogenous miR-
20b downregulated cell proliferation by 50% (Khuu, Jevnaker et al. 2014). 
Interestingly, miR-20b, along with miR-21 and miR-24, has been found to be 
downregulated in the plasma of patients with Type 2 Diabetes Mellitus 
(Zampetaki, Kiechl et al. 2010). In LCC9 cells, mir-20b is upregulated 
compared to LCC1 and MCF7 (Mulrane, Terrile et al. 2013). LCC9 is derived 
from LCC1 (which is derived from MCF7), is completely oestrogen 
independent and exhibits resistance to fulvestrant and tamoxifen. However, 
LCC1 and MCF7 (derived from breast cancer cell line) are sensitive to 
tamoxifen (block oestrogen action) and fulvestrant (selective oestrogen 
receptor degrader) (Skerry Benjamin James Oliver 2013). 
Again, miR-766-3p was consistently upregulated by all three stimulations 
according to microarray analysis (Basal vs stimulated cells). The upregulation 
pattern was confirmed by qRT-PCR for Angio II (p<0.05) but not dbcAMP or 
KCl treatment. In another study, expression of miR-766 was downregulated 
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in tumour-associated macrophage gastrointestinal cancer compared to 
normal gastrointestinal cells (Sugihara, Ishimoto et al. 2013). A study on 
microarray expression comparing a normal bladder cell line (SV-HUC-1) and 
bladder cancer cell lines revealed that miR-766 was downregulated in cancer 
cell lines ((Ueno, Hirata et al. 2012). 
Microarray is known for its sensitivity and fast generation of large amounts of 
data, requiring minimal RNA relative to other techniques e.g. Northern 
Blotting. As microarray is not a ‘gold standard’ quantitative method, qRT-
PCR is extensively employed to validate its key findings with greater 
confidence (Klein 2002). Many of the significant changes observed by 
microarray in the previous chapter could not be subsequently validated by 
qRT-PCR. There are several possible reasons for this, one of which may be 
insufficient power in the replication study i.e. a greater number of 
experimental replicates may have been required to identify significant 
changes between the basal and treatment groups for a qRT-PCR study. 
Although power calculations may have helped to identify this problem in 
advance, this would have required prior knowledge of the true size of 
expression change (if any), which was the aim of the experiment itself. The 
decision to use the group size employed here was based on previous studies 
which had been able to identify significant changes in this cell type. Another 
possible reason for the disparity between microarray and qRT-PCR results 
involves the RNA samples used. Although subjected to the same 
experimental conditions, the RNA samples analysed for microarray were 
different to those used for qRT-PCR, and were sourced from a different 
batch of H295R cells. The use of different batches of cells, or carry-over of 
contaminating factors from RNA isolation (e.g phenol, alcohol, airborne 
contamination) can cause adverse effect to RNA analyses (Freeman, Walker 
et al. 1999). Moreover, it has been reported that different efficiencies of 
cDNA production via reverse transcriptase method can also affect findings 
between qRT-PCR and microarray experiments (Freeman, Walker et al. 
1999). On the other hand, qRT-PCR may also give rise to spurious results 
through the introduction of exponential amplification error (Freeman, 
Walker et al. 1999), mispriming and formation of primers dimers (Bustin 
2002). However, it should be noted that primer dimers were excluded from 
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any realtime qRT-PCR analysis in the present study and good laboratory 
method aimed to reduce and, where possible, identify other errors through 
the use of control reactions, etc.  
6.10 Conclusions 
The microarray data presented in this chapter provide the first analysis of 
miRNA profiles in H295R cells following 3 types of stimulation (Angio II, 
dbcAMP and KCl). This revealed two main clusters, miR-17/19b and miR-
106a/20b, to be consistently downregulated during all 3 stimulations. Many 
previous studies have linked miR-17/19b with tumour formation but this is 
the first study relating this cluster to the adrenal cortex. Using IPA, it also 
presents evidence and possible mechanisms by which the two miRNAs might 
act in several relevant canonical pathways.  
Regardless of the reasons for inconsistent findings between the microarray 
and realtime qRT-PCR analyses (which are widely recognised and largely 
attributable to the semi-quantitative nature of microarray analysis), this 
study has validated certain key effects. This includes the fact that certain 
miRNAs are consistently altered across all 3 stimulations, and that one such 
miRNA inhibits the expression of LDLR, a gene relevant to steroidogenesis 
through its participation in cholesterol biosynthesis. The remaining 3 miRNAs 
showed no significant changes in quantity with the exception, of miR-125a-
5p, which responded to dbcAMP, as shown in the previous chapter. 
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7 General Discussion 
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Hypertension is the key risk factor for cardiovascular morbidity and mortality 
around the world. Abnormal levels of both systolic and diastolic blood pressure 
can cause adverse effects to heart, brain, kidney and other vital organs although 
most hypertensive cases are absent of symptoms. Despite the unknown aetiology 
of primary hypertension (PH), secondary hypertension offers a more definite 
causative root. Primary aldosteronism (PA) is the main cause of secondary 
hypertension (Scholl and Lifton 2013), with studies showing patients with PA 
have increased rates of cardiovascular events relative to PH patients of the same 
blood pressure (Milliez, Girerd et al. 2005). Approximately 15% of PA cases result 
from unilateral aldosterone producing adenoma (APA) (Ye, Mariniello et al. 
2007). Therefore, I conducted studies into APA and the mechanisms by which 
microRNA might regulate its pathology. This involved miRNA profiling of APA and 
normal adrenal tissue followed by bioinformatic prediction of possible effects, 
several of which were validated by in vitro experiment. A similar study was then 
conducted that examined changes to the miRNA profile of H295R adrenocortical 
cells following stimulation of aldosterone production. 
Microarray is a powerful tool for molecular study, capable of analysing 
expression of thousands of RNAs from multiple samples simultaneously. Many 
microarray studies have been implemented for cancer profiling (i.e. cancer vs 
non cancer), cancer stratification (i.e. carcinoma vs benign) or evaluation of 
tumour progression (i.e. early stage carcinoma vs late stage carcinoma) and 
assessment of tumour post-treatment (Giuseppe Russo 2003).  
In this study, total RNA samples from APA and NA were collected from formalin-
fixed paraffin-embedded (FFPE) and frozen tissue (Wood, M.MacKenzie et al. 
2011). Frozen tissue samples have been described as having better RNA and 
protein integrity compared to FFPE and many antibodies that work in frozen 
tissues do not respond well in FFPE (Giuseppe Russo 2003). Furthermore, utilising 
small specimen for microarray analysis has raised questions whether the sample 
truly represents the entire tumour’s gene expression. However, this technique 
can be improved by including multiple tissues punches for every sample in the 
microarray studies (Sallinen, Sallinen et al. 2000, Hoos, Urist et al. 2001). In my 
study, the adrenal and APA samples contain non-homogenous cell populations, 
therefore the miRNA detected in microarray studies are unlikely to represent 
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zone-specific expression. However, this can be improved by having zone-specific 
dissection and further qRT-PCR validation for the miRNA and mRNA expression. 
The quantitative limitations of microarray are well known, hence the need to 
validate significant changes in miRNA quantity by other methods, such as qRT-
PCR. It should be noted that several such changes identified by microarray did 
not emerge as significant when a more accurate quantitative method was used, 
so such findings should always be treated with caution. It may be that 
microarray has now been overtaken as the prime method for such analysis by 
RNA sequencing (RNAseq), which has the advantage of being more truly 
quantitative and of being able to identify novel transcripts, unlike microarray 
which is limited to known molecules represented on the chip. As the previously 
prohibitive costs of RNAseq continue to fall, it will probably become the main 
method employed for such studies. 
In spite of its limitations, in this study microarray was able to identify several 
significant changes in miRNA levels that were verified by qRT-PCR validation. It 
is also striking that certain changes in miRNA levels between APA and NA were 
also apparent in H295R cells following stimulation of aldosterone secretion 
(Figure 7-1). This may point to common mechanisms between the pathology of 
APA, with its raised aldosterone secretion, and the normal physiology of 
aldosterone regulation. It also points to a regulatory role for microRNAs in these 
mechanisms. In light of these findings, it seemed logical to investigate plausible 
targets of these dysregulated miRNAs that could be relevant to aldosterone 
biosynthesis and/or APA pathology. 
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Basal vs dbcAMP (H295R)
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Basal vs KCl (H295R)
hs
a-
m
iR
-2
9c
-3
p
hs
a-
m
iR
-3
0a
-5
p
hs
a-
m
iR
-3
0b
-5
p
hs
a-
m
iR
-3
0c
-5
p
hs
a-
m
iR
-5
74
-5
p
0
5000
10000
15000
Basal
KCl
†
†
†
†
†
M
e
a
n
 F
lu
o
re
s
c
e
n
c
e
 I
n
te
n
s
it
y
 
Figure 7-1: Consistent miRNA expression in adrenal tissues; NA vs APA (A) and in H295R 
cell line; basal vs Angio II (B), basal vs dbcAMP (C) and basal vs KCl (D). 
The dotted line indicates the detection cut-off point of 500 AU (n=4 in adrenal tissues and n=3 in 
each group of stimulation of H295R cell line). *miRNAs > 500 AU in NA or APA; †miRNAs present 
in both tissues/ both basal and stimulated cells (p<0.05). 
Within the evolving field of miRNA research, which depends on various 
quantitative techniques and predictive tools for target identification, a strong 
and reliable apparatus is needed to identify the most relevant biological target 
and pathways. Ingenuity Pathway Analysis supports such research by providing 
several tools e.g. miRNA Target Filter, which prioritises relevant miRNAs and 
mRNA targets. Furthermore, IPA is able to identify significant network and 
canonical pathways associated with the differentially expressed miRNA and 
targeted mRNA (Jiménez-Marín, Collado-Romero et al. 2009). IPA uses a 
manually curated non-public bibliographic database, which confers the ability to 
classify genes implicated in specific functions or diseases. For example, in this 
A B 
C D 
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study, it linked differentially-expressed miRNAs in stimulated H295R cells to the 
LDLR and HMGCR genes involved in cholesterol regulation. However, a downside 
of IPA is its bias towards cardiovascular and cancer mechanisms and pathways 
relative to other areas, such as endocrine disorders; this is a reflection of the 
overall bias in the research literature. Its manually-curated method for journal 
selection also limits its ability to deliver truly up to date findings, with an 
inevitable lag between publication of findings and its inclusion in the IPA 
database. For these reasons, IPA must be used with caution and a great deal of 
effort must be taken by the user to ensure that findings are properly filtered, 
are of physiological relevance and have a better than random level of actually 
occurring in a biological system. Nevertheless, IPA has provided several 
interesting findings for further study, in addition to the more obvious pathways.  
Clearly, the most obvious initial place to examine the impact of miRNAs in APA is 
the steroidogenic pathway. The CYP11B2 gene, encoding aldosterone synthase, 
is at the endpoint of this pathway. miR-125a-5p is upregulated in NA compared 
to APA and it is hypothesised that miR-125a-5p inhibits expression of CYP11B2, 
according to IPA. This finding is further supported by downregulation of CYP11B2 
following transfection of H295R cells with miR-125a-5p precursor mimic. 
Moreover, in a previous pEZX-reporter plasmid study, miR-125a-5p repressed 
CYP11B2 by directly targeting the 3’UTR (Stacy Wood 2011), providing the first 
direct evidence that miRNA may have a significant role in aldosterone 
biosynthesis. 
Using IPA to identify other pathways, cholesterol handling emerged as one of the 
key systems likely to be regulated at various points and by several of the 
differentially-expressed miRNAs. A high level of LDL is an established risk factor 
for atherosclerosis, the underlying aetiology of cerebrovascular disease and 
coronary heart syndrome. Statins are the most effective drugs in reducing 
circulating LDL, decreasing risk of stroke and cardiac events (Grundy 1998) by 
inhibiting HMGCR, the rate-limiting enzyme in production of cholesterol. This 
decreases intracellular sterol levels and reduces transport of the SCAP-SREB 
complex from endoplasmic reticulum (ER) to Golgi. Subsequently, it increases 
LDLR expression, transporting circulating LDL into cells (hepatocytes) and 
thereby downregulating blood LDL levels.  One study characterized a new class 
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of compound that reduces cholesterol level in vivo by upregulating LDLR through 
direct action on the SCAP-SREB complex in a hamster model (Grand-Perret, 
Bouillot et al. 2001). The compound reduced LDL and triglycerides by up to 80% 
and increased LDLR mRNA in the liver. From the perspective of the current 
study, it is interesting to note the interplay of LDLR and HMGCR expression in 
determining circulating cholesterol levels. 
If cholesterol levels can be regulated in this way, does this necessarily translate 
into significant changes in steroid biosynthesis? It has been assumed for many 
years that cholesterol supply was unimportant in determining steroid secretion 
as the rate-limiting stages of the process occurred further down the chain, 
either with the supply of cholesterol by StAR, or with the catalytic turnover of 
such enzymes as aldosterone synthase. Now, however, a different story is 
emerging. Baudrand et al recently reported that the HMGCR blockers statins 
effectively reduce aldosterone levels in hypertensive and diabetic subjects; 
interestingly, no similar cortisol suppression was observed (Baudrand, Pojoga et 
al. 2015). This finding is supported by a previous study showing that simvastatin 
treatment in hyperlipidaemic postmenopausal women also results in significant 
plasma aldosterone suppression but no changes in cortisol (Ide, Fujiya et al. 
1990). Furthermore, Dahl rats fed with a high salt diet and treated with 
simvastatin showed significant suppression of aldosterone (Bayorh, Ganafa et al. 
2005). A placebo-control study has also been conducted on men with 
hypercholesterolemia, with one group being treated with a high dose of 
simvastatin (80 mg). After 12 weeks, no changes in cortisol were observed in 
treated patients (Dobs, Schrott et al. 2000). Therefore, these studies appear to 
support the idea that changes in the handling and supply of cholesterol – through 
a pathway involving HMGCR – can result in significant effects on aldosterone 
secretion. 
If miRNAs are significant regulators of cholesterol, could their clinical actions be 
countered directly in vivo? Results from clinical trials of miRNA-related therapies 
suggest this is a possibility. miR-122 antagonist (Miravirsen) was introduced for 
phase II clinical trial in hepatitis C patients in an attempt to counter the 
properties of miR-122, which binds the HCV genome and protects it from 
degradation. Miravirsen act as specific miR-122 blocker and was shown to 
245 
 
effectively reduce HCV replication in vivo (Lanford, Hildebrandt-Eriksen et al. 
2010, Janssen, Reesink et al. 2013). Another clinical trial involved miRNA-
related treatment of liver carcinoma (Christoph 2013). MRX-34, a miR-34a mimic 
has a tumour suppressor function, increasing G1 cell cycle arrest and 
participating in the p53 tumour suppressor pathway. Such studies suggest 
miRNAs could have a promising therapeutic future.  
Future studies should explore the miRNA-mediated effects identified here, in 
order to verify that these result in actual changes to the proteins themselves, 
and to confirm their mechanism and physiological impact. It would also be 
valuable to repeat the H295R studies (possibly using the now-cheaper RNAseq 
rather than microarray), but this time simultaneously measuring mRNA levels as 
well as miRNA. This direct comparison of miRNA and mRNA in the same samples 
would be far more powerful than simply analysing miRNA alone, and would allow 
much more powerful analytical functions of the IPA software to be used.  
To conclude, in this thesis I have presented several novel findings demonstrating 
differential expression of certain adrenocortical miRNAs in physiological and 
pathophysiological conditions. Furthermore, with the aid of bioinformatic 
prediction and in vitro validation, I have shown that certain of these miRNAs 
have direct regulatory effects on key genes relevant to these systems, including 
CYP11B2 and HMGCR. Key miRNAs are significantly downregulated in APA tissues. 
It is hypothesized that reduced levels of these miRNAs may ‘de-repress’ 
expression of HMGCR, resulting in increased cholesterol synthesis which, in turn, 
would feed through into increased steroidogenesis.  
So, while these findings add to the small but growing body of evidence that 
miRNAs have a significant regulatory effect on corticosteroidogenesis through 
direct targeting of steroidogenic mRNAs, the influence of these miRNAs on 
availability of cholesterol – the vital substrate for all steroid production – is also 
apparent. Given that cholesterol supply is emerging as an important regulatory 
factor in corticosteroidogenesis, it may be that this study has uncovered a key 
mechanism that could be exploited in order to treat the consequences of 
dysregulated corticosteroid production.
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Table 8-1: Highly expressed miRNAs in NA (mir-10a to miR-195). 
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-
ordinates 
End Co-
ordinates 
hsa-mir-10a hsa-miR-10a-
5p 
UACCCUGUAGAUCCGAAUUUGUG 17 No  48579838 48579947 
hsa-miR-
125a 
hsa-miR-125a-
5p 
UCCCUGAGACCCUUUAACCUGUGA 19 Yes hsa-miR-125a 51693254 51693339 
     hsa-let-7e 51692786 51692864 
     hsa-miR-99b 51692612 51692681 
hsa-miR-126 hsa-miR-126-
3p 
UCGUACCGUGAGUAAUAAUGCG 9 No - 136670602 136670686 
hsa-miR-139 hsa-miR-139-
5p 
UCUACAGUGCACGUGUCUCCAGU 11 No  72615063 72615130 
hsa-miR-
148a 
hsa-miR-148a-
3p 
UCAGUGCACUACAGAACUUUGU 7 No - 25949919 25949986 
hsa-miR-15a hsa-miR-15a-
5p 
UAGCAGCACAUAAUGGUUUGUG 13 Yes hsa-miR-15a 50049119 50049201 
     hsa-mir-16-1 50048973 50049061 
hsa-miR-195 hsa-miR-195-
5p 
UAGCAGCACAGAAAUAUUGGC 17 Yes hsa-miR-195 7017615 7017701 
     hsa-mir-497 7017911 7018022 
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Table 8-2: Highly expressed miRNAs in NA (mir-202* to miR-29c). 
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA within 
cluster 
Start Co-ordinates End Co-
ordinates 
hsa-miR-202* hsa-miR-202-5p UUCCUAUGCAUAUACUUCUUUG 10 No - 133247511 133247620 
hsa-miR-21 hsa-miR-21-5p UAGCUUAUCAGACUGAUGUUGA 17 No - 59841266 59841337 
hsa-miR-24 hsa-miR-24-3p UGGCUCAGUUCAGCAGGAACAG 19 Yes hsa-mir-24-2 loop 13836287 13836359 
     hsa-mir-23a 13836587 13836659 
     hsa-mir-27a 13836440 13836517 
   9 Yes hsa-mir-24-1 loop 95086021 95086088 
     hsa-mir-23b 95085208 95085304 
     hsa-mir-27b 95085445 95085541 
     hsa-mir-3074 95086014 95086094 
hsa-miR-26b hsa-miR-26b-5p UUCAAGUAAUUCAGGAUAGGU 2 No - 218402646 218402722 
hsa-miR-27a hsa-miR-27a-3p UUCACAGUGGCUAAGUUCCGC 19 Yes hsa-miR-27a 13836440 13836517 
     hsa-mir-23a 13836587 13836659 
     hsa-mir-24-2 13836287 13836359 
hsa-miR-27b hsa-miR-27b-3p UUCACAGUGGCUAAGUUCUGC 9 Yes hsa-miR-27b 95085445 95085541 
     hsa-mir-23b 95085208 95085304 
     hsa-mir-24-1 95086021 95086088 
     hsa-mir-3074 95086014 95086094 
hsa-miR-29a hsa-miR-29a-3p UAGCACCAUCUGAAAUCGGUUA 7 Yes hsa-miR-29a 130876747 130876810 
     hsa-mir-29b-1 130877459 130877539 
hsa-miR-29b hsa-miR-29b-3p UAGCACCAUUUGAAAUCAGUGUU 7 Yes hsa-mir-29b-1 loop 130877459 130877539 
     hsa-mir-29a 130876747 130876810 
   1 Yes hsa-mir-29b-2 loop 207802443 207802523 
     hsa-mir-29c 207801852 207801939 
hsa-miR-29c hsa-miR-29c-3p UAGCACCAUUUGAAAUCGGUUA 1 Yes hsa-miR-29c 207801852 207801939 
     hsa-mir-29b-2 207802443 207802523 
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Table 8-3: Highly expressed miRNAs in NA (mir-30a to miR-376c).  
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA within 
cluster 
Start Co-ordinates End Co-
ordinates 
hsa-miR-30a hsa-miR-30a-5p UGUAAACAUCCUCGACUGGAAG 6 No - 71403551 71403621 
hsa-miR-30b hsa-miR-30b-5p UGUAAACAUCCUACACUCAGCU 8 Yes hsa-miR-30b 134800520 134800607 
     hsa-miR-30d 134804876 134804945 
hsa-miR-30c hsa-miR-30c-5p UGUAAACAUCCUACACUCUCAGC 6 No hsa-mir-30c-2 loop 71376960 71377031 
   1 Yes hsa-mir-30c-1 loop 40757284 40757372 
     hsa-mir-30e 40754355 40754446 
hsa-miR-335 hsa-miR-335-5p UCAAGAGCAAUAACGAAAAAUGU 7 No - 130496111 130496204 
hsa-mir-376c hsa-miR-376c-3p AACAUAGAGGAAAUUCCACGU 14 Yes hsa-mir-376c 101039690 101039755 
     hsa-mir-1193 101030052- 101030129 
     hsa-mir-1185-1 101042977 101043062 
     hsa-mir-1185-2 101044198 101044283 
     hsa-mir-300 101041363 101041445 
     hsa-mir-376a-1 101040782 101040849 
     hsa-mir-376a-2 101040069 101040148 
     hsa-mir-376b 101040436- 101040535 
     hsa-mir-381 101045920 101045994 
     hsa-mir-487b 101046455 101046538 
     hsa-mir-495 101033755 101033836 
     hsa-mir-539 101047321 101047398 
     hsa-mir-543 101031987 101032064 
     hsa-mir-544a 101048658 101048748 
     hsa-mir-654 101040219- 101040299 
     hsa-mir-655 101049550 101049646 
     hsa-mir-889 101047901 101047979 
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Table 8-4: Highly expressed miRNAs in NA (mir-376 to miR-424).  
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-
ordinates 
End Co-
ordinates 
hsa-miR-379 hsa-miR-379-5p UGGUAGACUAUGGAACGUAGG 14 Yes hsa-miR-379 101022066 101022132 
     hsa-mir-1193 101030052 101030129 
     hsa-mir-1197 101025564 101025651 
     hsa-mir-299 101023794 101023856 
     hsa-mir-323a 101025732 101025817 
     hsa-mir-329-1 101026785 101026864 
     hsa-mir-329-2 101027100 101027183 
     hsa-mir-380 101025017 101025077 
     hsa-mir-411 101023325 101023420 
     hsa-mir-494 101029634 101029714 
     hsa-mir-543 101031987 101032064 
     hsa-mir-758 101026020 101026107 
hsa-miR-424 hsa-miR-424-5p CAGCAGCAAUUCAUGUUUUGAA X Yes hsa-miR-424 134546614 134546711 
     hsa-mir-450a-1 134540341 134540431 
     hsa-mir-450a-2 134540508 134540607 
     hsa-mir-450b 134540185 134540262 
     hsa-mir-503 134546328 134546398 
     hsa-mir-542 134541341 134541437 
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Table 8-5: Highly expressed miRNAs in APA (let-7a to let-7d).  
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-ordinates End Co-
ordinates 
hsa-let-7a hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU 9 Yes hsa-let-7a-1 loop 94175957 94176036 
     hsa-let-7d 94178834 94178920 
     hsa-let-7f-1 94176347 94176433 
   11 Yes hsa-let-7a-2 loop 122146522 122146593 
     hsa-mir-100 122152229 122152308 
   22 Yes hsa-let-7a-3 loop 46112749 46112822 
     hsa-let-7b 46113686 46113768 
     hsa-mir-4763 46113566 46113657 
hsa-let-7b hsa-let-7b-5p UGAGGUAGUAGGUUGUGUGGUU 22 Yes hsa-let-7b 46113686 46113768 
     hsa-let-7a-3 46112749 46112822 
     hsa-mir-4763 46113566 46113657 
hsa-let-7c hsa-let-7c UGAGGUAGUAGGUUGUAUGGUU 21 Yes  16539828- 16539911 
     hsa-mir-99a 16539089- 16539169 
hsa-let-7d hsa-let-7d-5p AGAGGUAGUAGGUUGCAUAGUU 9 Yes  94178834 94178920 
     hsa-let-7a-1 94175957 94176036 
     hsa-let-7f-1 94176347 94176433 
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Table 8-6: Highly expressed miRNAs in APA (miR-103 to miR-149*). 
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA within 
cluster 
Start Co-ordinates End Co-ordinates 
hsa-miR-103 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUGA 20 Yes hsa-mir-103a-2 loop 3917494 3917571 
     hsa-mir-103b-2 3917502 3917563 
   5 Yes hsa-mir-103a-1 loop 168560896 168560973 
     hsa-mir-103b-1 168560904 168560965 
hsa-miR-107 hsa-miR-107 AGCAGCAUUGUACAGGGCUAUCA 10 No - 89592747 89592827 
hsa-miR-122 hsa-miR-122-5p UGGAGUGUGACAAUGGUGUUUG 18 Yes hsa-miR-122 58451074 58451158 
     hsa-mir-3591 58451080- 58451152 
hsa-miR-134 hsa-miR-134-5p UGUGACUGGUUGACCAGAGGGG 14 Yes hsa-miR-134 101054687 101054759 
     hsa-mir-154 101059755 101059838 
     hsa-mir-323b 101056219 101056300 
     hsa-mir-377 101062050 101062118 
     hsa-mir-381 101045920 101045994 
     hsa-mir-382 101054306 101054381 
     hsa-mir-485 101055419 101055491 
     hsa-mir-487a 101052446 101052525 
     hsa-mir-487b 101046455 101046538 
     hsa-mir-496 101060573- 101060674 
     hsa-mir-539 101047321 101047398 
     hsa-mir-541 101064495 101064578 
     hsa-mir-544a 101048658 101048748 
     hsa-mir-655 101049550 101049646 
     hsa-mir-668 101055258 101055323 
     hsa-mir-889 101047901 101047979 
hsa-miR-140 hsa-miR-140-3p UACCACAGGGUAGAACCACGG 16 No  69933081 69933180 
hsa-miR-149* hsa-miR-149-3p AGGGAGGGACGGGGGCUGUGC 2 No  240456001 240456089 
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Table 8-7: Highly expressed miRNAs in APA (miR-320a to miR-382). 
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-ordinates End Co-
ordinates 
hsa-miR-320 hsa-miR-320a AAAAGCUGGGUUGAGAGGGCGA 8 No  22244962 22245043 
hsa-miR-34a hsa-miR-34a-5p UGGCAGUGUCUUAGCUGGUUGU 1 No  9151668 9151777 
hsa-miR-34c-3p hsa-miR-34c-3p AAUCACUAACCACACGGCCAGG 11 Yes hsa-miR-34c-3p 111513439 111513515 
     hsa-mir-34b 111512938 111513021 
hsa-miR-361 hsa-miR-361-5p UUAUCAGAAUCUCCAGGGGUAC X No  85903636 85903707 
hsa-miR-375 hsa-mir-375 UUUGUUCGUUCGGCUCGCGUGA 2 No  219001645 219001708 
hsa-miR-382 hsa-miR-382-5p GAAGUUGUUCGUGGUGGAUUCG 14 Yes hsa-miR-382 101054306- 101054381 
     hsa-miR-134 101054687 101054759 
     hsa-mir-154 101059755 101059838 
     hsa-mir-323b 101056219 101056300 
     hsa-mir-377 101062050 101062118 
     hsa-mir-381 101045920 101045994 
     hsa-mir-382 101054306 101054381 
     hsa-mir-485 101055419 101055491 
     hsa-mir-487a 101052446 101052525 
     hsa-mir-487b 101046455 101046538 
     hsa-mir-496 101060573- 101060674 
     hsa-mir-539 101047321 101047398 
     hsa-mir-544a 101048658 101048748 
     hsa-mir-655 101049550 101049646 
     hsa-mir-668 101055258 101055323 
     hsa-mir-889 101047901 101047979 
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Table 8-8: Highly expressed miRNAs in APA (miR-432 to miR-483-5p). 
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-
ordinates 
End Co-
ordinates 
hsa-miR-432  UCUUGGAGUAGGUCAUUGGGU
GG 
14 Yes hsa-miR-432 
100884483 
100884576 
     hsa-mir-337 100874493 100874585 
     hsa-mir-665 100875033 100875104 
     hsa-mir-431 100881007 100881120 
     hsa-mir-433 100881886 100881978 
     hsa-mir-127 100882979 100883075 
     hsa-mir-136 100884702 100884783 
hsa-miR-451 hsa-miR-451a AAACCGUUACCAUUACUGAGUU 17 Yes hsa-miR-451 28861369 28861440 
     hsa-mir-144 28861533 28861618 
     hsa-mir-451b 28861371 28861438 
     hsa-mir-4732 28861655 28861730 
hsa-miR-483-
5p 
hsa-miR-483-5p AAGACGGGAGGAAAGAAGGGA
G 
11 No  2134134 2134209 
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Table 8-9: Highly expressed miRNAs in APA (miR-509 to miR-574-5p). 
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-ordinates End Co-
ordinates 
hsa-miR-509 hsa-miR-509-
3p 
UGAUUGGUACGUCUGUGGGUAG X Yes hsa-miR-509-1 
loop 
147260532 
147260625 
     hsa-mir-509-2 147258760 147258850 
     hsa-mir-509-3 147259652- 147259726 
     hsa-mir-509-2 
loop 
147258760 147258850 
     hsa-miR-509-1  147260532 147260625 
     hsa-mir-509-3 147259652- 147259726 
     hsa-mir-514b 147250151- 147250230 
     hsa-mir-509-3 
loop 
147259652- 147259726 
     hsa-miR-509-1  147260532 147260625 
     hsa-mir-509-2 147258760 147258850 
     hsa-mir-514b 147250151- 147250230 
hsa-miR-574 hsa-miR-574-
3p 
CACGCUCAUGCACACACCCACA 4 No  38868032 38868127 
hsa-miR-574-
5p 
hsa-miR-574-
5p 
UGAGUGUGUGUGUGUGAGUGU
GU 
4 No  38868032 38868127 
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Table 8-10: Highly expressed miRNAs in APA (miR-92a to miR-92b).  
Based on miRBase Database Release 21: June 2014. 
microRNA 
(previous ID) 
microRNA 
(latest ID) 
Sequence Chromosome 
Location 
Cluster Other microRNA 
within cluster 
Start Co-
ordinates 
End Co-
ordinates 
hsa-miR-92a hsa-miR-92a-
3p 
UAUUGCACUUGUCCCGGCCUGU 13 Yes hsa-mir-92a-1 
loop 
91351314 91351391 
     hsa-mir-17 91350605 91350688 
     hsa-mir-18a 91350751 91350821 
     hsa-mir-19a 91350891 91350972 
     hsa-mir-20a 91351065 91351135 
     hsa-mir-19b-1 91351192 91351278 
   X Yes hsa-mir-92a-2 
loop 
134169538 134169612 
     hsa-mir-106a 134170198 134170278 
     hsa-mir-18b 134170041 134170111 
     hsa-mir-19b-2 134169671 134169766 
     hsa-mir-20b 134169809 134169877 
     hsa-mir-363 134169378 134169452 
hsa-miR-92b hsa-miR-92b-
3p 
UAUUGCACUCGUCCCGGCCUCC 1 No  155195177 155195272 
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Table 8-11: miRNAs that are differentially expressed in Angio II-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs 
(IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-106a-5p hsa-miR-17-5p, hsa-miR-20a-5p,  
hsa-miR-20b-5p 
AAAAGUGCUUACAGUGCAGGUAG x 1418 
hsa-miR-1185-1-3p - - - No match miRNA in IPA 
hsa-miR-126-3p hsa-miR-126-3p UCGUACCGUGAGUAAUAAUGCG 9 111 
hsa-miR-1275 - GUGGGGGAGAGGCUGUC 6 1870 
hsa-miR-140-5p - CAGUGGUUUUACCCUAUGGUAG 16 751 
hsa-miR-154-3p - AAUCAUACACGGUUGACCUAUU 14 309 
hsa-miR-17-5p hsa-miR-106a-5p, hsa-miR-20a-5p, hsa-
miR-20b-5p 
CAAAGUGCUUACAGUGCAGGUAG 13 1418 
hsa-miR-196b-5p hsa-miR-196a-5p UAGGUAGUUUCCUGUUGUUGGG 7 628 
hsa-miR-19a-3p hsa-miR-19b-3p UGUGCAAAUCUAUGCAAAACUGA 13 1448 
hsa-miR-20a-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-20a-5p hsa-miR-17-5p, hsa-miR-106a-5p, hsa-
miR-20b-5p 
UAAAGUGCUUAUAGUGCAGGUAG 13 1418 
hsa-miR-20b-5p hsa-miR-17-5p, hsa-miR-106a-5p, hsa-
miR-20a-5p 
CAAAGUGCUCAUAGUGCAGGUAG X 1418 
hsa-miR-218-1-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-222-3p hsa-miR-221-3p AGCUACAUCUGGCUACUGGGU X 807 
hsa-miR-345-5p - GCUGACUCCUAGUCCAGGGCUC 14 476 
hsa-miR-3613-5p - UGUUGUACUUUUUUUUUUGUUC 13 263 
hsa-miR-376a-5p - GUAGAUUCUCCUUCUAUGAGUA 14 3 
hsa-miR-4323 - CAGCCCCACAGCCUCAGA 19 1272 
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Table 8-12: miRNAs that are differentially expressed in Angio II-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ 
Overlapped 
miRNAs (IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-4741 hsa-miR-4675 CGGGCUGUCCGGAGGGGUCGGCU 18 1188 
hsa-miR-4743-5p - UGGCCGGAUGGGACAGGAGGCAU 18 699 
hsa-miR-488-3p - UUGAAAGGCUAUUUCUUGGUC 1 735 
hsa-miR-493-5p - - - Not included in IPA Target Filter analysis 
hsa-miR-5100 - - - Not included in IPA Target Filter analysis 
hsa-miR-5190 - - - Not included in IPA Target Filter analysis 
hsa-miR-539-3p hsa-miR-485-3p AUCAUACAAGGACAAUUUCUUU 14 557 
hsa-miR-548v - AGCUACAGUUACUUUUGCACCA 8 627 
hsa-miR-568 - AUGUAUAAAUGUAUACACAC 3 319 
hsa-miR-574-5p - UGAGUGUGUGUGUGUGAGUGUGU 4 564 
hsa-miR-647 - GUGGCUGCACUCACUUCCUUC 20 1034 
hsa-miR-7-5p hsa-miR-7a-5p UGGAAGACUAGUGAUUUUGUUGU  
(from precursor: hsa-mir-7-1) 
UGGAAGACUAGUGAUUUUGUUGU  
(from precursor: hsa-mir-7-2)  
UGGAAGACUAGUGAUUUUGUUGU  
(from precursor: hsa-mir-7-3) 
9 
 
15 
 
19 
916 
hsa-miR-766-3p - ACUCCAGCCCCACAGCCUCAGC X 1096 
hsa-miR-937-5p - - - Not included in IPA Target Filter analysis 
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Table 8-13: miRNAs that are differentially expressed in dbcAMP-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs 
(IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-100-5p hsa-miR-99a-5p AACCCGUAGAUCCGAACUUGUG 11 193 
hsa-miR-106a-5p hsa-miR-17-5p, hsa-miR-106b-5p, hsa-
miR-20a-5p, hsa-miR-20b-5p 
hsa-miR-93-5p 
AAAAGUGCUUACAGUGCAGGUAG X 1418 
hsa-miR-106b-5p hsa-miR-17-5p, hsa-miR-106a-5p, hsa-
miR-20a-5p, hsa-miR-20b-5p 
hsa-miR-93-5p 
UAAAGUGCUGACAGUGCAGAU 7 1418 
hsa-miR-107 hsa-miR-103a-3p AGCAGCAUUGUACAGGGCUAUCA 10 1255 
hsa-miR-1185-1-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-1224-5p - GUGAGGACUCGGGAGGUGG 3 593 
hsa-miR-125a-5p hsa-miR-125b-5p UCCCUGAGACCCUUUAACCUGUGA 19 1530 
hsa-miR-125b-5p hsa-miR-125a-5p UCCCUGAGACCCUAACUUGUGA (from 
precursor: hsa-mir-125b-1) 
UCCCUGAGACCCUAACUUGUGA (from 
precursor: hsa-mir-125b-2) 
11 
 
21 
1530 
hsa-miR-126-3p hsa-miR-126a-3p UCGUACCGUGAGUAAUAAUGCG 9 111 
hsa-miR-1275 - GUGGGGGAGAGGCUGUC 6 1870 
hsa-miR-132-3p - UAACAGUCUACAGCCAUGGUCG 17 767 
hsa-miR-136-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-140-5p - CAGUGGUUUUACCCUAUGGUAG 16 751 
hsa-miR-145-5p - GUCCAGUUUUCCCAGGAAUCCCU 5 1228 
hsa-miR-146b-5p hsa-miR-146a-5p UGAGAACUGAAUUCCAUAGGCU 10 650 
hsa-miR-15a-5p hsa-miR-16-5p UAGCAGCACAUAAUGGUUUGUG 13 2020 
 
260 
 
Table 8-14: miRNAs that are differentially expressed in dbcAMP-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs 
(IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-154-3p hsa-miR-487a-3p AAUCAUACACGGUUGACCUAUU 14 309 
hsa-miR-16-2-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-17-5p hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-
miR-20a-5p, hsa-miR-20b-5p 
hsa-miR-93-5p 
CAAAGUGCUUACAGUGCAGGUAG 13 1418 
hsa-miR-181b-5p hsa-miR-181a-5p, hsa-miR-181c-5p AACAUUCAUUGCUGUCGGUGGGU 
(from precursor: hsa-mir-181b-1) 
AACAUUCAUUGCUGUCGGUGGGU 
(from precursor: hsa-mir-181b-2) 
1 
 
9 
1496 
hsa-miR-181c-5p hsa-miR-181a-5p, hsa-miR-181b-5p AACAUUCAACCUGUCGGUGAGU 19 1496 
hsa-miR-186-5p - CAAAGAAUUCUCCUUUUGGGCU 1 922 
hsa-miR-194-5p - UGUAACAGCAACUCCAUGUGGA (from 
precursor: hsa-mir-194-1) 
UGUAACAGCAACUCCAUGUGGA (from 
precursor: hsa-mir-194-2) 
1 
 
11 
709 
hsa-miR-196b-5p hsa-miR-196a-5p UAGGUAGUUUCCUGUUGUUGGG 7 628 
hsa-miR-197-5p - CGGGUAGAGAGGGCAGUGGGAGG 1 641 
hsa-miR-19a-3p hsa-miR-19b-3p UGUGCAAAUCUAUGCAAAACUGA 13 1448 
hsa-miR-19b-3p hsa-miR-19a-3p UGUGCAAAUCCAUGCAAAACUGA 
(from precursor: hsa-mir-19b-1) 
UGUGCAAAUCCAUGCAAAACUGA 
(from precursor: hsa-mir-19b-2) 
13 
 
X 
1448 
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Table 8-15: miRNAs that are differentially expressed in dbcAMP-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-20a-5p hsa-miR-17-5p, hsa-miR-106a-5p, 
hsa-miR-106b-5p, hsa-miR-20b-5p 
hsa-miR-93-5p 
UAAAGUGCUUAUAGUGCAGGUAG 13 1418 
hsa-miR-20b-5p hsa-miR-17-5p, hsa-miR-106a-5p, 
hsa-miR-106b-5p, hsa-miR-20a-5p 
hsa-miR-93-5p 
CAAAGUGCUCAUAGUGCAGGUAG X 1418 
hsa-miR-21-5p - UAGCUUAUCAGACUGAUGUUGA 17 615 
hsa-miR-222-3p hsa-miR-221-3p AGCUACAUCUGGCUACUGGGU X 807 
hsa-miR-23a-3p hsa-miR-23b-3p, hsa-miR-23c-3p AUCACAUUGCCAGGGAUUUCC 19 807 
hsa-miR-23b-3p hsa-miR-23a-3p, hsa-miR-23c-3p AUCACAUUGCCAGGGAUUACC 9 807 
hsa-miR-23c hsa-miR-23a-3p, hsa-miR-23b-3p AUCACAUUGCCAGUGAUUACCC X 807 
hsa-miR-24-3p - UGGCUCAGUUCAGCAGGAACAG 
(from precursor: hsa-mir-24-1) 
UGGCUCAGUUCAGCAGGAACAG 
(from precursor: hsa-mir-24-2) 
9 
 
19 
1505 
hsa-miR-29a-3p hsa-miR-29b-3p, hsa-miR-29c-3p UAGCACCAUCUGAAAUCGGUUA 7 1492 
hsa-miR-29c-3p hsa-miR-29b-3p, hsa-miR-29a-3p UAGCACCAUUUGAAAUCGGUUA 1 1492 
hsa-miR-30a-5p hsa-miR-30c-5p, hsa-miR-30b-5p, 
hsa-miR-30e-5p 
UGUAAACAUCCUCGACUGGAAG 6 1592 
hsa-miR-30b-5p hsa-miR-30c-5p, hsa-miR-30a-5p, 
hsa-miR-30e-5p 
UGUAAACAUCCUACACUCAGCU 8 1592 
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Table 8-16: miRNAs that are differentially expressed in dbcAMP-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs 
(IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-30c-5p hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-
miR-30e-5p 
UGUAAACAUCCUACACUCUCAGC 
(from precursor: hsa-mir-30c-1) 
UGUAAACAUCCUACACUCUCAGC (from 
precursor: hsa-mir-30c-2) 
1 
 
6 
1592 
hsa-miR-30e-5p hsa-miR-30c-5p, hsa-miR-30a-5p, hsa-
miR-30b-5p 
UGUAAACAUCCUUGACUGGAAG 1 1592 
hsa-miR-329-3p - AACACACCUGGUUAACCUCUUU (from 
precursor: hsa-mir-329-1) 
AACACACCUGGUUAACCUCUUU (from 
precursor: hsa-mir-329-2) 
14 
 
14 
913 
hsa-miR-335-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-337-3p - CUCCUAUAUGAUGCCUUUCUUC 14 373 
hsa-miR-337-5p - GAACGGCUUCAUACAGGAGUU 14 249 
hsa-miR-3613-5p - UGUUGUACUUUUUUUUUUGUUC 13 263 
hsa-miR-3620-5p hsa-miR-1587 GUGGGCUGGGCUGGGCUGGGCC 1 994 
hsa-miR-365a-3p - UAAUGCCCCUAAAAAUCCUUAU 16 715 
hsa-miR-369-5p - AGAUCGACCGUGUUAUAUUCGC 14 107 
hsa-miR-370-3p - GCCUGCUGGGGUGGAACCUGGU 14 1217 
hsa-miR-376a-5p - GUAGAUUCUCCUUCUAUGAGUA 14 3 
hsa-miR-376b-3p hsa-miR-376a-3p AUCAUAGAGGAAAAUCCAUGUU 14 581 
hsa-miR-376b-5p - - - Not included in IPA Target Filter analysis 
hsa-miR-376c-3p - AACAUAGAGGAAAUUCCACGU 14 667 
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Table 8-17: miRNAs that are differentially expressed in dbcAMP-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs 
(IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-376c-5p hsa-miR-376b-5p - - Not included in IPA Target Filter analysis 
hsa-miR-377-3p - AUCACACAAAGGCAACUUUUGU 14 1227 
hsa-miR-409-3p - GAAUGUUGCUCGGUGAACCCCU 14 188 
hsa-miR-410-3p mmu-miR-344d-3p AAUAUAACACAGAUGGCCUGU 14 733 
hsa-miR-411-5p - UAGUAGACCGUAUAGCGUACG 14 337 
hsa-miR-424-3p - CAAAACGUGAGGCGCUGCUAU X 3 
hsa-miR-4270 - UCAGGGAGUCAGGGGAGGGC 3 1302 
hsa-miR-4284 - GGGCUCACAUCACCCCAU 7 1253 
hsa-miR-4286 - ACCCCACUCCUGGUACC 8 1195 
hsa-miR-4324 - CCCUGAGACCCUAACCUUAA 19 757 
hsa-miR-433-3p - AUCAUGAUGGGCUCCUCGGUGU 14 584 
hsa-miR-4444 - CUCGAGUUGGAAGAGGCG  
(from precursor: hsa-mir-4444-1) 
CUCGAGUUGGAAGAGGCG  
(from precursor: hsa-mir-4444-2) 
2 
 
3 
164 
hsa-miR-4454 - GGAUCCGAGUCACGGCACCA 4 111 
hsa-miR-454-3p hsa-miR-130a-3p UAGUGCAAUAUUGCUUAUAGGGU 17 1252 
hsa-miR-4727-5p mmu-miR-3084-3p UUCUGCCAGUCUCCUUCAGAC 17 948 
hsa-miR-4732-5p - UGUAGAGCAGGGAGCAGGAAGCU 17 322 
hsa-miR-4741 hsa-miR-4675 CGGGCUGUCCGGAGGGGUCGGCU 18 1188 
hsa-miR-4743-5p - UGGCCGGAUGGGACAGGAGGCAU 18 699 
hsa-miR-487a hsa-miR-154-3p AAUCAUACAGGGACAUCCAGUU 14 309 
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Table 8-18: miRNAs that are differentially expressed in dbcAMP-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-488-3p - UUGAAAGGCUAUUUCUUGGUC 1 735 
hsa-miR-494 - UGAAACAUACACGGGAAACCUC 14 789 
hsa-miR-539-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-542-3p - UGUGACAGAUUGAUAACUGAAA X 795 
hsa-miR-6076 - - - Not included in IPA Target Filter analysis 
hsa-miR-647 - GUGGCUGCACUCACUUCCUUC 20 1034 
hsa-miR-758-3p - UUUGUGACCUGGUCCACUAACC 14 542 
hsa-miR-766-3p - ACUCCAGCCCCACAGCCUCAGC X 1096 
hsa-miR-889 - UUAAUAUCGGACAACCAUUGU 14 140 
hsa-miR-93-5p hsa-miR-17-5p, hsa-miR-106a-5p, 
hsa-miR-106b-5p, hsa-miR-20a-5p 
hsa-miR-20b-5p 
CAAAGUGCUGUUCGUGCAGGUAG 7 1418 
hsa-miR-99a-5p hsa-miR-100-5p AACCCGUAGAUCCGAACUUGUG 21 193 
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Table 8-19: miRNAs that are differentially expressed in KCl-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs (IPA)  Sequence Chromosome Number of targeted mRNA 
hsa-let-7g-5p hsa-let-7a-5p UGAGGUAGUAGUUUGUACAGUU 3 1396 
hsa-miR-100-5p hsa-miR-99a-5p AACCCGUAGAUCCGAACUUGUG 11 193 
hsa-miR-106a-5p hsa-miR-17-5p, hsa-miR-106b-5p, hsa-miR-20a-5p, 
hsa-miR-20b-5p, hsa-miR-93-5p 
AAAAGUGCUUACAGUGCAGGUAG X 1418 
hsa-miR-10b-5p hsa-miR-10a-5p UACCCUGUAGAACCGAAUUUGUG 2 780 
hsa-miR-125a-5p hsa-miR-125b-5p UCCCUGAGACCCUUUAACCUGUGA 19 1530 
hsa-miR-1271-5p hsa-miR-96-5p CUUGGCACCUAGCAAGCACUCA 5 1394 
hsa-miR-128-3p - UCACAGUGAACCGGUCUCUUU 
(from precursor: hsa-mir-128-1) 
UCACAGUGAACCGGUCUCUUU 
(from precursor: hsa-mir-128-2) 
2 
 
3 
1461 
hsa-miR-139-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-15b-5p hsa-miR-16-5p UAGCAGCACAUAAUGGUUUGUG 13 2020 
hsa-miR-154-3p hsa-miR-487a-3p AAUCAUACACGGUUGACCUAUU 14 309 
hsa-miR-16-2-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-17-5p hsa-miR-17-5p, hsa-miR-106b-5p, hsa-miR-20a-5p, 
hsa-miR-20b-5p, hsa-miR-93-5p 
CAAAGUGCUUACAGUGCAGGUAG 13 1418 
hsa-miR-186-5p - CAAAGAAUUCUCCUUUUGGGCU 1 922 
hsa-miR-195-5p hsa-miR-16-5p  17 2020 
hsa-miR-196b-5p hsa-miR-196a-5p UAGGUAGUUUCAUGUUGUUGGG 7 628 
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Table 8-20: miRNAs that are differentially expressed in KCl-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped miRNAs (IPA)  Sequence Chromosome Number of targeted mRNA 
hsa-miR-19a-3p hsa-miR-19b-3p UGUGCAAAUCUAUGCAAAACUGA 13 1448 
hsa-miR-19b-3p hsa-miR-19a-3p UGUGCAAAUCCAUGCAAAACUGA 
(from precursor: hsa-mir-19b-1) 
UGUGCAAAUCCAUGCAAAACUGA 
(from precursor: hsa-mir-19b-2) 
13 
 
X 
1448 
hsa-miR-20a-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-20b-5p hsa-miR-17-5p, hsa-miR-106a-5p, hsa-miR-106b-5p, 
hsa-miR-20a-5p 
hsa-miR-93-5p 
CAAAGUGCUCAUAGUGCAGGUAG X 1418 
hsa-miR-21-5p - UAGCUUAUCAGACUGAUGUUGA 17 615 
hsa-miR-23a-3p hsa-miR-23b-3p, hsa-miR-23c AUCACAUUGCCAGGGAUUUCC 19 807 
hsa-miR-23b-3p hsa-miR-23a-3p, hsa-miR-23c AUCACAUUGCCAGGGAUUACC 9 807 
hsa-miR-23c hsa-miR-23a-3p, hsa-miR-23b-3p AUCACAUUGCCAGUGAUUACCC X 807 
hsa-miR-28-5p hsa-miR-708-5p AAGGAGCUCACAGUCUAUUGAG 3 874 
hsa-miR-29c-3p hsa-miR-29b-3p, hsa-miR-29a-3p UAGCACCAUUUGAAAUCGGUUA 1 1492 
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Table 8-21: miRNAs that are differentially expressed in KCl-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-30a-5p hsa-miR-30c-5p, hsa-miR-30b-5p, hsa-
miR-30e-5p 
UGUAAACAUCCUCGACUGGAAG 6 1592 
hsa-miR-30b-5p hsa-miR-30c-5p, hsa-miR-30a-5p, hsa-
miR-30e-5p 
UGUAAACAUCCUACACUCAGCU 8 1592 
hsa-miR-30c-5p hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-
miR-30e-5p 
UGUAAACAUCCUACACUCUCAGC 
(from precursor: hsa-mir-30c-2) 
UGUAAACAUCCUACACUCUCAGC (from 
precursor: hsa-mir-30c-1) 
1 
 
6 
1592 
hsa-miR-30e-5p hsa-miR-30c-5p, hsa-miR-30a-5p, hsa-
miR-30b-5p 
UGUAAACAUCCUUGACUGGAAG 1 1592 
hsa-miR-3120-3p - CACAGCAAGUGUAGACAGGCA 1 869 
hsa-miR-3178 - GGGGCGCGGCCGGAUCG 16 529 
hsa-miR-3195 - CGCGCCGGGCCCGGGUU 20 241 
hsa-miR-329 - AACACACCUGGUUAACCUCUUU 
(from precursor: hsa-mir-329-1) 
AACACACCUGGUUAACCUCUUU 
(from precursor: hsa-mir-329-2) 
14 
 
14 
913 
 
913 
hsa-miR-335-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-337-3p - CUCCUAUAUGAUGCCUUUCUUC 14 373 
hsa-miR-3617-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-376b-3p hsa-miR-376a-3p AUCAUAGAGGAAAAUCCAUGUU 14 581 
hsa-miR-376b-5p hsa-miR-376c-5p - - Not included in IPA Target Filter analysis 
hsa-miR-376c-5p hsa-miR-376b-5p - - Not included in IPA Target Filter analysis 
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Table 8-22: miRNAs that are differentially expressed in KCl-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-3922-5p - UCAAGGCCAGAGGUCCCACAGCA 12 834 
hsa-miR-409-3p - GAAUGUUGCUCGGUGAACCCCU 14 188 
hsa-miR-424-3p - CAAAACGUGAGGCGCUGCUAU X 3 
hsa-miR-4284 - GGGCUCACAUCACCCCAU 7 1253 
hsa-miR-4288 - UUGUCUGCUGAGUUUCC 8 666 
hsa-miR-4497 - CUCCGGGACGGCUGGGC 12 414 
hsa-miR-454-3p hsa-miR-130a-3p UAGUGCAAUAUUGCUUAUAGGGU 17 1252 
hsa-miR-4730 - CUGGCGGAGCCCAUUCCAUGCCA 17 301 
hsa-miR-4732-5p - UGUAGAGCAGGGAGCAGGAAGCU 17 322 
hsa-miR-483-3p - UCACUCCUCUCCUCCCGUCUU 11 615 
hsa-miR-487a-3p hsa-miR-154-3p AAUCAUACAGGGACAUCCAGUU 14 309 
hsa-miR-489-3p - GUGACAUCACAUAUACGGCAGC 11 410 
hsa-miR-494 - UGAAACAUACACGGGAAACCUC 14 789 
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Table 8-23: miRNAs that are differentially expressed in KCl-stimulated cells (>500 AU).  
Synonym means the miRNAs have similar seed sequence and share similar mRNA targets according to IPA analysis. Bold and underlined sequences are the seed 
sequence of the miRNA. 
miRNA (miRBase Acession) Synonym miRNAs/ Overlapped 
miRNAs (IPA) 
 Sequence Chromosome Number of targeted mRNA 
hsa-miR-542-3p - UGUGACAGAUUGAUAACUGAAA X 795 
hsa-miR-543 - AAACAUUCGCGGUGCACUUCUU 14 916 
hsa-miR-568 - AUGUAUAAAUGUAUACACAC 3 319 
hsa-miR-574-5p - UGAGUGUGUGUGUGUGAGUGUGU 4 564 
hsa-miR-7-1-3p - - - Not included in IPA Target Filter analysis 
hsa-miR-766-3p - ACUCCAGCCCCACAGCCUCAGC X 1096 
hsa-miR-874-3p - CUGCCCUGGCCCGAGGGACCGA 5 1069 
hsa-miR-92a-3p hsa-miR-92b-3p UAUUGCACUUGUCCCGGCCUGU 
(from precursor: hsa-mir-92a-1) 
UAUUGCACUUGUCCCGGCCUGU 
(from precursor: hsa-mir-92a-2) 
13 
 
X 
1138 
hsa-miR-92b-3p hsa-miR-92a-3p UAUUGCACUCGUCCCGGCCUCC 1 1138 
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